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Thesis Summary 
 
Liposomes were selected as a delivery system due to their amphiphilic nature and their use 
in a wide variety of medications already on the market.  Carbon nanotubes were selected as 
there is still uncertainty as to their influence on biological systems and, due to their increasing 
prevalence, this needs to be addressed.  This includes the uncertainty surrounding their 
influence on the immune system and whether this is a positive or a negative effect. 
Liposomes quite often require size reduction after being formed through lipid film hydration.  
This size reduction can occur through several different methods including probe sonication, 
bath sonication and extrusion.  The Bioruptor bath sonication systems were used in this study 
to reduce the size of liposomes from the micron range to below 100 nm.  A number of different 
systems were studied, and all were shown to be effective.  A number of different formulations 
were investigated, and this culminated in a study showing a number of different lipophilic drugs 
being loaded into the liposomes formed using this bath sonication system. 
Carbon nanotubes were successfully dispersed in water using a number of different 
surfactants including MPC, which is a biologically safe phospholipid.  These were all done 
using the Bioruptor bath sonication systems.  Carbon nanotubes were also successfully 
defected using an acid mixture and it was shown that increasing the temperature too much 
caused total carbon nanotube destruction.  Finally, the carbon nanotubes were added to the 
liposomal formulations. 
It was shown that the bath sonication systems employed could be used to formulate small 
liposomes that could be used for vaccine and drug delivery.  The same systems were used to 
disperse carbon nanotubes in water, which could then be used for a number of different 
biological uses. 
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DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced using the Bioruptor® Standard 
and then sonicated for 15 minutes of 30, 0 at the power level M using a 0.1 mL sample.  Each 
position in the holder was assigned an arbitrary number between 1 and 6 and each ran 3 times 
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Figure 4.1 All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1 % 
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Figure 4.10: All runs were with probe sonicator, 0.01 % carbon nanotube concentration, 0.1 
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1. Introduction 
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1.1 The problem at hand 
 
Vaccines are a vital part of the healthcare system throughout the world and are a major 
preventer of disease.  Vaccines work by inducing an immune system response with what is 
known as an antigen.  An antigen is any substance such as a virus, bacteria or fungi that 
stimulates a response from the immune system to create antibodies.  These antibodies are 
then used when the actual disease does invade the body as the immune system is now 
prepared to recognise the foreign body and destroy it before the disease can take hold and 
cause damage (Schwendener, 2014).  Liposomes are already in use as a vaccine delivery 
system as their amphiphilic structure allows for delivery of the antigen and other parts such as 
an adjuvant which is used to enhance the immune response, as well as possibly antibiotics, 
preservatives and stabilisers (Tandrup Schmidt et al., 2016).  Carbon nanotubes could be 
used in conjunction with the liposomes to enhance the immune system response and this was 
the aim of this work.  Carbon nanotubes have been shown in some forms to suppress the 
immune system and others shown to enhance the response.  Some forms have been shown 
to be toxic and others have been shown to cause no toxicity (Fadel and Fahmy, 2014).  
Therefore, this work also wanted to focus on forming multiple different forms of carbon 
nanotubes, different in length, chirality and modification, to investigate their toxicity and other 
effects on cells. 
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1.2 Liposomes as a spherical nanoscale drug and vaccine delivery 
system 
 
1.2.1 Liposomes background 
Liposomes are spherical vesicles made up of mostly phospholipid bilayers that can be in either 
the nanometre or micrometre range in diameter.  Liposomes can be formed with multiple 
bilayers encapsulating a hydrophilic centre such as multilamellar vesicles (MLV), or just have 
the one lipid bilayer such as small unilamellar vesicles or large unilamellar vesicles (SUV and 
LUV) (Szoka and Papahadjopoulos, 1978, Philippot and Schuber, 1994, Liu, 2011).   
Depending on the critical packing parameter (CPP), lipids can also form a micelle, where a 
single layer of lipids comes together to form a spherical structure with the head groups on the 
outside and the tails within the ball as shown below in Figure 1.1 (Menger, 1979, Dominguez 
et al., 1997). 
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Figure 1.1: The shapes and structures formed by the lipids and surfactants used in this work 
as well as their structures and approximate CPP values. 
The equation used to describe the critical packing parameter is defined as v/a0lc.  V is defined 
as the volume of the lipophilic chain, a0 is the area occupied by the hydrophilic head group, 
and lc is the length of the lipophilic chain (Israelachvili, 2011).  The CPP then can be used to 
predict the particular packing arrangement an individual lipid will take.  A lipid with a CPP value 
of 1/3 or smaller favours forming a spherical micelle, because of the large hydrophilic head 
group.  Those between 1/3 and 1/2 favour the cylindrical micelle conformation.  For a flexible 
vesicle, the CPP should be somewhere between 1/2 and 1 and for a bilayer it should be 
approximately 1.  The final structure that can be formed is an inverted micelle where the 
lipophilic chains are larger than the head group. 
A large range of lipids are used for liposome formulations, with many formulations having a 
mixture of lipids to combine the good factors of the different lipids used.  They can be modified 
in many different ways depending on their purpose.  This can include the addition of 
polyethylene glycol (PEG) to allow the liposomes to hide from the immune system and 
therefore reach their site of action without being removed.  This is done by reducing the charge 
of the liposome surface closer to neutral and by occupying the space immediately next to the 
liposome surface; since PEG is a large molecule, this inhibits other macromolecules from 
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interacting with the liposome, such as macrophages.  The addition of cholesterol helps 
stabilise the lipid bilayer membranes.  They can also be thermally modified to allow release of 
the drug inside at a certain temperature, using an external device to heat the certain area once 
the liposomes have been injected.  They can also be magnetised which means when the 
liposomes are injected and then a magnet applied to the area where the liposomes are 
required, they are held and release their drug over time.   This reduces the side effects as the 
liposomes then do not release their drug in other areas of the body. 
 
1.2.2 Current methods for the formation of liposomes 
Lipids on their own do not have the energy to form these lipid bilayers below their lipid film 
transition temperature and therefore energy is required to be added into the system to form 
bilayers for many lipids (Gregoriadis and Perrie, 2010).  The formation of liposomes can be 
done in a number of different ways (Torchilin and Weissig, 2003).  Some methods, such as 
extrusion and probe sonication have been around nearly as long as liposomes have been 
known about since the 1960s (Bangham et al., 1965).  These methods generally follow the 
top down approach (Figure 1.2). 
 
Figure 1.2: Liposomes being produced using the top down method, whereby lipids form a 
bilayer, and then using the lipid hydration method are formed into MLV and then through a 
variety of methods such as sonication, both bath and probe, extrusion and high shear mixing, 
are reduced in size to the SUV level (Avanti, 2015, Rathod and Deshpande, 2010). 
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One of the most common and well used top down methods of liposome production is 
sonication (Kreuter, 1994).  Sonication works by using sonic energy that puts pressure on the 
MLV bilayer and breaks them up so that they form smaller liposomes within the Nano size 
range (Maulucci et al., 2005, Dua, 2012).  Sonication is a common and often preferred method 
because it is quick and easy with only two relatively simple steps of sonication and 
centrifugation (Akbarzadeh et al., 2013).  This method is split into two different forms, probe 
sonication and bath sonication (Figure 1.3).  Probe sonication is the more common method 
used as it is a cheap, simple and quick method and has been far more extensively investigated 
compared to bath sonication (Lapinski et al., 2007, Duzgunes, 2005, Liu, 2008, Jain, 2008, 
Vo-Dinh, 2003).  However, it can cause lipid degradation resulting from excessive heat and 
titanium contamination from the probe tip, necessitating subsequent centrifugation to remove 
these particles (Philippot and Schuber, 1994, Foged et al., 2014, Venkateswarlu I, 2011).  A 
methodology for probe sonication liposome size reduction is shown below in Figure 1.4.  
  
Figure 1.3: Bath (A) and probe (B) sonication diagrams showing how each method works to 
reduce the size of the sample.  For bath sonication shown in Figure 1.3 A, the samples are 
placed into a temperature-controlled water bath.  This whole water bath is then sonicated 
using a device fitted to the bottom of the water bath, thereby giving non-contact sonication to 
the sample, reducing its size.  For probe sonication shown in Figure 1.3 B, the sonic energy 
is transmitted directly down a probe that is placed directly into the sample. 
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Figure 1.4: Probe sonication liposome size reduction method.  Sample is sonicated in a glass 
vial with the tip of the probe touching the sample.  Sample changes from milky to clear.  
Sample is then centrifuged in a centrifuge tube to remove titanium particles and large MLV 
which settle to the bottom.  
However bath sonication does offer advantages, including better temperature control and the 
ability to run multiple samples under exactly the same conditions at the same time (Dua, 2012). 
Another major advantage of bath sonication, particularly with the Bioruptor® system, is that 
multiple samples can be prepared simultaneously.  This reduces the risk of inter – sample 
variability. However, issues currently with bath sonication revolve around two main issues: 
that there is limited research done using a bath sonicator and liposomes, and those processes 
used tend to be slow compared to probe sonication and other methods (hielscher, 2015).  A 
methodology for bath sonication liposome size reduction is shown below in Figure 1.5. 
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Figure 1.5: Method for producing MLV through lipid film hydration and then forming SUV 
through bath sonication.  Lipid in Chloroform: Methanol is added to a round bottom flask and 
then the solvents are removed through the use of a rotary evaporator.  Buffer is warmed and 
added to the lipid film that forms on the bottom of the flask and vortexed to form a milky solution 
of MLV.  Sample is added to a warmed water bath in plastic tubes and sonicated. 
 
As mentioned, other methods of size reduction, such as extrusion and high shear mixing, have 
also been investigated (Bhardwaj and Burgess, 2010, Cagdas et al., 2011, Lasic and 
Barenholz, 1996, Olson et al., 1979).  Extrusion works by forcing the liposomes in solution 
through smaller and smaller membranes which have a set pore size (Berger et al., 2001, Nayar 
et al., 1989, Chapman et al., 1991, Turanek, 1994).  This method can give very good size 
results with extremely good polydispersity (PDI) of below 0.1 but suffers from contamination 
issues and limited size range due to the use of membranes.  Other methods such as 
microfluidics and high shear mixing have come around in more recent decades, with 
microfluidics becoming more prominent in the last 15 to 20 years (Yu et al., 2009, van Swaay 
and deMello, 2013, Kastner et al., 2014, Jahn et al., 2007).  These newer methods look to 
build on what the original methods could do, with added bonuses or by reducing the unwanted 
side effects.  High shear mixing has been used for other lipids, notably the formulation of 
cationic liposome adjuvants (Andreasan, 2013, Foged et al., 2014).  Whereas sonication 
works by inducing massive stress, high shear mixing works by the milling effect.  Microfluidics 
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is a different method for producing liposomes within the nanometre range.  It is known as a 
bottom up instead of a top down method.  This is because instead of producing large MLVs 
first and then reducing their size, the lipid is instead formed into SUV through just the one 
process.  This done through the fluid streams of lipid and solvent forming a well-defined 
interface by laminar flow (Yu et al., 2009),  Bath sonication was chosen as the alternative 
method to probe sonication because bath sonication allows for a much higher throughput of 
samples compared to high shear mixing, extrusion and microfluidics.  Also, the temperature 
control which can be achieved through the use of the water bath is a distinct advantage of 
bath sonication compared to probe sonication in particular.  This is because the water bath 
allows for the sample temperature to be controlled to within a degree or two, but the probe 
sonicator can only be cooled using an ice bath which allows for much less control. 
 
1.2.3 Analysis of liposomes after formation 
 
Dynamic light scattering (DLS) is the main form of analysis post liposome formation.  DLS 
allows for size and PDI data to be gathered in a quick and efficient way.  Samples of liposomes 
are simply diluted in water and placed in a cuvette and ran in a couple of minutes.  DLS works 
simply by the sample being illuminated with a laser and then the changes in the scattered light 
are detected at a known scattering angle by the detector.  Different sized particles change the 
scattered light distribution and various algorithms and equations are used to infer the particle 
size from the amount of scattering. 
 
 High performance liquid chromatography (HPLC) can be used to quantify how much lipid is 
left after the liposomes have been made, to avoid significant loss of lipid through the process 
(Graeve and Janssen, 2009, Rodríguez-Alcalá and Fontecha, 2010, Rocha et al., 2010).  Lipid 
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quantification is needed to prove that all or almost all the lipid put in at the beginning of the 
process is recovered at the end of the process. 
 
HPLC can also be used to quantify other substances such as propofol.  Propofol is a lipophilic 
drug so can be used as an example drug to show the encapsulation efficiency of particular 
formulations formed using a specific method (Kastner et al., 2015, Ali et al., 2013).   
 
One of the most common methods used to image and track liposomes is the use a fluorescent 
dye.  These images can be used to investigate structural attributes, size and cellular and 
biodistribution (Parker et al., 1981, Verma et al., 2003).  For this, two different dyes can be 
used separately, Carboxyfluorescein (CF) and 1, 1’-Dioctadecyl-3, 3, 3’, 3’-
Tetramethylindocarbocyanine Perchlorate (DilC). 
CF is a hydrophilic green dye and as such gets trapped in the hydrophilic core of a liposome 
(Ralston et al., 1981, Stevenson et al., 1984, Chen and Knutson, 1988).  For example, 
Barbeau et al used CF to investigate the stability of their drug delivery molecule, an 
archaeosome, and compare it to other drug carriers including PEGylated liposomes (Barbeau 
et al., 2011).  The slower release of the CF from their study showed that their drug carrier was 
significantly more stable than the liposome.  CF has also been used as a molecular beacon 
by Zhou et al in the detection of deoxyribonucleic acid (DNA) damage, with the different 
quenching efficiencies being an indicator as to whether DNA damage had or had not occurred 
(Zhou et al., 2012). 
The red DilC dye is added along with the lipid when it is in its organic solvent.  This then gets 
trapped within the lipid bilayers of the liposomes, as DilC is hydrophobic (Kamperdijk et al., 
2012, N. A. Abdul Nasir, 2013 , Kaur et al., 2014, Joshi et al., 2014).  DilC has been used for 
example as an alternative cell marker for Mesenchymal stem cells and as a neuronal tracer 
(Weir et al., 2008, Supprian et al., 1993).  
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Both dyes can then be imaged using a confocal microscope (Kamperdijk et al., 2012, N. A. 
Abdul Nasir, 2013 ).  The reasons for these images being required is to prove that the 
liposomes being produced using the probe sonication and bath sonication methods in 
particular, are small unilamellar vesicles,  and no other structures such as micelles of 
multilamellar vesicles (Forssen et al., 1996).  Confocal microscopy is particularly useful as 
liposomes, due to their amphiphilic nature, can be loaded with either a lipophilic fluorescent 
dye such as DilC or a hydrophilic dye such as CF.  In some cases, both dyes are loaded at 
the same time so both the liposome core and bilayer can be investigated.  A major use for this 
technology with liposomes is to study liposomal uptake into mammalian and bacterial cells 
such as Ducat et al (Ducat et al., 2011).  Ahmed et al took a slightly different approach and 
investigated uptake of liposomes into the biofilm of bacteria (Ahmed et al., 2002).  These 
techniques could be useful for this project to look into liposomal uptake into various cells 
associated with the immune system response. 
 
1.2.4 Uses today 
 
A large range of lipids are used for liposome formulations, with many formulations having a 
mixture of lipids to combine the good factors of the different lipids used.  Some of the 
formulations currently on the market are shown below in Table 1.1 (Fan and Zhang, 2013). 
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Table 1.1: Current approved liposome formulations on the market.  Nearly all liposome 
formulations on the current market contain cholesterol to be a stabilising agent, nearly all are 
administered intravenous, many contain PEG, and many contain multiple lipids to optimise the 
formulation for its role.  Roles include to fight cancer, pain management and to combat fungal 
infections. 
 
Drug Product name Type Lipid 
Composition 
Route of 
administration 
Approved 
treatment 
Amphotericin 
B 
Ambiosome Liposome L-α-
phosphatidylcho
line, 
hydrogenated 
(Soy) (HSPC), 
1, 2-Distearoyl-
Sn-glycero-3-
phospho-rac-(1-
glycerol) sodium 
salt (DSPG) and 
cholesterol 
Intravenous Severe fungal 
infection 
Doxorubicin Myocet 
 
Doxil 
 
 
Lipo – dox 
Liposome 
 
PEGylated 
liposome 
 
 
PEGylated 
liposome 
1, 2-dioleoyl-sn-
glycero-3-
ethylphosphoch
oline (chloride 
salt) (EPC) and 
cholesterol 
 
HSPC, 
cholesterol and 
1, 2-Distearoyl-
sn-glycero-3-
phosphocholine 
- Polyethylene 
Glycol (DSPC – 
PEG2000) 
 
1, 2-Distearoyl-
sn-glycero-3-
phosphocholine 
(DSPC), 
cholesterol and 
Intravenous 
 
Intravenous 
 
 
Intravenous 
Metastatic 
breast cancer 
Kaposi’s 
sarcoma, 
ovarian and 
breast cancer 
Kaposi’s 
sarcoma, 
ovarian and 
breast cancer 
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DSPC – 
PEG2000 
Daunorubici
n 
Daunoxome Liposome DSPC and 
cholesterol 
Intravenous Blood cancer 
Verteprofin Visudyne Liposome EPC and 1, 2-
ditetradecanoyl-
sn-glycero-3-
phosphocholine 
(DMPC) 
Intravenous Age – related 
molecular 
degeneration 
Cytarabine Depocyt Liposome DOPC, 1, 2-
Dipalmitoyl-sn-
glycero-3-
phosphocholine 
(DPPC), 
cholesterol and 
triolein 
Spinal Neoplastic 
meningitis and 
lymphomatous 
meningitis 
Morphine 
sulfate 
DepoDur Liposome DOPC, 1, 2-
Dipalmitoyl-Sn-
glycero-3-
phospho-rac-(1-
glycerol) 
ammonium salt 
(DPPG), 
cholesterol and 
triolein 
Epidural Pain 
Vincristine 
sulfate 
Marqibo Liposome Egg 
sphingomyelin 
and cholesterol 
Intravenous Acute 
lymphoblastic 
leukaemia 
 
 
The most common type of lipid used is phospholipids because they are commonly found within 
the body cell membranes and their amphiphilic nature.  The formulation that is chosen looks 
at taking advantage of the wide variety of transition temperatures, possible addition of 
cholesterol, zeta potential charge, cost and how saturated the fatty acid tails are which affects 
stability of the formulation of the different lipids (Lasic, 1996).  Transition temperature is when 
the ordered gel phase to the disordered liquid crystalline phase.  When the lipid bilayer is in 
its ordered gel state, its tails are more closely packed and hydrophobically bonded to each 
other which doesn’t allow the bilayer to change or deform, so cannot be worked with.  
However, above the transition temperature the fatty acid tails are more mobile and bent, 
allowing the bilayer to be broken and reformed (Das, 1978).  Highly cationic lipids have been 
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shown to have preferential cell uptake due to being able to electrostatically react with the 
negative cell surface, but may suffer problems with toxicology and have modified behaviour in 
the presence of serum (Alonso and Garcia-Fuentes, 2014).  Highly anionic liposomes 
meanwhile are more readily taken up by macrophages due to scavenger receptors (Coates et 
al., 2011). 
When cholesterol is added to the formulation, the rigid ring system of the cholesterol molecule 
allows less movement within the lipid bilayer, thereby elevating the transition temperature of 
the formulation. This lower membrane fluidity increases the stability of the bilayer in vitro and 
in vivo which is useful for many of the current liposome formulations on the market by 
preventing lipoprotein-induced vesicle destabilisation and release of the drug within at the 
wrong time in the wrong place (Duzgunes, 2005). However, with the right amount of 
cholesterol the drug release can be controlled, a vital part to any drug delivery system 
(Torchilin and Weissig, 2003).    
 
1.3 Carbon nanotubes dispersion, modification and uses 
 
1.3.1 Carbon nanotubes background 
 
Since their discovery back in 1991 by Sumio Iijima (Iijima, 1991), carbon nanotubes have been 
the source of much interest for a wide variety of different areas of science and engineering 
(Zhang et al., 2013, De Volder et al., 2013, Thostenson et al., 2001).  These uses are far 
ranging from chemical sensors (Kong et al., 2000), field emission materials (Tans et al., 1998), 
catalyst support (Planeix et al., 1994), electronic devices (Peng et al., 2014), high sensitivity 
nanobalance for nanoscopic particles (Lucci et al., 2007), nanotweezers (Kim and Lieber, 
1999), reinforcements in high performance composites, and as nanoprobes in meteorology 
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and biomedical and chemical investigations, anode for lithium ion in batteries (Che et al., 
1998), nanoelectronic devices (Zhbanov et al.), supercapacitors (Pan et al., 2010) to hydrogen 
storage (Dillon et al., 1997). 
 
Carbon nanotubes are formed of individual carbon atoms put together into a tube made up of 
benzene rings and can be made up of just one layer or many layers.  It is analogous to 
graphene, although rolled as opposed to a flat sheet.  These tubes can be up to several 
microns in length but are just 1 – 2 nm in width in the case of single walled carbon nanotubes 
(Chen et al., 2014).  For double – walled or multi – walled carbon nanotubes, their width can 
be in the tens of nanometres with a gap between each layer of less than 0.5 nm.  These 
differences in the number of layers is known to effect for example the electrical and stability 
properties of the carbon nanotubes (Asgari and Lohrasbi, 2013).  Figure 1.6 below shows the 
difference between a carbon nanotube surface that is pristine.  This means that no 
modification or defects have occurred.  It also shows the changes that occur when defects 
and modifications are introduced, and this is known as covalent functionalisation. 
 
A) B)  
Figure 1.6: A) A pristine carbon nanotube surface made up of carbon atoms with no defects 
or modification.  This makes these tubes highly hydrophobic. B) A carbon nanotube surface 
post carboxylation, with the carboxyl groups increasing the hydrophilicity of the carbon 
nanotube, and also disrupting the carbon nanotubes surface, affecting its properties. 
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Non – covalent functionalisation can also occur and is shown below in Figure 1.7.  This is 
where the surface remains untouched but instead a surfactant is used which non – covalently 
binds to the surface of the carbon nanotube.  Examples of such surfactants are shown below 
in Figure 1.8. 
 
Figure 1.7 Sodium dodecyl sulfate (SDS) dispersed carbon nanotubes showing the SDS non 
– covalently bound to the carbon nanotube surface, allowing for dispersion in an aqueous 
solution, but no change to the carbon nanotube surface and therefore keeping its properties 
as before. 
 
Figure 1.8: Structures of the three surfactants used in these studies to non – covalently 
disperse the carbon nanotubes.  They are SDS, Sodium dodecylbenzenesulfonate (SDBS) 
and 1-ditetradecanoyl-sn-glycero-3-phosphocholine (MPC). 
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The way these carbon atoms are arranged gives rise to different conformations.  These 
conformations are armchair, zigzag and chiral and are shown below in Figure 1.9 and Figure 
1.10.  The way the carbon nanotube is wrapped is represented by a pair of indices (n, m). The 
integer’s n and m denote the number of unit vectors along two directions in the honeycomb 
crystal lattice (Brischetto et al., 2015).   
 
Figure 1.9: Chirality of carbon nanotubes with either A) armchair B) chiral) or C) zig zag 
conformation.   
 
Figure 1.10: Carbon nanotube conformation showing the A) armchair B) chiral and C) zigzag 
conformations. 
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For the armchair conformation, the two vectors are defined as n = m, for zigzag they are n, 0 
and for chiral they are n, m.  These changes in vectors can cause differences in the 
conductance of the nanotube, its density, its lattice structure, and other properties. For 
example, a carbon nanotube is considered metallic if the value n - m is divisible by three. 
Otherwise, the nanotube is semiconducting (Ganesh, 2013).  What also has a great effect on 
the properties of a carbon nanotube is the extent of the curvature of the carbon nanotube 
relative to a graphene sheet (Jorio et al., 2007).  These effects are dependent on the chirality 
of the carbon nanotube in question.   
 
The length of a carbon nanotube is also known to affect its properties.  For example Russ et 
al. were able to show that long carbon nanotubes were “highly conducting and were suitable 
for electromagnetic interference shielding as well as electrostatic dissipation applications” 
(Russ et al., 2013). The short carbon nanotubes were easier to process and were able to be 
used for electrostatic dissipation applications but were unsuitable for the electromagnetic 
interference shielding.  Wang et al. were able to show that higher thermal and electrical 
conductivities were exhibited with longer multi – walled carbon nanotubes compared to their 
shorter counterparts but the tensile strength was not length dependent (Wang et al., 2013). 
This all shows that length, curvature and therefore width and the chirality of a carbon nanotube 
each effect its properties and therefore it’s potential in a given field. 
Carbon nanotubes do have some properties that are not so useful though, especially for the 
biological field.  Chief of these is its tendency to aggregate and not be miscible with water.  
“Physical approaches using amphiphilic surfactants have proven capable of debundling 
carbon nanotube   bundles   and   stabilizing   individual   tubes   while maintaining their 
integrity and intrinsic properties” (Wang et al., 2004).  With the addition of surfactant, carbon 
nanotubes are able to be broken up into smaller and smaller bundles and even into individual 
tubes, with the surfactant surrounding it.  They work by having both polar and non - polar 
groups which adsorb at the interface two immiscible phases, such as oil and water, air and 
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water or particles and solution (Vaisman et al., 2006).  This acts to reduce the surface tension 
and therefore allow the dispersion in this case of the carbon nanotubes and overcome those 
high van der Waals forces.   
 
1.3.2 Carbon nanotube analysis 
 
The analysis of carbon nanotubes is vitally important and can be done through a variety of 
means including Ultra Violet – Visible – Near infra-red (UV – Vis – NIR) spectroscopy, 
Photoluminescence (PL), X-ray photoelectron spectroscopy (XPS), Raman spectroscopy and 
imaging techniques such as atomic force microscopy (AFM) and transmission electron 
microscopy (TEM) (Rance et al., 2010, Hamilton et al., 2013, Wepasnick et al., 2010, Piao et 
al., 2013, Dresselhaus et al., 2005, Safarova, 2007).  This is because the biodistribution and 
pharmacokinetics of nanoparticles which are affected by many physicochemical 
characteristics such as shape, size, chemical composition, aggregation, solubility surface, and 
fictionalisation (Eatemadi et al., 2014).   
 
Techniques such as UV – Vis – NIR spectroscopy and PL can be used to investigate the 
chirality and structure of the carbon nanotubes.   The chirality and structure of the carbon 
nanotubes is important to know because their band gap can vary from zero to about 2 eV, 
their Youngs modulus and tensile strength can be affected, and their electrical conductivity 
can show metallic or semiconducting behaviour depending on the chirality of the carbon 
nanotube (Bellucci, 2005).  Band gap refers to the energy range in which no electrons can 
exist within a solid.  What this means for carbon nanotube properties is depending on whether 
a carbon nanotube is in the armchair, zig zag or some kind of chiral conformation, the carbon 
nanotube can be referred to as either a metallic or semiconducting carbon nanotube with each 
of the different types having different properties favourable for different electronic applications  
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(Liu and Cheng, 2016).  Youngs modulus and the tensile strength refer to the ability of the 
carbon nanotube to withstand a great amount of stretching and compression in one direction; 
in this case from either end of the tube.  However, this reduces significantly when multiple 
tubes are involved such as with double or multi-walled carbon nanotubes.  Carbon nanotubes 
are also not nearly as strong when pressure is applied across the tube or tubes due to their 
hollow structure.   
XPS and Raman can be used to investigate the surface functionalisation of the carbon 
nanotubes which is an important way of determining how soluble the carbon nanotubes are 
likely to be in water, and how much modification has taken place of the carbon nanotube 
surface due to the addition of extra groups (Tsang et al., 1993). Imaging techniques such as 
AFM and TEM can be used to investigate the size and morphology of the carbon nanotubes.  
The size of a carbon nanotube can affect its application and the morphology, whether it is an 
single - walled carbon nanotube or multi – walled carbon nanotube, affects a number of 
properties including strength, electrical and thermal properties (Sinnott and Andrews, 2001).  
For this work, UV – Vis spectroscopy, PL, XPS, Raman spectroscopy and TEM will all be used 
to investigate the dispersion of the carbon nanotubes, the size of the carbon nanotubes post 
cutting and the chemical makeup of the surface post modification. 
1.3.3 Carbon nanotubes uses today 
 
Carbon nanotubes have been shown to stimulate the body’s immune system.  However the 
reasons for this are not so well known, and there is still a dispute as to whether this stimulation 
is a good thing or a bad thing for the body, and whether this stimulation is something specific 
to the carbon nanotube or simply because the carbon nanotube is seen as a particulate and 
therefore dealt with as such (Fadel and Fahmy, 2014).  Carbon nanotubes properties are 
attractive for the next generation of immunotherapeutic platforms due to their ability to promote 
“efficient proliferation of antigen-specific effector cell populations, enhanced defence against 
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immunoevasive or chronic pathogens, and successful immunisation with limited or minimal 
parenteral administration”.  carbon nanotubes can also be used to present antigens at a high 
density which enhances the immune systems response (Steenblock et al., 2009).  They have 
also been shown to be a good platform to target antigen presenting cells and to translocate 
through the lipid bilayer for priming a cellular immune response (Konduru et al., 2009).  These 
three routes are fluid phase pinocytosis and endocytosis and diffusion.  Finally the tendency 
for carbon nanotubes to activate proinflammatory pathways and trigger the classic 
complement pathway may enhance the antigens proficiency (Demento et al., Rybak-Smith 
and Sim, 2011, Dumortier, 2013).  Liu et al were able to show through (TEM) images confirmed 
that multi walled carbon nanotubes-NH₃⁺ penetrate the cell membranes and are widely 
dispersed in the cell.  The results showed that the multi walled carbon nanotubes-NH₃⁺: DNA 
complexes are able to transfect cells effectively at different charge ratio than naked DNA (Liu 
et al., 2016).   
 
Carbon nanotubes have also been used for various other biological uses as shown in Figure 
1.11 (He et al., 2013a).  Carbon nanotubes can carry drug molecules to the nuclear membrane 
of a cell through the lipid bilayer within inducing a toxic effect.  The drug can either enter 
through the membrane on its own or along with the carbon nanotube carrier, with the latter 
being more effective due to the lack of possible drug degradation of the drug prior to 
internalisation.  Other uses include immunotherapy, cancer therapy, tissue regeneration, 
biological sensors and drug extractors. They have been first proven to be an excellent vehicle 
for drug delivery directly into cells without metabolism by the body (Zhang et al., 2011, He et 
al., 2013a, Al Faraj et al., 2016). Then other applications of carbon nanotubes have been 
extensively performed not only for drug and gene therapies but also for tissue regeneration 
(Veetil and Ye, 2009), biosensor diagnosis (Yang et al., 2015), enantiomer separation of chiral 
drugs (Tanaka et al., 2015) and extraction and analysis of drugs and pollutants (Pan et al., 
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2005).  They have also been found to instigate a specific immune response (Orecchioni et al., 
2014) and act as an inherent adjuvant (Gottardi and Douradinha, 2013). 
 
Figure 1.11: A schematic of the various pharmaceutical applications carbon nanotubes are 
used for (He et al., 2013a).  These include delivery of drugs, tissue regeneration and as 
biosensor vehicles for diagnostics. 
 
1.4 Current methods for the dispersion of carbon nanotubes in water for 
biological systems 
 
1.4.1 Carbon nanotubes dispersed with surfactants 
 
Carbon nanotubes are made up of carbon atoms in a graphite configuration rolled up into a 
tube (Meyyappan, 2004).  These tubes can be concentric to form multi walled carbon 
nanotubes or on their one as single walled carbon nanotubes  (Eatemadi et al., 2014).  These 
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tubes have unique electrical, optical and mechanical properties and have also been shown to 
be useful for drug loading and as potential adjuvants, making them applicable for the biological 
and immunological fields (Peng et al., 2014, Sharma et al., 2015, Liu et al., 2012, Coleman et 
al., 2006, Heister et al., 2012, Tsai et al., 2013, Orecchioni et al., 2014, Fadel and Fahmy, 
2014, Xing et al., 2016, Pondman et al., 2014).  However the major drawback for these uses 
is that carbon nanotubes in their pristine form are practically insoluble (Dyke and Tour, 2004).  
This is due to the very high Van der Waals forces between the carbon nanotubes causing 
them to form large insoluble aggregates when introduced to water (Ansari et al., 2013, 
Zhbanov et al., 2010).  These can be overcome using two different methods; covalent or non-
covalent functionalisation.   
Non-covalent functionalisation works by using an external compound such as SDS, SDBS or 
MPC to non-covalently attach to the carbon nanotube surface, as shown in Figure 1.9 (Yang 
et al., 2013, Fernandes et al., 2015, Dong Wook Chang, 2010, Wu et al., 2006).  This works 
because compounds such as surfactants are amphiphilic.  This means that they have a part 
of the molecule which is hydrophobic and a part which is hydrophilic.  The hydrophobic part 
then interacts with the carbon nanotube surface and the hydrophilic part interacts with the 
water around.  This then solubilises the carbon nanotube with affecting any of the carbon 
nanotubes other properties as this method does not directly affect the carbon nanotube 
structure. 
Various methods of non-covalent functionalisation are used but most follow the same general 
premise.  This being the carbon nanotubes and the dispersal agents are placed in water and 
then sonicated for a period of time.  This disrupts the carbon nanotubes and dispersal agents 
allowing the carbon nanotubes to be solubilised.  Generally, this is then followed by some form 
or centrifugation or filtration or both to remove any carbon nanotube aggregates which can 
cause the samples to reaggregate more quickly than they otherwise would.  This is shown 
below in Figure 1.12 where using this method, neither the structure nor the length of the carbon 
nanotubes is affected during the process. 
62 
 
 
 
 
 
Figure 1.12: A) Method for dispersion of carbon nanotubes using SDS non – covalently so 
no damage to the carbon nanotube surface. B) Method for the dispersion of carbon 
nanotubes using a surfactant and bath sonication.  Carbon nanotubes are placed in water 
with surfactant and then sonicated in a warmed water bath.  These are then centrifuged and 
analysed using UV – Vis – NIR and PL. 
 
1.4.2 Carbon nanotube carboxylation 
 
Functionalisation and cutting of carbon nanotubes are required for bio-medical applications 
such as the loading of proteins and other biological molecules covalently to the surface and 
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increasing the hydrophilicity and decreasing the length of the carbon nanotube, without 
causing obvious toxicity to the cells around.  An example methodology is shown below in 
Figure 1.13. 
A limited number of defects can be tolerated by carbon nanotubes without losing their 
macroscopic electronic and mechanical properties (Balasubramanian and Burghard, 2005, 
Esplandiu et al., 2009, Aziz et al., 2007, Sánchez et al., 2008). In addition, the caps of the 
tubes, forming a hemispherical fullerene, have stronger reactivity than the sidewalls because 
of their higher curvature (Viswanathan et al., 2009, Malhotra et al., 2010). When treated with 
strong oxidizing agents such as nitric acid or sulfuric acid, carbon nanotubes can be opened 
and cut into short tubes (Malhotra et al., 2010, Yang et al., 2009, Munge et al., 2010). 
Moreover, oxygenated functional groups such as carboxylic acid, ketone, alcohol and ester 
groups can be generated by the oxidisation process to the ends and the defect sites of the 
nanotubes (Shamsipur et al., 2010). 
Using the nanotube-bound carboxylic acid groups introduced by oxidisation treatment, further 
functionalisation can be performed via amidation, esterification or the zwitterion (COO-NH3+) 
formation. Before covalent modification, the carboxylic acids are often activated by thionyl 
chloride, carbodiimide [ e.g. N-(3 - dimethylaminopropyl) - N’-ethylcarbodiimide (EDC), N, N’-
dicyclohexylcarbodiimide (DCC)] or N-hydroxysuccinimide (NHS), to get highly reactive 
intermediate groups. Esterification can be achieved by the nucleophilic substitution reaction 
of nanotube carboxylate salt with alkyl halides (Jha and Ramaprabhu, 2010). Various lipophilic  
and  hydrophilic  compounds can then be attached  to carbon nanotubes via amide or  ester 
linkages, which significantly improved the solubility of carbon nanotubes in organic or  
aqueous  solvents (Xu et al., 2008).  These groups could be subsequently removed under 
basic or acidic hydrolysis conditions. 
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Figure 1.13: covalently functionalised carbon nanotube surface with carboxyl groups 
showing the disruption to the carbon nanotube structure and shortening that occurs with the 
addition of acid that causes defects in the carbon nanotube surface that eventually form 
larger defects and cause the carbon nanotube to become cut. 
 
1.4.3 Carbon nanotube cutting 
 
Carbon nanotubes are generally 200 to 5000 nm in length.  However they can be made more 
homogenous and shorter by using a variety of methods including the use of neat acids, 
fluoridation followed by pyrolysis or the use of mechanical energy such as sonication, as 
shown in Figure 1.14 (Ashcroft et al., 2006, Donkor and Tang, 2014, Gao et al., 2015, Ma et 
al., 2013).  All of the methods work on the basis of introducing defects into the carbon nanotube 
surface which can then be further broken and thereby cut the carbon nanotube.  Through 
these methods, carbon nanotubes can be reduced down to the tens of nanometres in length.   
Chen et al were able to form soluble, ultra-short (length < 60 nm), carboxylated, single-walled 
carbon nanotube by a scalable procedure that simultaneously cuts and functionalizes carbon 
nanotubes using a mixture of sulfuric and nitric acids (Chen et al., 2006). This process using 
oleum's (100% H2SO4 with excess SO3) ability to intercalate between individual carbon 
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nanotubes inside carbon nanotube ropes. The solubility of these ultra-short carbon nanotubes 
in organic solvents, super acid and water is about 2 wt %.  Li et al were able to successfully 
cut into different lengths multi walled carbon nanotubes, by controlling H2SO4/HNO3 (5:3) 
oxidation time (Li and Zhang, 2006). During the cutting process H2SO4 and HNO3 were added 
independently and the oxidation processes were carried out at a lower temperature to avoid 
excess weight loss and damage to carbon nanotube. The resulting shorted carbon nanotubes 
formed stable dispersions in the polar solvents without the help of surfactants that provided 
possibility for further functionalisation and application.  Ziegler et al however were able to use 
slightly different solutions to try and get a more controlled cutting and functionalisation.  The 
oxidation reaction of piranha solutions, a mixture of sulfuric acid and hydrogen peroxide, with 
purified HiPco carbon nanotubes was measured as a function of temperature (Ziegler et al., 
2005a). At high temperatures, piranha is capable of attacking existing damage sites, 
generating vacancies in the graphene sidewall, and consuming the oxidised vacancies to yield 
short, cut nanotubes. Increased reaction time results in increasingly shorter nanotubes. 
However, significant sidewall damage occurs as well as selective cutting of the smaller 
diameter nanotubes. On the other hand, room-temperature piranha treatments show the 
capability of cutting existing damage sites with minimal carbon loss, slow cut rates, and little 
sidewall damage. Combined with a method of introducing controlled amounts of damage sites, 
these room-temperature piranha solutions have the potential to yield an efficient means of 
creating short, cut nanotubes.  They were also able to run room-temperature piranha and 
ammonium persulfate solutions and show their ability to exploit the damage sites and etch 
single walled carbon nanotubes in a controlled manner. Despite the aggressive nature of these 
oxidizing solutions, the cut rate for carbon nanotubes is relatively slow and almost no new 
sidewall damage is introduced (Ziegler et al., 2005b). 
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Figure 1.14: Cutting and functionalisation of carbon nanotubes using both covalent and non-
covalent functionalisation methods.  These use either harsh acids or mechanical power to 
cause defects in the carbon nanotube surface in such a way that causes bigger and bigger 
defects to occur that eventually results in the cutting of the carbon nanotube into shorter 
pieces. 
 
1.4.4 Carbon nanotube separation 
 
Once the carbon nanotubes have been cut, there remains the problem of presence the large 
variation in carbon nanotubes lengths including very small fragments of carbon.  It is therefore 
important that there is some method of removing the very small and very large particles so to 
give the best chance of finding out what effect the ultra-short carbon nanotubes can have.  
These methods broadly separate into two.  The first is using density gradient ultra-
centrifugation, normally with iodixanol as a density gradient medium.  For example, Fagan et 
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al were able to perform separation of single-wall carbon nanotube by length via centrifugation 
in a high density medium, in this case iodixanol.  They also found that the distribution width 
was coupled to the rate of the separation. Less rapid separation was shown to produce 
narrower distributions (Fagan et al., 2008). 
 
The second approach is using HPLC to separate the carbon nanotubes along a column and 
then take set amounts at the end for each size sample. Yang et al were able to perform 
purification and length separation of oxidatively shortened single-walled carbon nanotubes by 
size exclusion chromatography (SEC) without assistant reagents for dispersion using a PL 
aqua gel - OH column (300mm×7.5 mm). Almost all the carbonaceous impurities, such as 
carbonaceous particles, graphene fragments, were removed from the oxidatively shortened 
nanotubes materials. The short carbon nanotubes were separated into fractions according to 
nanotube lengths, and the length distribution of each fraction was relatively narrow (Yang et 
al., 2005).  Liu et al were also able to perform size exclusion chromatography using size-
exclusion columns (COSMOSIL carbon nanotube, Nacalai Tesque Inc). They used two types 
of columns (dimension: 7.5 mm × 300 mm, pore size: 300 and 1,000 Å) connected in series to 
separate both samples. Dispersed DNA – carbon nanotube solutions were filtrated through a 
0.22-μm membrane and loaded (∼0.5 ml) onto the column series. The hybrid was eluted with 
pH 7.0 buffer containing 40 mM Tris, 0.5 mM Ethylenediaminetetraacetic acid (EDTA) and 
0.2 M NaCl (Liu et al., 2013). 
 
 
 
 
68 
 
1.5 Previous liposome – carbon nanotube work 
 
1.5.1 Nano-trains 
 
Some previous work on carbon nanotube – liposome complexes has already been done.  For 
example, Miyako et al. were able to formulate what they called carbon nanotube – liposome 
supramolecular nanotrains formed of carbon nanotubes coated in avidin – polyethylene glycol 
(PEG2000) and then covered in temperature sensitive liposomes loaded with biotin and N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl) dioleoyl phosphatidylethanolamine (NBD – F) (Miyako et al., 
2012). 
They have also been investigated where again liposomes are loaded onto carbon nanotubes 
with a drug loaded into the liposomes for drug delivery.  In this case, multiple different drugs 
were loaded so as to deliver more than one agent at a time and so lead towards a more 
personalised medicine (Karchemski et al., 2012). 
 
Another type of carbon nanotube – liposome complex was shown by Kim et al. where they 
formulated superlattices of carbon nanotubes and cationic liposomes which helps “provide a 
new insight into the interactions of functionalised carbon nanotubes in lipid membranes, which 
are essential for the biological or biomedical applications of carbon nanotubes such as drug 
delivery” (Kim et al., 2012). 
 
1.5.2 Porins 
 
Carbon nanotube porins are lengths of carbon nanotube that are short enough, generally sub 
10 nm, to be inserted into the pore of a cell or liposome.  These are then used for a variety of 
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reasons including investigating ultra-fast proton transport, the transport of other ions and 
uncharged particles and investigating bacterial porins through mimicking their structure using 
the carbon nanotube porins (Tunuguntla et al., 2017, Tunuguntla et al., 2016, Kim et al., 2014, 
Tran et al., 2016, Garcia-Fandino and Sansom, 2012).  For example, Tunuguntla et al were 
able to show that carbon nanotube porins represent a “versatile nanopore building block for 
creating higher-order functional biomimetic materials”.  They also showed that by using a 
combination of UV – Vis spectroscopy, Raman and DLS can be used to monitor the quality 
and progress of the carbon nanotube porin synthesis.  Kim et al were able to show carbon 
nanotube porins can be used to transport and investigate the transport of ions and uncharged 
species through carbon nanotube porins embedded in a bilayer.  Garcia – Fandino et al were 
able to design a set of cation – selective nanopores allowing to stress test” the understanding 
of design principles of nanopores and channels. 
 
1.6 Bioruptor® applications 
 
1.6.1 The need for a cheap and fast method of internally validating 
optimised sonication conditions 
 
Currently to determine sonication efficiency, DNA shearing is used as the validation tool.  It is 
robust method but is both expensive and time consuming.  Therefore, a new method is 
required to reduce the cost and time taken whilst still maintaining the robustness of the DNA 
shearing method.  Previous methods include chemical reactions (Kimura et al., 1996), elastic 
sphere Radiometry (Hasegawa and Yosioka, 1969), aluminium foil erosion (Pugin, 1987), 
calorimetric and optical methods (Majumdar et al., 1998, Kimura et al., 2007, Zieniuk and 
Chivers, 1976)  and thermoprobes (Pugin, 1987).Previous work has shown how a 
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sonochemical reaction can be used to help placement of tubes within a sonication bath to best 
maximise efficiency using the potassium iodide coupled with ammonium molybdate reaction 
(Nascentes et al., 2001).  The energy of ultrasound is not uniformly available from the 
ultrasonic bath. Only a small fraction of the total liquid volume in the immediate vicinity of the 
ultrasound source experiments the effects of cavitation. The intensity of ultrasound is 
continuously attenuated by the molecules present in the liquid due to various cohesive forces 
acting on the liquid (Majumdar et al., 1998). The ultrasonic intensity profile in the baths 
depends entirely on the design and location of the transducers. For commercially available 
ultrasonic baths a variety of transducers with different configurations are used (Mason, 1996).  
 
1.6.2 The need for a new version of the Diagenode (Bioruptor® Pico) 
Formalin-Fixed Paraffin-Embedded (FFPE) DNA kit to increase 
profitability  
 
There are four commonly used extraction procedures for DNA extraction (Hoff-Olsen et al., 
1999), 
1.  Organic extraction that uses liquid chemicals to produce clean high yield DNA although is 
very labour intensive (Moré et al., 1994). 
2.  Inorganic silica which uses just a one-tube extraction process to yield single stranded DNA 
(Walsh et al., 1991, Debra A. Dederich, 2002) 
3.  Solid phase extraction methods binding to beads made of compounds such as silica.  Such 
kits include the Promega’s DNA IQ (Eminovic et al., 2005), Applied Biosystems’ PrepFiler 
(Brevnov et al., 2009) and Qiagen’s QIAamp kits  (Sefers et al., 2006). 
4.  Differential extraction: a multistep process used to separate sperm from other cells; used 
for analysing biological evidence from sexual assault cases (Vuichard et al., 2011) 
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Diagenode has developed and sold a kit for FFPE DNA extraction which is a silica-columns 
based purification approach (Diagenode). The first step in FFPE DNA extraction workflow is a 
paraffin removal. Traditional methods use toxic organic solvents (xylen or similar) followed by 
gradual rehydration of samples in ethanol solutions (from 100% EtOH down to 20%).  
Xylen and ethanol steps are replaced by short sonication (Bioruptor®) of FFPE slices using 
FFPE extraction buffer in Diagenode protocol. This results in a paraffin emulsification (milky 
solution) that can be directly used in next steps.  Proteinase K digestion to digest proteins and 
release DNA and then reversal of crosslinks (heating at 65°C).  Sample filtration through 
DiaFilter columns to remove particles which may interfere with columns based DNA 
purification and DNA purification using silica-columns.  This works very well as shown with the 
work by Bak et al (Bak et al., 2016).  Using the kit they were able to propose that simple 
Polymerase chain reaction (PCR)-based quality control experiments at the genetic and DNA 
methylation level can be used for the best-performing FFPE samples. The apparent 
preservation of genetic and DNA methylation patterns in archival FFPE samples may be able 
to be used to identify genetic and epigenetic changes associated with brain-manifested 
diseases. 
The production cost of the kit is quite high resulting in a very limited profitability but Diagenode 
wants to keep FFPE solution in its portfolio. At the time, Diagenode commercializes MicroChIP 
DiaPure columns/buffers   which are very similar to the columns/buffers used in DNA FFPE 
kit.  
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1.7 Aims and objectives for this work 
 
The aim of this work was to formulate a new liposome – carbon nanotube complex using the 
Bioruptor Bath sonication systems for vaccine and drug delivery development.  The first 
objective of this work was to create liposome formation protocols for the Bioruptor bath 
sonication systems that would be comparable to other methods such as probe sonication and 
extrusion.  These would have to be comparable or better in the speed of liposome size 
reduction, how small the liposomes are that are formed and the volume of liposomal solution 
that could be formed in a certain period of time.  A number of different Bioruptor bath sonication 
systems were available and had a number of advantages and disadvantages which are shown 
below in Table 1.2.  The second objective was to further investigate the sonication systems 
themselves and look into how they could be more efficiently used and look at new and cheaper 
ways of testing the machines output.  The third objective was to investigate the current 
Bioruptor bath sonication systems to see if they could be used for carbon nanotube dispersion 
in water and if a biologically safe surfactant could be used instead of the standard SDS and 
SDBS.  The final objective was to investigate covalently functionalizing the carbon nanotubes 
to make them hydrophilic without the need for a surfactant.  This same process would be 
investigated to see whether it could be used to cut the carbon nanotubes in length down from 
microns in length to a few hundred nanometres or less.  These would then be added to a 
liposome solution and sonicated to see how the two entities would interact. 
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Table 1.2: Advantages and disadvantages or each Bioruptor machine used in the formation 
and optimisation of the liposome size reduction protocols. 
 
Bioruptor Machine Advantages Disadvantages 
Bioruptor XL • Can sonicate a range of 
volumes (0.1 mL up to 3 
mL) allowing for a range of 
laboratory uses 
• 4 possible power outputs 
• Old model (not on the 
market) 
Bioruptor Standard • Can sonicate a range of 
volumes (0.1 mL up to 3 
mL) allowing for a range of 
laboratory uses 
• 3 possible power outputs 
• Old model (not on the 
market) 
Bioruptor Plus • Currently on the market 
• Can sonicate a range of 
volumes (0.1 mL up to 3 
mL) allowing for a range of 
laboratory uses 
• More powerful machine 
(40 kHz) 
• Only two power outputs 
available 
Bioruptor Pico • Currently on the market 
• Small sample volumes 
(down to 0.01 mL) allows 
for high throughput, low 
volume experiments 
• More powerful machine 
(40 kHz) 
• Unable to sonicate large 
volumes (0.5 mL plus)  
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2 Formation and optimisation of the process of 
reducing liposome size through bath sonication using 
the Bioruptor® bath sonicator systems 
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2.1 Aims and objectives 
 
Previous work has focussed on using a probe sonicator to reduce the liposome size from the 
micron level to the nano level.  This is important as smaller liposomes give a more 
homogeneous size mix which allows for a more homogeneous drug or vaccine concentration 
spread through the volume.  This also allows for liposomes to be formed below 100 nm in 
diameter which is important especially for drug delivery.  This is because below 100 nm, 
liposomes effectively hide from the immune system due to their size.  They cannot be too 
small though as many delivery components are stored in the hydrophilic core of the liposome 
and if they are made too small, this core reduces in size too much, reducing the carrying 
capacity significantly.   
For vaccines, the size of the liposome is less important as the antigen the liposome is 
delivering is meant to be found and used by the immune system.  It is still important to try and 
achieve a small and consistent size range, however, to ensure a more homogeneous spread 
of the vaccine; this cannot be achieved through the use of MLVs formed through the lipid film 
hydration method, as they are extremely heterogeneous in size and as such have a very large 
PDI value.  Also, the use of SUV as opposed to MLV allows for a more even dispersion of the 
payload as the drug or antigen or other component only has to translocate over one lipid 
bilayer and not several. 
Therefore, the aim of this work is to formulate protocols using the various Bioruptor® bath 
sonicator systems to reduce liposome size effectively and consistently.  The objectives of this 
work were first of all to create a protocol for reduction of DMPC and DMPC: Cholesterol 
liposomes using a probe sonicator and compare also to a high shear mixer; a different 
technique.  The Bioruptor® systems were then investigated in turn to see how effective they 
are at reducing the liposome size compared to each other and to the probe sonicator.  These 
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systems were also investigated to create protocols for reducing liposome size over a variety 
of lipids, volumes and other factors.   
2.2 Materials and Methods 
 
2.2.1 Lipid Film Hydration Method for the production of MLV 
 
MLVs were prepared by the lipid hydration method. Weighed amounts of the required lipids 
were each dissolved in chloroform/methanol (9:1 v/v). These lipids were added together to a 
final concentration of either 8 mM DMPC or DMPC in combination with cholesterol 6:4 mM, 6: 
2mM and 4: 4mM respectively.  The organic solvent was extracted using a roto-evaporator 
followed by flushing with N2 to form a thin lipid film on the bottom of a round bottom flask. The 
lipid film was hydrated using 10 mM Tris or Phosphate Buffered Saline (PBS) buffer at pH 7.4 
and at ~ 20 ˚C above the transition temperature for the main lipid in the formulation. 
 
2.2.2 Formulation of size reduced liposomes using probe sonication 
 
For each liposome formulation, the particle size was reduced using a sonication probe. The 
suspension of MLV was sonicated (at 10 amplitude for 6 minutes) using a titanium probe (MSE 
Soniprep 150 plus with MSE PG100 probe (UK)) slightly immersed into the solution. This 
sonication procedure causes the breaking of the lipid bilayer of liposomes, converting a slightly 
milky suspension of MLV into a clear suspension of size reduced liposomes. They were the 
placed in a centrifuge for 15 minutes at 25°C at 1393g (2500 revolutions per minute (RPM).  
These vesicles were characterised for their size, PDI and zeta potential.  
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The amplitude level was then tested to see whether this would affect liposome size.  An MLV 
liposome formation using DMPC of 8 mM was produced.  The milky suspension was then 
placed in a small vial and sonicated at two different amplitude levels, 8 and 10 amplitude, for 
a total of 10 minutes each.  A sample was taken at 1 minute and at every minute after that 
until the 10-minute limit had been reached.  These were then analysed for their size and PDI. 
Next the sonication time was tested.  This time, 3 formulations were produced at either 8 mM 
DMPC or DMPC in combination with cholesterol 6:2 mM and 4:4 mM respectively.  The milky 
suspension was then placed in vials and sonicated for a total of 10 minutes each.  A sample 
was taken at 1 minute and at every minute after that until the 10-minute limit had been reached.  
These were then analysed for their size and PDI. 
Concentration was also investigated to see whether this made a significant difference to 
liposome size reduction.  An MLV liposome formation using DMPC of between 2 and 30 mM 
was produced for each concentration. The milky suspension was then placed in vials and 
sonicated for a total of 6 minutes each at 10 amplitude. They were the placed in a centrifuge 
for 15 minutes at 25°C at 2500rpm.  These were then analysed for their size and PDI. 
Finally, the optimised settings of 10 amplitude for 6 minutes at 8 mM were ran.  3 formulations 
were produced using the above formulation method at either 8 mM DMPC or DMPC in 
combination with cholesterol 6:2 mM and 4:4 mM respectively. For each liposome formulation, 
the optimised method was used where the particle size was reduced using a sonication 
procedure. The suspension of MLV was sonicated at 10 amplitude for 6 minutes using a 
titanium probe (MSE PG100 probe) slightly immersed into the solution. They were the placed 
in a centrifuge for 15 minutes at 25°C at 2500rpm.  These vesicles were characterised for their 
size, PDI and zeta potential.  
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2.2.3 Formulation of size reduced liposomes by the high shear mixing 
(HSM) homogenisation method studies 
 
DMPC and DMPC: Cholesterol 6:2 MLV were formed using the lipid film hydration method 
and then Tris buffer (10 mM; pH 7.4) was added to the lipid film, which was then placed and 
mounted in a 60°C water bath on a Jenway 1000 hotplate and stirrer (UK). The use of a 
Heidolph silent crusher M (Germany) was used at a range of speeds (5,000, 10,000, 15,000, 
20,000 and 25,000 rpm) and time (5 minutes increments up to 30 minutes). These vesicles 
were characterised for their size and PDI. 
 
2.2.4 Formulation of size reduced liposomes using Bioruptor® XL 
studies 
For each liposome formulation, the particle size was reduced using a bath sonicator 
Diagenode Bioruptor® XL (Belgium).  Firstly, MLVs were made as part 2.1 states with DMPC 
and DMPC: Cholesterol 6: 2 formulations being made for investigation.  
For the time experiment, DMPC and DMPC: Cholesterol 6:2 liposomes were produced using 
the Bioruptor® XL at 45°C using 1000 µL in 1.5 mL tubes.  They were then sonicated at power 
M2 for different periods of time with various cycles.  Each cycle had a 30 second delay before 
the next cycle began, and a 30 second delay at the end of each measurement was used too.  
These vesicles were characterised for their size and PDI. 
For the power experiment, DMPC and DMPC: Cholesterol 6:2 liposomes were produced using 
the Bioruptor® XL at 45°C using 1000 µL in 1.5 mL tubes.  They were then sonicated for 15 
minutes of continuous sonication with a 30 second delay at the end, at the 4 different power 
levels of Low (L), Medium Low (M1), Medium High (M2) and High (H).  These vesicles were 
characterised for their size and PDI. 
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For the volume experiment, DMPC and DMPC: Cholesterol 6:2 liposomes were produced 
using the Bioruptor® XL at 45°C using different volumes ranging from 100 to 1000 µL in 1.5 
mL tubes.  They were then sonicated at power level M2 for 15 minutes of continuous sonication 
with a 30 second delay at the end. These vesicles were characterised for their size and PDI. 
For the concentration experiment, DMPC liposomes were produced using the lipid hydration 
method.  Using the Bioruptor® XL, the samples were sonicated at 45°C using 300 µL in 1.5 
mL tubes.  They were sonicated at power level M2 for 15 minutes of continuous sonication 
with a 30 second delay at the end.  These vesicles were characterised for their size and PDI. 
 
2.2.5 Formulation of size reduced liposomes using Bioruptor® Standard 
studies 
 
For each liposome formulation, the particle size was reduced using a bath sonicator 
Diagenode Bioruptor® Standard (Belgium). Firstly, MLVs were made as part 2.1 states with 
DMPC and DMPC: Cholesterol 4: 4 formulations being made for investigation. 
For the power experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were produced using 
the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  They were then sonicated for 
15 minutes of 30, 30 at the 3 different power levels of L, M and H. These vesicles were 
characterised for their size and PDI. 
For the second power experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were 
produced using the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  They were 
then sonicated for 15 minutes of 30, 0 at the 3 different power levels of L, M and H. These 
vesicles were characterised for their size and PDI. 
For the pulse experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were produced using 
the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  They were then sonicated for 
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15 minutes at power level L with a reduction in time off of 5 seconds per experiment from 30, 
30 to 30, and 0. These vesicles were characterised for their size and PDI. 
For the time experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were produced using 
the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  They were then sonicated at 
power M for different periods of time up to 15 minutes.  Each cycle was 30 seconds on, 30 
seconds off cycle. These vesicles were characterised for their size and PDI. 
For the further time experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were produced 
using the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  They were then 
sonicated at power M for different periods of time from 15 to 30 minutes.  Each cycle was 30 
seconds on, 0 seconds off cycle. These vesicles were characterised for their size and PDI. 
For the volume experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were produced 
using the Bioruptor® Standard and then sonicated for 15 minutes of 30, 0 at the power level 
M.  The volume was tested between 100 µL and 1000 µL in 1.5 mL tubes. These vesicles 
were characterised for their size and PDI. 
For the next volume experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were produced 
using the Bioruptor® Standard and then sonicated for 15 minutes of 30, 0 at the power level 
M.  The volume was tested between 0.5 and 3 mL in 15 mL tubes. These vesicles were 
characterised for their size and PDI. 
For the position experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were produced 
using the Bioruptor® Standard and then sonicated for 15 minutes of 30, 0 at the power level 
M.  Each position in the holder was assigned an arbitrary number between 1 and 6 and each 
ran 3 times to compare how much variability there was in the same position over multiple tests 
and between the 6 different positions available. These vesicles were characterised for their 
size and PDI. 
For the temperature experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were produced 
using the Bioruptor® Standard using 300 µL in 1.5 mL tubes.  They were then sonicated for 
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15 minutes of 30, 0 at the power level M.  The temperature was tested in 5 degree increments 
between 5 and 50 °C.  These vesicles were characterised for their size and PDI. 
The next few tests all involved using a Polypropylene (PP) tube instead of the previously 
provided Polytetrafluoroethylene (PTFE) tubes to see what difference the plastic choice 
makes.  For the power experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were 
produced using the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL PP tubes.  They were 
then sonicated for 15 minutes of 30, 30 at the 3 different power levels of L M, and H. These 
vesicles were characterised for their size and PDI. 
For the time experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were produced using 
the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL PP tubes.  They were then sonicated 
at power M for different periods of time.  Each cycle was 30 seconds on, 30 seconds off cycle. 
These vesicles were characterised for their size and PDI. 
For the small volume experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were 
produced using the Bioruptor® Standard and then sonicated for 15 minutes of 30, 0 at the 
power level M.  The volume was tested between 100 µL and 1000 µL in 1.5 mL PP tubes. 
These vesicles were characterised for their size and PDI. 
For the larger volume experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were 
produced using the Bioruptor® Standard and then sonicated for 15 minutes of 30, 0 at the 
power level M.  The volume was tested between 0.5- and 2-mL PP tubes. These vesicles were 
characterised for their size and PDI. 
For the formulation experiment, 6 formulations were investigated. DMPC, DMPC: Cholesterol 
4:4, Phosphatidylcholine (PC): Cholesterol 4:4, DSPC: Cholesterol 4:4, DMPC: Cholesterol: 
1, 2-Dimyristoyl-Sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DMPG) 4:4:1 and DMPC: 
Cholesterol: N-[1-(2, 3-Dioleoyloxy) propyl]-N, N, N-trimethylammonium chloride (DOTAP) 
4:4:1 liposomes were produced using the Bioruptor® Standard and then sonicated for 15 
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minutes of 30, 0 at the power level M with a 100 µL volume in a 1.5 mL TPX®® tube. These 
vesicles were characterised for their size, PDI and zeta potential. 
 
2.2.6 Formulation of size reduced liposomes using Bioruptor® Plus 
studies 
 
For each liposome formulation, the particle size was reduced using a bath sonicator 
Diagenode Bioruptor® Plus (Belgium). Firstly, MLVs were made as part 2.1 states with DMPC 
and DMPC: Cholesterol 4: 4 formulations being made for investigation.  All samples unless 
stated otherwise were sonicated in a TPX® tube. 
For the cycles experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were produced using 
the Bioruptor® Plus using 100 µL in 1.5 mL tubes.  They were then sonicated for up to 30 
cycles in 5 cycle increments at H power or L power. These vesicles were characterised for 
their size and PDI. 
For the concentration experiment, DMPC liposomes were produced using the Bioruptor® Plus 
using 100 µL in 1.5 mL tubes using 8, 16- and 24-mM concentrations, sonicated for 15 cycles 
at the H power level. These vesicles were characterised for their size and PDI. 
For the temperature experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were produced 
using the Bioruptor® Plus using 100 µL in 1.5 mL tubes.  They were then sonicated for 15 
cycles at L and H power levels.  The temperature was tested in at 20, 30 and 40 °C. These 
vesicles were characterised for their size and PDI. 
For the small volume experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were 
produced using the Bioruptor® Plus and then sonicated for 15 cycles at H power level.  The 
volume was tested between 100 µL and 300 µL in 1.5 mL TX tubes. These vesicles were 
characterised for their size and PDI. 
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For the small volume plastics experiment, DMPC liposomes were produced using the 
Bioruptor® Plus and then sonicated for 15 cycles at H power level using a 100 µL sample in 
either a TPX® or PP 1.5 mL tube. These vesicles were characterised for their size and PDI. 
For the largest volume plastics experiment, DMPC liposomes were produced using the 
Bioruptor® Plus and then sonicated for 15 cycles at H power level using a 0.5, 1 or 2 mL 
sample in either a TPX®, Polycarbonate tubing (PCT), Polypropylene Co-polymer (PPCO) or 
PP 50 mL tube. These vesicles were characterised for their size and PDI. 
For the larger volume plastics experiment, DMPC liposomes were produced using the 
Bioruptor® Plus and then sonicated for 15 cycles at L and H power levels using a 100 or 500 
µL sample in either a TPX® or PP 15 mL tube. These vesicles were characterised for their 
size and PDI. 
For the larger cholesterol ratio experiment, DMPC: Cholesterol liposomes were produced 
using the Bioruptor® Plus in 4:4, 5:3, 6:2 and 7:1 ratio and then sonicated for 15 cycles at L 
and H power levels using a 100 µL sample in a TPX® 1.5 mL tube. These vesicles were 
characterised for their size and PDI. 
For the lipid concentration test, DMPC: Cholesterol 4:4 liposomes were produced with either 
0, 1, 2 or 4 mM of either 1, 2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), DOTAP or 
DMPG added.  These were sonicated for 15 cycles at H power using a 100 µL sample in a 
TPX® 1.5 mL tube. These vesicles were characterised for their size, PDI and zeta potential. 
 
2.2.7 Formulation of size reduced liposomes using Bioruptor® Pico 
studies 
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For each liposome formulation, the particle size was reduced using a bath sonicator 
Diagenode Bioruptor® Pico (Belgium). Firstly, MLVs were made as part 2.1 states with DMPC 
and DMPC: Cholesterol 4: 4 formulations being made for investigation. 
For the cycles experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were produced using 
the Bioruptor® Pico using 100 µL in 1.5 mL tubes.  They were then sonicated for up to 10 
cycles. These vesicles were characterised for their size and PDI. 
For the small volume experiment, DMPC and DMPC: Cholesterol 4:4 liposomes were 
produced using the Bioruptor® Pico and then sonicated for 10 cycles.  The volume was tested 
between 100 µL and 300 µL in 1.5 mL TX tubes. These vesicles were characterised for their 
size and PDI. 
 
2.2.8 Characterisation of liposomes 
 
The liposomes were then characterised using a Brookhaven Nanobrook (USA).  A 100 µL 
sample was placed in a 4 clear sided cuvette.  1.9 mL of deionised water was added and the 
sample vortexed to ensure thorough mixing.  The sample was then allowed to stand for a few 
minutes, and then placed in the machine.  Each of the three batches was ran three times and 
the average and standard deviation calculated for both the size and PDI once outliers had 
been removed. 
 
2.3 Results and discussion 
2.3.1 A probe sonication study into liposome size reduction 
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Probe sonication was the first method to be investigated as it is very well established within 
the literature.  Probe sonication has been used to reduce the size of liposomes since their first 
conception back in the 60s.  Since then, hundreds of papers have been published using probe 
sonication as the means for reducing liposome size after initial formation using the lipid film 
hydration method.  For example, compared to other methods such as extrusion and 
microfluidics, there has been consistently more papers published decade on decade using 
sonication than either of these two methods, as shown in Figure 2.1.  This shows that this 
method is well used and well known within the scientific domain.  This is due to a number of 
factors including how easy it is to use the equipment with no special skills required and how 
quick it reduces the liposomes size, generally within just a couple of minutes.  Probe sonication 
far outweighs bath in number of publications with 376 publications specifying probe sonication 
for liposome work but only 70 specifying bath sonication.  This again is due to how quick the 
probe reduces liposome size compared to a bath sonicator.  Therefore, the probe sonicator is 
a good place to start and it is important to get a good baseline for comparison to the bath 
sonicator protocols that are later going to be formulated and optimised.   
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Figure 2.1: Number of publications for microfluidics, sonication and extrusion for liposome 
formation using the name of the method and the word liposome in their titles on all databases 
on web of science.  
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2.3.1.1 Initial probe sonication study 
 
Initial experiments were run to form MLV by the lipid hydration method and then forming size 
reduced liposomes by sonication using DMPC and DMPC Cholesterol in a 6: 4 ratio.  These 
results are shown below in Table 2.1.  It was found that MLV liposomes were in the order of 
several microns, whereas once they had been sonicated and centrifuged under the initial 
conditions, they were much smaller with DMPC liposomes forming a size of 81.6 ± 5.9 nm and 
DMPC: Cholesterol 6:4 being 136 ± 30.5 nm.  A reduction in PDI was also noted, with drops 
to 0.272 ± 0.014 for DMPC, and 0.307 ± 0.095 for DMPC Cholesterol 6:4.  For the sonication 
method, a PDI of below 0.3 is seen as an acceptable PDI.  For other methods such as 
extrusion and microfluidics, a lower PDI of below 0.15 can be achieved meaning the liposomes 
formed using these methods are more homogenous than those formed using sonication 
methods.  The zeta potential for these lipids was also found to get more negative once they 
had been sonicated. 
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Table 2.1: Initial experimental results for DMPC and DMPC Cholesterol 6:4 using the lipid 
hydration and sonication methods. 
 
FORMULATION SIZE 
REDUCED/MLV 
Z AVERAGE SIZE 
(D. NM) 
AVERAGE ZETA 
POTENTIAL / MV 
PDI 
DMPC MLV 4713 ± 2412 -7.86 ± 12.1 0.344 ± 
0.067 
DMPC Size reduced 81.6 ± 5.93 -17.6 ± 15.6 0.272 ± 
0.014 
DMPC: 
CHOLESTEROL 
MLV 3321.5 ± 887.2 -1.36 ± 1.01 0.727 ± 
0.198 
DMPC: 
CHOLESTEROL 
Size reduced 135.97 30.47 -30.1 ± 10.1 0.307 ± 
0.095 
 
 
2.3.1.2 Probe sonication study into how amplitude level and time 
affects liposome size reduction 
 
The level of sonication afforded to the liposomes with two different levels, 10 amplitude and 8 
amplitude, being used was tested first.  These showed very little difference in how long they 
took to form the size reduced liposomes, or how small the size reduced liposomes were, up 
until 8 minutes as shown in Figure 2.2.  There was no significant difference shown between 3 
and 7 minutes for the 8 amplitude size data and between 5 and 7 minutes for the 10 amplitude 
data.  The smallest size achieved for 8 amplitude was at 7 minutes being 112.8 ± 23.8 nm and 
88.9 + 2.1 nm for 10 amplitude. After that, a significant increase in the size seen was noted 
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with both amplitudes, between 8 and 9 minutes for 8 amplitude using a t test with a p value of 
< 0.0001 and between 9 and 10 minutes for 10 amplitude with a p value of 0.0026.  Although 
this is unclear why, it could be down to the liposomes being broken up and forming larger 
constructs or by being attacked by the free radicals that are formed (Maulucci et al., 2005).  
These results also showed that once the liposomes had been sonicated, a lower PDI was also 
found. However no significant difference was seen between any of the 8 amplitude PDI apart 
from between 1 and 8 minute marks with a p value of 0.0381.  With the 10 amplitude data, 
significant differences were only seen between the 1 minute mark and several other time 
points, and between the 10 minute mark and several other time points.  What this showed was 
that the PDI was decreased once sonicated was applied to the sample, but this would increase 
and decrease over time and not in a uniform pattern.  This could be because as the liposomes 
are broken and reformed, the PDI of the mixture increases and decreases with this process. 
It also showed that although there wasn’t a significant difference between the size of 
polydispersities at 6 minutes between 8 and 10 amplitude, the tenfold increase in standard 
deviation seen with 8 amplitude compared to 10 amplitude showed that for a more consistent 
size, it is better to use 10 amplitude.  The results for the 10 amplitude size were also lower, 
although not significantly so, compared to the 8 amplitude size data. 
Overall what this shows is that the amplitude of sonication does not have a significant effect 
on the size of PDI of liposomes produced at the same time point.  What this data did show 
was that by decreasing the amplitude, an increase in relative standard deviation was seen.  It 
also showed that by sonicating for 6 minutes, this would allow for as small a size as possible 
to be achieved without the risk of over sonicating the sample and starting to break it down, 
thereby increasing the size result. 
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Figure 2.2: A and B) Size of probe sonicated DMPC liposomes sonicated over 10 minutes with 
samples taken every minute at either 8 (A) or 10 (B) amplitude.  C and D) PDI of probe 
sonicated DMPC liposomes sonicated over 10 minutes with samples taken every minute at 
either 8 (A) or 10 (B) amplitude.   
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2.3.1.3 Probe sonication study into how cholesterol concentration 
affects liposome size reduction 
 
Following this, 3 different formulations were then tried over a 10 minute period at 10 amplitude 
to see if the different formulations could require different sonication times.  Each formulation 
was showed that once a sonication time of 6 minutes had been reached, a small and 
consistent size and a smaller PDI was seen, as shown in Figure 2.3.  Also, at the 6 minute 
mark, there is a significant difference between the sizes seen for DMPC compared to its DMPC 
Cholesterol counterparts.  DMPC: Cholesterol 6:2 and DMPC: Cholesterol 4:4 showed no 
significant difference.  This showed that the size of the DMPC liposomes being produced were 
significantly smaller than their DMPC: Cholesterol counterparts and that although a different 
sonication time wouldn’t be needed for the different formulations, that the DMPC: Cholesterol 
liposomes produced are significantly bigger than the DMPC liposomes. 
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Figure 2.3: A – C) Size of 3 different formulations; DMPC (A), DMPC: Cholesterol 6:2 (B) and DMPC: Cholesterol 4:4 (C) sonicated over a 10 
minute time period at 10 amplitude. D - F) PDI of 3 different formulations; DMPC (D), DMPC: Cholesterol 6:2 (E) and DMPC: Cholesterol 4:4 (F) 
sonicated over a 10 minute time period at 10 amplitude. 
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2.3.1.4 Probe sonication study into how concentration affects DMPC 
liposome size reduction 
 
Concentration is also an important factor to test as a concentration change will affect the 
number of liposomes in any given volume and change factors such as viscosity and how much 
energy each individual liposome will receive in order to be broken down and reformed into the 
smaller liposomes.  The results showed in Figure 2.4 showed no significant difference between 
2 and 8 mM of with sizes all around 85 nm.  There was a significant increase for 20 mM of 
116.6 ± 1.7 nm and 30 mM of 120.4 ± 2.5 nm. There were statistically significant differences 
for PDI but no increase above 0.3 or below 0.25 so not significant for this work.  What this 
showed is that concentration only begins to affect size reduction slowly over a large range, in 
this case from 2 to 30 mM. 
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Figure 2.4: A) Size of sonicated DMPC liposomes at a range of concentrations from 2 to 30 
mM sonicated at 10 amplitude for 6 minutes.  B) PDI of sonicated DMPC liposomes at a range 
of concentrations from 2 to 30 mM sonicated at 10 amplitude for 6 minutes.   
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2.3.1.5 Probe sonication study using the optimised conditions  
 
The amplitude, concentration and time optimisation were put together to form the final probe 
sonication results as shown in Figure 2.5.  It was found that there was a significant difference 
between each formulation size. DMPC had a size of 85.9 ± 3.8 nm up to 110 ± 0.6 nm for 
DMPC: Cholesterol 6:2 and up to 134 ±1.7 nm for DMPC: Cholesterol 4:4.  PDI showed no 
significant difference between the Cholesterol forms, 0.202 ± 0.013 and 0.209 ± 0.011 for 6:2 
and 4:4 respectively.  DMPC had a statistically higher PDI at 0.239 ± 0.058.  What these 
showed is that as cholesterol was added to the formulation, the size increased but the PDI 
dropped, showing the liposomes were reduced in size less but there was an increase in 
uniformity.  Though these increases in size were significant, they weren’t large as they only 
increase by tens of nanometres.  Therefore, the method could easily be modified slightly, with 
an increase in time for example, to take into account the different formulation to then produce 
smaller liposomes comparable to the DMPC liposomes produced. 
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Figure 2.5: A) Size of final formulations of DMPC, DMPC: Cholesterol 6:2 and DMPC: 
Cholesterol 4:4 made using optimised sonication conditions of 10 amplitude for 6 minutes.  B) 
PDI of final formulations of DMPC, DMPC: Cholesterol 6:2 and DMPC: Cholesterol 4:4 made 
using optimised sonication conditions of 10 amplitude for 6 minutes.   
 
 
2.3.1.6 Discussion 
 
What these results mean is that there is now a good baseline for probe sonicated DMPC and 
DMPC: Cholesterol liposomes which can then be used as a direct comparison to other 
methods such as high shear mixing and bath sonication.  It was shown that amplitude did not 
have a significant effect on the probes ability to reduce liposome size although 10 amplitude 
was chosen as it gave smaller standard deviations.  It was also shown that time is an important 
factor as the longer the samples were sonicated for, the smaller the size of the liposomes.  
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However, this size reduction was limited after 6 minutes of sonication and therefore this was 
the time point chosen.  Formulation was also shown to have an effect on the finished liposome 
size with samples of DMPC, DMPC: Cholesterol 6:2 and DMPC: Cholesterol 4:4 liposomes 
ran under the same conditions showing significant differences in both size and PDI.  It was 
shown that as you increased the cholesterol concentration, the liposome size increases and 
the PDI decreases.  This shows that if you require liposomes to be a certain size, the 
formulation has to be taken into account and if any changes are made to that formulation, then 
the other factors such as time may have to be changed as well. 
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2.3.2 Developing and optimising a protocol for the production of SUV 
using DMPC and DMPC: Cholesterol lipid formulations using high 
shear mixing 
 
HSM has been used for production of liposomes previously, with some success (Vemuri et al., 
1990, Foged et al., 2014).  HSM is used a lot more within the industrial sector because of its 
scalability compared to many of the other liposome size reduction methods currently used 
(Wagner and Vorauer-Uhl, 2011).  High shear mixing works differently to sonication where 
instead of using sonic energy to disrupt the bilayers and reduce the size of the liposomes, a 
milling effect is employed  (Khadka et al., 2014).Therefore, the aim of this study was to see 
whether DMPC and DMPC: Cholesterol liposomes could be also used by the HSM method 
using laboratory high shear mixers. 
 
2.3.2.1 High shear mixing study into the effect of rpm parameters on 
vesicle size reduction 
 
Each of the three formulations DMPC 8 mM, DMPC: Cholesterol 6:2 mM and DMPC: 
Cholesterol 4: 4 mM, was tested at different rpm ranging from 5k rpm to 25k rpm in increments 
of 5k.  Figure 2.6 shows that at the slowest speed of 5,000 rpm, there is no size reduction of 
the liposomes at all.  DMPC 8 mM liposomes came out at 3192 ± 273 nm, DMPC: Cholesterol 
6:2 came out at 7404 ± 3111 nm and DMPC: Cholesterol 4:4 came out at 10046 ± 8235 nm.  
A decrease in size was seen as an increase in rpm occurred, with a minimum size of 1223 ± 
269 nm, 1467 ± 81 nm and 1027 ± 133 nm being achieved respectively for each formulation.  
With PDI, an increase was seen with DMPC 8 mM liposomes, but decreases were seen with 
both DMPC: Cholesterol formulations.  DMPC 8 mM increased from 0.252 ± 0.086 at 5000 
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rpm to 0.317 ± 0.019 at 25000 rpm, DMPC: Cholesterol 6:2 decreased meanwhile from 0.453 
± 0.078 down to 0.360 ± 0.028 between 5000 and 25000 rpm and DMPC: Cholesterol 4:4 
reduced from 0.592 ± 0.221 to 0.352 ± 0.024.  This showed that even at the highest rpm that 
this model can achieve, the size of the liposomes produced is still far larger and with larger 
polydispersities compared to the probe sonicated liposomes.   
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Figure 2.6: A – C) Size of 3 different formulations; DMPC (A), DMPC: Cholesterol 6:2 (B) and 
DMPC: Cholesterol 4:4 (C) high shear mixed over 5000 to 25000 rpm.  D – F) PDI of 3 different 
formulations; DMPC (D), DMPC: Cholesterol 6:2 (E) and DMPC: Cholesterol 4:4 (F) high 
shear mixed over 5000 to 25000 rpm.   
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2.3.2.2 High shear mixing study into the effect of time on liposome 
size reduction 
 
Each of the three formulations DMPC 8 mM, DMPC: Cholesterol 6:2 mM and DMPC: 
Cholesterol 4: 4 mM, were subject to times ranging from 5 to 30 minutes at 5 minute time 
points to see if HSM the samples for longer would make a difference to their size.  As shown 
in Figure 2.7, all three liposome formulations were still above a micron in size after 5 minutes 
of high shear mixing, with a size for DMPC 8 mM of 1497 ± 193 nm, DMPC: Cholesterol 6:2 
of 1193 ± 155 nm and DMPC: Cholesterol 4:4 of 2166 ± 816 nm.  Each then further reduced 
in size down to a minimum of 517 ± 142 nm, 581 ± 104 nm and 691 ± 30.6 nm respectively.   
There were mixed results for the polydispersities.  DMPC 8 mM actually rose from 0.332 ± 
0.024 to 0.375 ± 0.037 from 5 to 30 minutes of high shear mixing (Figure 3.3B).  DMPC: 
Cholesterol 6:2 did not see any notable change, reducing from 0.355 ± 0.023 to 0.354 ± 0.025 
(Figure 3.3B).  DMPC: Cholesterol 4:4 saw a reduction in PDI, down from 0.383 ± 0.065 to 
0.283 ± 0.035 (Figure 3.3B).  Even after half an hour of high shear mixing, the size of the 
liposomes could not be reduced down to a size that was comparable with probe sonication.  
This could be down to the milling effect not being as effective at reducing the size of these 
lipid formulations under these conditions compared to the sonic energy using with probe 
sonication.   
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Figure 2.7: A – C) Size of 3 different formulations; DMPC (A), DMPC: Cholesterol 6:2 (B) and 
DMPC: Cholesterol 4:4 (C) high shear mixed over 5 to 30 minutes.  D – F) PDI of 3 different 
formulations; DMPC (D), DMPC: Cholesterol 6:2 (E) and DMPC: Cholesterol 4:4 (F) high 
shear mixed over 5 to 30 minutes.   
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2.3.2.3 Discussion 
 
So even though with this method and these lipids the size reduction wasn’t as great as desired, 
high shear mixing has been used to make liposomes and other nanoparticles well within the 
nano range before.  For example, Trotta et al investigated using a high shear mixer to form 
solid nanoparticles using glyceryl monostearate nanodispersions.  They succeeded in forming 
sub-micron nanoparticles with a smallest size of 205 nm.  What this shows was that by using 
an emulsifier at least, it is possible to form nanoparticles in the nano size range by just using 
a high shear mixer (Trotta et al., 2003).  Another study by Zakeri-Milani et al also showed that 
by using a high shear mixer, it is possible to form solid lipid nanoparticles in a 200 – 500 nm 
size range by using c (Zakeri-Milani et al., 2014). 
Other studies have been carried out where the high shear mixer has been used as a precursor 
element, and then the liposomes reduced to their optimum size using other methods such as 
sonication.  For example, Mohammadi et al was able to produce liposomes using lecithin and 
cholesterol with a particle size range of 82 to 89 nm.  This worked by producing the liposomes 
using the lipid film hydration method, and then high shear mixing them for 15 minutes at 60 
°C.  They were then probe sonicated for 5 minutes and sized (Mohammadi et al., 2014).  What 
this shows is that high shear mixing can be used to produce SUV, in conjunction with another 
size reduction method, something this study did not look in to.  High shear mixing has also 
been shown to be able to produce small liposomes on their own, using different lipid 
formulations as to those used in this study.  Dietrich et al was able to form liposomes 
Dimethyldioctadecylammonium (Bromide Salt) (DDA), D-(+)-trehalose 6, 6’-dibehenate (TDB) 
and a high shear mixer at 60 – 80 °C for 15 minutes after the liposomes had been formed 
using the lipid film hydration method.  These liposomes came out to be approximately 203 nm 
in size, growing slightly larger to 267 nm once the inactivated polio virus vaccine had been 
bound to the liposome (Dietrich et al., 2014).  Therefore, how this study fits in is that even 
though you can form lipid nanoparticles and liposomes using high shear mixing alone, you 
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cannot form DMPC and DMPC: Cholesterol liposomes in the required size range using high 
shear mixing alone.  
 
2.3.3 Bioruptor® XL liposome size reduction studies 
 
Previous studies have looked into reducing the size of liposomes using bath sonication 
(Hadian et al., 2014, Kim, 2015).  However, none have gone into much detail which is why this 
study was needed.  Also, no studies have been done that look at optimisation of DMPC 
liposome size using bath sonication, and no studies have been done to look at the Bioruptor® 
systems as a way of reducing liposome size.  Therefore, a number of different factors were 
investigated using a DMPC and DMPC: Cholesterol formulation looking at the Bioruptor® XL 
system.  The factors that were investigated were time, pulse, power, volume and 
concentration. 
 
2.3.3.1 Bioruptor® XL study into how the number of cycles affects 
liposome size reduction 
 
Various time periods were tested from 5 to 20 minutes, using a different number of cycles, 
with the result shown below in Figure 2.8.  These show that just by adding more cycles on top 
of one another doesn’t necessarily lead to smaller liposome formation.  Each time for example 
an extra 5 minute cycle was added to the first 5 minute cycle, up to 15 minutes total, a 
significant difference was seen as the size increased. What the results do show is that long 
periods of sonication is the best way to reduce the size of liposomes, with 15 minutes of 
continuous sonication giving the smallest significant results over the shortest period of time 
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for both formulations in question.  DMPC: Cholesterol liposomes were smaller for 2 cycles of 
10 minutes, but this was not significant.  The PDI results followed a roughly similar pattern 
with the smallest PDI for DMPC liposomes being for 15 minutes of continuous sonication which 
came to 0.279 ± 0.031.  There was no significant difference between any of the DMPC: 
Cholesterol liposomes PDI results.  Therefore, 15 minutes of continuous sonication was the 
chosen time period for this study. 
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Figure 2.8: A – B) Size of sonicated liposomes over various time and cycle settings up to a 
maximum of 20 minutes for DMPC (A) and DMPC: Cholesterol 6:2 (B) sonicated at power 
level M2 at 45°C using 1000 µL in 1.5 mL tubes.  C – D) PDI of sonicated liposomes over 
various time and cycle settings up to a maximum of 20 minutes for DMPC (A) and DMPC: 
Cholesterol 6:2 (B) sonicated at power level M2 at 45°C using 1000 µL in 1.5 mL tubes.   
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2.3.3.2 Bioruptor® XL study into how the power level affects 
liposome size reduction 
 
Next the four different power levels were tested with the machine, L, M1, M2 and H (130W, 
200W, 250W and 300W respectively).  What these results show in Figure 2.9 is that it doesn’t 
make too much of a difference how much power you put into, so long as it’s enough.  This can 
clearly be seen with the low power tests, with sizes of 8787 ± 6483 nm for DMPC liposomes 
and 4384 ± 1836 nm for DMPC: Cholesterol liposomes.  PDI was also high with values of 
0.391 ± 0.157 for DMPC liposomes at low power and 0.4 ± 0.117 for DMPC: Cholesterol 
liposomes on the same power level.  The other power levels had no significant differences to 
one another when run under the same conditions with lows of 256 ± 79 nm in size and a PDI 
of 0.302 ± 0.036 for DMPC liposomes and a size of 616 ± 92 nm and PDI of 0.367 ± 0.015 for 
DMPC: Cholesterol liposomes. Therefore, the middle power level of M2 was chosen as it 
would reduce the liposomes sufficiently. 
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Figure 2.9: A – B) Size of DMPC (A) and DMPC: Cholesterol 6:2 (B) liposomes sonicated 
using the 4 different power levels over 15 minutes of continuous sonication at 45°C using 1000 
µL in 1.5 mL tubes.  C – D) PDI of DMPC (A) and DMPC: Cholesterol 6:2 (B) liposomes 
sonicated using the 4 different power levels over 15 minutes of continuous sonication at 45°C 
using 1000 µL in 1.5 mL tubes. 
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2.3.3.3 Bioruptor® XL study into how volume affects liposome size 
reduction 
 
What we can see is that the sizes of these liposomes produced are still much larger than those 
formed by probe sonication, 200 nm + compared to 100 nm approximately.  However, once 
volume had been taken into account, things began to look a lot better.  As shown below in 
Figures 2.10, the original volume of 1000 µL was far too large, and the sonicator was unable 
to sonicate the entire sample, leading to the larger sizes recorded.   However, once volume 
had dropped below 500 µL, and particularly 300 µL, it was seen that sizes of liposomes could 
now be produced that were comparable to those found with probe sonication.  PDI too was 
seen to reduce markedly and reduce further in fact than that found with probe sonication.  
Using the smaller volumes, the smallest vesicle size for DMPC liposomes of 89.7 ± 4.1 nm 
and PDI 0.269 ± 0.005 was achieved for a 0.1 mL sample volume. For DMPC: Cholesterol 
6:2, the lowest vesicle size and PDI achieved were 65.3 ± 2.9 nm and 0.182 ± 0.012 
respectively, this time for a 0.2 mL sample, although there was no significant difference 
between these results and those for the 0.1 mL sample.  A significant difference was seen 
once the volume had been raised above 300 µL for DMPC: Cholesterol, and above 500 µL for 
DMPC liposomes.  Therefore, a volume of 300 µL was chosen for the optimisation because 
even though smaller sizes were noted with 100 µL and 200 µL, the aim is to produce as much 
of the size reduced liposomes as possible as for this work it is not imperative that the 
liposomes are reduced below 100 nm. 
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Figure 2.10: A – B) Size of DMPC (A) and DMPC: Cholesterol 6:2 (B) liposomes sonicated 
using a range of volumes from 0.1 to 0.75 mL over 15 minutes of continuous sonication at 
45°C using 1000 µL in 1.5 mL tubes at power level M2.  C – D) PDI of DMPC (A) and DMPC: 
Cholesterol 6:2 (B) liposomes sonicated using a range of volumes from 0.1 to 0.75 mL over 
15 minutes of continuous sonication at 45°C using 1000 µL in 1.5 mL tubes at power level M2. 
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2.3.3.4 Bioruptor® XL study into how concentration affects liposome 
size reduction 
 
Concentration for bath sonication was tested using the lipid DMPC at various concentrations.   
The results are shown below in Figure 2.11.  What they show is that very little difference 
between the various concentrations for either method, until the concentrations reach 20mM 
and 30mM.  There were some significant differences, but these can be discounted because 
of the very small standard deviations and that the sizes of the liposomes do not increase above 
150 nm for bath sonication until they reach 20 mM and above.  What these show is that at 
these levels, you begin to saturate the method, meaning that only so many size reduced 
liposomes can be produced within a given volume.  However, it also showed that the 
concentration currently used of 8 mM is perfectly fine and so kept for the optimisation. 
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Figure 2.11: Size (A) and PDI (B) of DMPC liposomes sonicated at power level M2 at 45°C 
using 300 µL in 1.5 mL tubes for 15 minutes of continuous sonication.  
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2.3.3.5 Discussion 
 
What these results showed was that all factors need to be investigated to optimise the method 
for producing small liposomes.  The need for small liposomes is important for drug delivery 
but liposome size modification is important for other uses including vaccine delivery.  For 
example, even though the number of cycles and time sonicated was optimised first, this still 
left the DMPC and DMPC: Cholesterol liposomes in the several hundred nanometres range.  
It also showed that even with the same sonication time, the way the cycles are formulated 
does have a significant bearing on the size reduction.  For example, 15 minutes of continuous 
sonication gave liposomes that were half the size of the liposomes formed by 3 cycles of 5 
minutes of sonication each.  The power level also showed that there is a minimum amount of 
power required to reduce liposome size and if this threshold is not crossed, then the liposomes 
will stay as MLVs and within the micron range as opposed to the nanometre range for a power 
level above this threshold.  The volume data is what really showed that the Bioruptor® could 
be used to produce liposomes of a similar size to those produced by probe sonication.  At 
volumes of 0.1 mL in a 1.5 mL tube, liposomes formed of both DMPC and DMPC: Cholesterol 
were found to be below 100 nm, an important factor as it is generally understood that 
liposomes of below 100 nm can evade the bodies innate immune system without the need for 
masking agents such as PEG.  However, for this work, it was more important to produce 
sufficient liposomes of a small size rather than of the smallest size which is why 0.3 mL was 
chosen as the volume to take forward.  Finally, concentration was again shown to have a small 
but significant effect with increases in size and PDI above 15 mM.  What this showed is that 
similar to probe sonication, a finite amount of energy is put into the system over a set amount 
of time and the more concentrated the liposomes are, the less able they are to reduce in size 
using that set amount of energy over the same amount of time.    
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2.3.4 Bioruptor® Standard liposome size reduction studies 
 
The Bioruptor® Standard is the precursor to the machines currently marketed by Diagenode, 
the Plus and the Pico.  Therefore, it is important to investigate and optimise the various factors 
associated to see how small these liposomes can be produced, and how quickly.  To this end, 
many factors including time, power level, temperature, volume, plastic and size of tube were 
all investigated.   
 
2.3.4.1 Bioruptor® Standard study into how power level affects 
liposome size reduction 
 
The first parameter tested was the three different power levels, L, M and H, as shown in Figure 
2.12.  These equate to 160, 200 and 320 W and showed something really interesting.  There 
was no significant difference across the board between any of the DMPC: Cholesterol 4:4 
samples with sizes of 187.2 ± 33.9nm, 184.7 ± 21.9 nm and 190.3 ± 20.7 nm respectively and 
polydispersities of 0.292 ± 0.014, 0.29 ± 0.015 and 0.298 ± 0.019.    However, with DMPC 8 
mM, there was a significant increase seen for both size and PDI at the Medium and High 
power.  Between L and M, an increase in size was noted from 194 ± 9.7 nm to 221 ± 10.5 nm 
and an increase in PDI from 0.23 ± 0.024 to 0.254 ± 0.015 respectively.  A further increase in 
size and PDI up to 295.9 ± 44.9 nm and 0.35 ± 0.026 was noted for H power.  These increases 
could be attributed to the increase in power starting to break apart the liposomes that have 
been formed, causing some aggregation and generally not allowing the DMPC liposomes to 
form as small as they would want (Lankin et al., 2002). Because of the significant differences 
seen with DMPC liposomes, the Low power was the level chosen for optimisation. 
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Figure 2.12: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes were 
produced using the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  They were 
then sonicated for 15 minutes of 30, 30 at the 3 different power levels of L, M and H.  C – D) 
PDI of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes were produced using the 
Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  They were then sonicated for 15 
minutes of 30, 30 at the 3 different power levels of L, M and H.   
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2.3.4.2 Bioruptor® Standard study into how power level with 
continuous sonication affects liposome size reduction 
 
As shown in Figure 2.13, the power level was run again using continuous sonication.  A 
significant rise in both size and PDI was seen with DMPC 8 mM liposomes when using the 
highest power of 320W but there was no significant difference this time between Low and 
Medium power.  This increase in size and PDI was from 177.5 ± 4.2 nm to 219.3 ± 33.3 nm 
and from 0.207 ± 0.016 to 0.283 ± 0.04 respectively.  The same pattern as before was seen 
with DMPC: Cholesterol 4:4 liposomes, with no significant difference between any of the power 
levels for either size or PDI.  There was a significant difference also between the best sizes 
attained for both formulations using the M power compared to when there was no continuous 
sonication.  Using continuous sonication saw a reduction in size for DMPC 8 mM liposomes 
from 221 ± 10.5 nm down to 177.5 ± 4.2 nm and a reduction in PDI from 0.256 ± 0.012 down 
to 0.207 ± 0.016, compared to when the samples had 30 seconds on, 30 seconds off cycle.  
A reduction was also noted for DMPC: Cholesterol 4:4, from 184.7 ± 21.9 nm down to 155.2 
± 13.6 nm and a reduction in PDI from 0.290 ± 0.015 down to 0.241 ± 0.026 respectively.  
Therefore, the M power was chosen now as the optimal power level because of this minimal 
size and PDI data.   
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Figure 2.13: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes were 
produced using the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  They were 
then sonicated for 15 minutes of 30, 0 at the 3 different power levels of L, M and H.  C – D) 
PDI of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes were produced using the 
Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  They were then sonicated for 15 
minutes of 30, 0 at the 3 different power levels of L, M and H.   
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2.3.4.3 Bioruptor® Standard study into how pulse settings affect 
liposome size reduction 
 
The next parameter tested was the different pulse levels as shown in Figure 2.14.  For this 
what was found was that for both formulations an overall decrease in size was seen as you 
reduced the amount of time off.  For DMPC 8 mM, a reduction in size was seen between 30 
seconds off and 0 seconds off from 199.1 ± 9.7 nm down to 179.1 ± 6.8 nm.  For DMPC: 
Cholesterol 4:4, a reduction was also seen from 199.6 ± 52.8 nm down to 158.5 ± 12 nm.  A 
slight increase in PDI was noted for DMPC 8 mM, from 0.231 ± 0.023 to 0.241 ± 0.017 and a 
slight decrease in PDI was noted for DMPC: Cholesterol 4 4:4 from 0.294 ± 0.017 down to 
0.263 ± 0.022.  What this showed was that as you decrease the amount of time off, and 
therefore increase the amount of sonication time overall, you get a further decrease in size for 
both formulations.  Therefore, a continuous sonication was chosen. 
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Figure 2.14: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes were 
produced using the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  They were 
then sonicated for 15 minutes at power level L with time on kept constant at 30 seconds and 
time off ranging from 0 to 30 seconds.  C – D) PDI of DMPC (A) and DMPC: Cholesterol 4:4 
(B) liposomes produced using the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  
They were then sonicated for 15 minutes at power level L with time on kept constant at 30 
seconds and time off ranging from 0 to 30 seconds.   
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2.3.4.4 Bioruptor® Standard study into how time affects liposome 
size reduction 
 
As shown in Figure 2.15, a reduction in size and PDI was seen as time increased.  For DMPC 
8 mM, a reduction in size from 5 to 15 minutes from 349.1 ± 63.8 nm down to 221 ± 10.5 nm 
was seen, and a reduction in PDI from 0.304 ± 0.022 down to 0.256 ± 0.012 was seen 
respectively.  For DMPC: Cholesterol 4:4, a reduction in size from 5 to 15 minutes was seen 
from 361.9 ± 26 nm down to 184.7 ± 21.9 nm and a reduction in PDI over the same time frame 
from 0.341 ± 0.016 down to 0.29 ± 0.015.  These results therefore showed that as you increase 
the time a liposome sample is sonicated, you reduce both the size and PDI of that formulation 
(Woodbury et al., 2006). 
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Figure 2.15: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced 
using the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes. They were then 
sonicated at power level L for 30 seconds on, 30 seconds off for between 5 and 15 minutes.  
C – D) PDI of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced using the 
Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  They were then sonicated at 
power level L for 30 seconds on, 30 seconds off for between 5 and 15 minutes. 
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2.3.4.5 Bioruptor® Standard study into how a longer period of time 
affects liposome size reduction 
 
Time had been investigated up to 15 minutes so a further increase in these parameters was 
used to see whether sonicating for even longer would lead to statistically smaller liposomes.  
The results showed in Figure 2.16 showed a significant decrease between 15 and 20 minutes 
for DMPC, 179 ± 6.8 nm down to 158 ± 3.5 nm.  No significant difference for 25 or 30 minutes 
was seen.  DMPC: Cholesterol had a small but significant decrease 15 to 20 minutes of 161 
± 14.8 nm down to 149 ± 7.8 nm, but back up for 25 minutes, up to 186 ± 21 nm.  No sig 
difference for DMPC for PDI, all around 0.24.  DMPC: Cholesterol saw again a significant 
decrease from 15 to 20 mins from 0.262 ± 0.028 to 0.235 v 0.016.  It then statistically increased 
for 25 minutes with a PDI of 0.286 ± 0.017.  What these showed is that by increasing the time 
to 20 minutes, there was a significant decrease in size of both DMPC and DMPC: Cholesterol 
liposomes with either a decrease or no difference seen with the PDI.  However, when 
increased to 25 minutes, there were no significant decreases and in fact some of the results 
had started to increase, although not significantly.  Therefore, sonicating for too long lead to 
overall liposome size increasing and PDI increasing, leading to larger liposomes with 
decreased uniformity or aggregation of liposomes increasing the overall size of the sample. 
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Figure 2.16: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced 
using the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes. They were then 
sonicated at power level L for 30 seconds on, 30 seconds off for between 15 and 30 minutes.  
C – D) PDI of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced using the 
Bioruptor® Standard at 45°C using 300 µL in 1.5 mL tubes.  They were then sonicated at 
power level L for 30 seconds on, 30 seconds off for between 15 and 30 minutes. 
 
 
123 
 
2.3.4.6 Bioruptor® Standard study into how volume affects liposome 
size reduction 
 
With the different volumes with the PTFE 1.5 mL tube, it was found that a size reduction for 
both formulations could be achieved, if the volume was set to 100 µL, as shown in Figure 2.17.  
The results attained for the DMPC 8 mM formulation were a smallest size of 114.6 ± 2.3 nm 
and PDI of 0.259 ± 0.013.  While for the DMPC: Cholesterol 4:4 liposomes, a smallest size of 
128.8 ± 1.7 nm and PDI of 0.171 ± 0.023 were attained.  As you increased the volume, the 
sizes and polydispersities of both formulations increased until at 1000 µL, DMPC 8 mM had a 
size and PDI of 430.3 ± 120.5 nm and 0.353 ± 0.029 respectively and DMPC 4:4 had a size 
and PDI of 550.1 ± 295 nm and a PDI of 0.345 ± 0.015.  What these showed was that like the 
Bioruptor® XL, the smallest sizes and polydispersities can be achieved using the minimum 
volume of sample, 100 µL. 
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Figure 2.17: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced 
using the Bioruptor® Standard at 45°C using a range of volumes from 0.1 to 1 mL in a 1.5 mL 
tube.  They were sonicated at power level M for 15 minutes of 30 seconds on, 0 seconds off 
cycle.  C – D) PDI of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced using the 
Bioruptor® Standard at 45°C using a range of volumes from 0.1 to 1 mL in a 1.5 mL tube.  
They were sonicated at power level M for 15 minutes of 30 seconds on, 0 seconds off cycle.   
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2.3.4.7 Bioruptor® Standard study into how the use of larger tubes 
affects liposome size reduction 
 
With the different volumes with the PTFE 15 mL tube, it was found that a size reduction for 
both formulations could be achieved, if the volume was set to 0.5 mL, as shown in Figure 2.18.  
The results attained for the DMPC 8 mM formulation were a smallest size of 137.8 ± 9.4 nm 
and PDI of 0.304 ± 0.01.  While for the DMPC: Cholesterol 4:4 liposomes, a smallest size of 
163 ± 10.8 nm and PDI of 0.294 ± 0.009 were attained.  As you increased the volume, the 
sizes and polydispersities of both formulations increased.  For DMPC 8 mM, the maximum 
size and PDI of 548 ± 50.9 nm and 0.357 ± 0.016 was attained for the 2 mL sample and for 
DMPC 4:4 had a size and PDI of 913.2 ± 125.6 nm and a PDI of 0.369 ± 0.015 at 3 mL of 
sample.  What these showed was that like the 1.5 mL tubes, the smallest sizes and 
polydispersities can be achieved using the minimum volume of sample, 0.5 mL. 
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Figure 2.18 A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced 
using the Bioruptor® Standard at 45°C using a range of volumes from 0.5 to 3 mL in a 15 mL 
tube.  They were sonicated at power level M for 15 minutes of 30 seconds on, 0 seconds off 
cycle.  C – D) PDI of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced using the 
Bioruptor® Standard at 45°C using a range of volumes from 0.5 to 3 mL in a 15 mL tube.  They 
were sonicated at power level M for 15 minutes of 30 seconds on, 0 seconds off cycle.   
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2.3.4.8 Bioruptor® Standard study into how position within the water 
bath affects liposome size reduction 
 
With the different position test, it was found that there was some variability within the different 
positions as shown in Figure 2.19.  For DMPC 8 mM, these ranged from 93.5 ± 3.6 nm to 141 
± 46 nm in size and from 0.257 ± 0.0.25 to 0.289 ± 0.028 for PDI.  While for the DMPC: 
Cholesterol 4:4 liposomes, the size ranged from 172 ± 15nm to 252 ± 30 nm and PDI from 
0.27 ± 0.018 to 0.322 ± 0.017.  For DMPC 8 mM, the only significantly different position 
however was position 1.  For the DMPC: Cholesterol 4:4 liposomes, positions 1, 4 and 6 were 
significantly different from 2, 3 and 5.  The average size and PDI for DMPC 8 mM was 117.7 
± 29.6 nm and 0.269 ± 0.03 respectively.  While for the DMPC: Cholesterol 4:4 liposomes, the 
average size and PDI were 210.1 ± 51.3 nm and 0.295 ± 0.029 respectively.  What this shows 
is that there is inter variability between the different positions, although the reason behind this 
is unclear.  It could be that the water bath temperature isn’t uniform across the different 
positions, although the motor that turns the system should alleviate this problem.  The other 
reason could be that the liposomes are not given enough time to reduce in temperature after 
sonication before they are sized. 
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Figure 2.19: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced 
using the Bioruptor® Standard and then sonicated for 15 minutes of 30, 0 at the power level 
M using a 0.1 mL sample.  Each position in the holder was assigned an arbitrary number 
between 1 and 6 and each ran 3 times to compare how much variability there was in the same 
position over multiple tests and between the 6 different positions available.   C – D) PDI of 
DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced using the Bioruptor® Standard 
and then sonicated for 15 minutes of 30, 0 at the power level M using a 0.1 mL sample.  Each 
position in the holder was assigned an arbitrary number between 1 and 6 and each ran 3 times 
to compare how much variability there was in the same position over multiple tests and 
between the 6 different positions available.    
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2.3.4.9 Bioruptor® Standard study into how temperature affects 
liposome size reduction 
 
With temperature, as temperature was reduced then the size and PDI increased of both 
formulations as shown in Figure 2.20.  This increase was particularly acute when the 
temperature was dropped below the 24 °C transition temperature of DMPC.  However, this 
was not immediate or total as the reduced temperature makes it more difficult but not 
impossible for the liposome size to be reduced and the temperature within the tube is known 
to be several degrees higher than the overall water bath during sonication. 
DMPC 8 mM liposomes had a minimum size at 35 °C of 164.9 ± 6.2 nm and minimum PDI at 
50 °C of 0.224 ± 0.015.  The best size and PDI combined was at 45 °C with a slightly bigger 
size of 179.1 ± 6.8 nm and a PDI of 0.268 ± 0.02.  The size and polydispersities then increased 
as the temperature reduced, with a maximum size and PDI at 5 °C of 1562 ± 308 nm and 
0.381 ± 0.025 respectively.  Meanwhile, DMPC 4:4 liposomes had a minimum size at 50 °C of 
157.4 ± 20.4 nm and minimum PDI of 0.198 ± 0.05.  The best size and PDI at 45 °C were a 
size of 158.5 ± 12 nm and a PDI of 0.263 ± 0.022.  The size and polydispersities then increased 
as the temperature reduced, with a maximum size and PDI at 25 °C of 608.7 ± 184 nm and 
0.373 ± 0.046 respectively.  This clearly shows that as you decrease the temperature, then 
the size increases for both formulations, especially once you drop below the transition 
temperature as this is vital in keeping the bilayer in a disordered phase so it can be modified 
(Duzgunes, 2003).  What Figure 4.4A also shows is that even below the transition 
temperature, you can still reduce the size of your liposomes, although not to the smallest sizes 
achieved at the higher temperatures.  It also shows that the addition of cholesterol stabilises 
the membrane, meaning both at the low temperatures like 5 or 10 °C you get smaller 
liposomes because when they are first formed as MLV they are smaller, and that at the 
temperatures around the transition temperature of DMPC, you don’t get as much of a size 
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reduction compared to the formulation made with DMPC.  This could be down to cholesterol 
having the effect of abolishing the transition temperature of the lipid system as seen in 
previous work by Bajoria et al (Bajoria and Contractor, 1997). 
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Figure 2.20: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced 
using the Bioruptor® Standard at 45°C using a range of volumes from 0.5 to 3 mL in a 15 mL 
tube.  They were sonicated at power level M for 15 minutes of 30 seconds on, 0 seconds off 
cycle.  C – D) PDI of DMPC (C) and DMPC: Cholesterol 4:4 (D) liposomes produced using 
the Bioruptor® Standard at 45°C using a range of volumes from 0.5 to 3 mL in a 15 mL tube.  
They were sonicated at power level M for 15 minutes of 30 seconds on, 0 seconds off cycle.   
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2.3.4.10 Bioruptor® Standard study into how the use of PP tubes and 
power level affects liposome size reduction 
 
Power was the first parameter to be tested with the results below in Figure 2.21.  These show 
that as you increase the power to power level M, you either increase or make no difference to 
the size and PDI of your formulations.  For DMPC 8 mM liposomes, the size decreases slightly 
between L and M power from 139.6 ± 11 nm down to 132.7 ± 30.8 nm but PDI increases from 
0.257 ± 0.012 to 0.295 ± 0.014.  For DMPC: Cholesterol 4:4, size again decreases from 183.6 
± 18.8 nm to 177.8 ± 12.4 nm and PDI also drops from 0.304 ± 0.016 to 0.286 ± 0.016.  
However, as you then increase the power level to H, you see a significant increase in the size 
of DMPC 8 mM liposomes up to 157.4 ± 4 nm but a decrease in the PDI down to 0.246 ± 
0.011.  For DMPC: Cholesterol 4:4 there is no significant change in either the size or PDI.  
What this shows is that again if you put too much power into the system, and you do not have 
a stabilising agent such as cholesterol in your formulation, then you will see an increase in 
size and PDI as the lipids become damaged.  Therefore, M power was chosen as the optimal 
value. 
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Figure 2.21: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes were 
produced using the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL PP tubes.  They were 
then sonicated for 15 minutes of 30, 30 at the 3 different power levels of L, M and H.  C – D) 
PDI of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes were produced using the 
Bioruptor® Standard at 45°C using 300 µL in 1.5 mL PP tubes.  They were then sonicated for 
15 minutes of 30, 30 at the 3 different power levels of L, M and H.   
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2.3.4.11 Bioruptor® Standard study into how the use of PP tubes and 
time affects liposome size reduction 
 
Time was the next parameter to be tested, with the results below in Figure 2.22.  These show 
that as you increase the time, you decrease the size and PDI of your formulations, as seen 
before.  The best results attained for the DMPC formulation were at 15 minutes and were a 
best size of 111.6 ± 4.4 nm and PDI of 0.295 ± 0.011.  While for the DMPC: Cholesterol 4 4:4, 
a size of 177.8 ± 12.4 nm and PDI of 0.286 ± 0.016 were achieved at 15 minutes.  For DMPC: 
Cholesterol 4:4 liposomes, this size and PDI is comparable to that achieved using the PTFE 
tubes, while for DMPC 8 mM it is significantly smaller, reduced down from 221 ± 10.5 nm but 
with a higher PDI than that attained with PTFE tubes.  The tube type affects size and 
polydispersity because the different plastics have different attributes such as hardness and 
how well it transfers the sonic energy through the plastic to the liposomes inside. 
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Figure 2.22: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes were 
produced using the Bioruptor® Standard at 45°C using 300 µL in 1.5 mL PP tubes.  They were 
then sonicated for 5 to 15 minutes of 30, 30 at power level M.  C – D) PDI of DMPC (A) and 
DMPC: Cholesterol 4:4 (B) liposomes were produced using the Bioruptor® Standard at 45°C 
using 300 µL in 1.5 mL PP tubes.  They were then sonicated for 5 to 15 minutes of 30, 30 at 
power level M. 
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2.3.4.12 Bioruptor® Standard study into how the use of PP tubes and 
volume affects liposome size reduction 
 
With the different volumes with the PP 1.5 mL tube, it was found that a size reduction for both 
formulations could be achieved, if the volume was set to 100 µL, as shown in Figure 2.23.  
The results attained for the DMPC 8 mM formulation were a smallest size of 108.6 ± 9.3 nm 
and PDI of 0.24 ± 0.016.  While for the DMPC: Cholesterol 4:4 liposomes, a smallest size of 
146.2 ± 16.1 nm and PDI of 0.31 ± 0.02 were attained.  As you increased the volume, the 
sizes and polydispersities of both formulations increased.  For DMPC 8 mM, the biggest values 
occurred with 750 µL which had a size and PDI of 1239 ± 553 nm and 0.334 ± 0.03 respectively 
and DMPC 4:4 had the biggest values occur at 1000 µL with a size and PDI of 3378 ± 1495 
nm and a PDI of 0.41 ± 0.068.  What these showed was that like the Bioruptor® XL, the 
smallest sizes and polydispersities can be achieved using the minimum volume of sample, 
100 µL.  What these also showed was that the results attained for the PP tubes compared to 
the PTFE tubes were mixed.  For DMPC 8 mM a slightly smaller size and PDI was attained 
but for DMPC: Cholesterol 4:4, the opposite was true. 
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Figure 2.23: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes were 
produced using the Bioruptor® Standard at 45°C using 100 to 1000 µL in 1.5 mL PP tubes.  
They were then sonicated for 15 minutes of 30, 0 at power level M.  C – D) PDI of DMPC (A) 
and DMPC: Cholesterol 4:4 (B) liposomes were produced using the Bioruptor® Standard at 
45°C using 100 - 1000 µL in 1.5 mL PP tubes.  They were then sonicated for 15 minutes of 
30, 0 at power level M. 
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2.3.4.13 Bioruptor® Standard study into how the use of larger PP 
tubes affects liposome size reduction 
 
With the different volumes with the PP 15 mL tube, it was found that a size reduction for both 
formulations could be achieved, if the volume was set to 0.5 mL, as shown in Figure 2.24.  
The results attained for the DMPC 8 mM formulation were a smallest size of 108.9 ± 4.6 nm 
and PDI of 0.321 ± 0.005.  While for the DMPC: Cholesterol 4:4 liposomes, a smallest size of 
148.4 ± 14 nm and PDI of 0.316 ± 0.025 were attained.  As you increased the volume, the size 
increased but polydispersities either decreased or were not significantly different of both 
formulations.  For DMPC 8 mM, the maximum size and PDI of 263.1 ± 111.1 nm and 0.27 ± 
0.048 was attained for the 2 mL sample and for DMPC 4:4 had a size and PDI of 287.1 ± 
165.4 nm and a PDI of 0.32 ± 0.021 at 2 mL of sample.  What these showed was that like the 
1.5 mL tubes, the smallest sizes and polydispersities can be achieved using the minimum 
volume of sample, 0.5 mL. 
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Figure 2.24: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes were 
produced using the Bioruptor® Standard at 45°C using 0.5 to 2 mL in 15 mL PP tubes.  They 
were then sonicated for 15 minutes of 30, 0 at power level M.  C – D) PDI of DMPC (A) and 
DMPC: Cholesterol 4:4 (B) liposomes were produced using the Bioruptor® Standard at 45°C 
using 0.5 to 2 mL in 15 mL PP tubes.  They were then sonicated for 15 minutes of 30, 0 at 
power level M. 
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2.3.4.14 Bioruptor® Standard study into how formulation affects 
liposome size reduction 
 
4 different formulations along with the 2 already looked at, DMPC and DMPC: Cholesterol, 
were investigated using the same conditions with each sample run at the same time as each 
other.  The conditions used were the optimised conditions for the DMPC and DMPC: 
Cholesterol liposomes and the results are shown below in Figure 2.25.  Firstly, when DMPC 
liposomes had cholesterol added to them, the size increased from 169.7 ± 9.5 nm to 472.5 ± 
24.8 nm.  However, once DMPG or DOTAP had been added, a significant decrease in size 
was seen when either the anionic or cationic lipid were added with drops down to 106.6 ± 6.8 
nm and 111.2 ± 20.4 nm respectively.  DMPG has a transition temperature of 23 °C and 
DOTAP has a transition temperature of 0 °C.  The same pattern was also noted with the PDI. 
For the use of a higher transition temperature lipid, DSPC, there was no significant difference 
between the sizes achieved compared to the lower transition temperature lipid of DMPC.  For 
DSPC, a size of 417.2 ± 39.3 nm was achieved which is comparable to the 472.5 ± 24.8 nm 
achieved for the DMPC: Cholesterol liposomes.  However, when using an even lower 
transition temperature, PC, a drop in size was achieved down to 155.5 ± 38.5 nm.  DSPC has 
a transition temperature of 55 °C and PC has a transition temperature of -15 °C.  Again, the 
same pattern was seen in the PDI.   
For the zeta potential, each of the formulations that do not contain any charged lipids the zeta 
potential was found to be near neutral.  DMPC, DMPC: Cholesterol, DSPC: Cholesterol and 
PC: Cholesterol had zeta potentials of -4.6 ± 2.01 mV, -9.48 ± 1.2 mV, -0.68 ± 1.35 mV and -
3.72 ± 1.93 mV respectively.  When an anionic lipid is added, the zeta potential drops to -
18.16 ± 1.32 mV whilst when a cationic lipid is added, the zeta potential increases to 23.53 ± 
1.21 mV.  This is all in line with what was expected.  
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Therefore, in conclusion the bath sonicator is able to be used to produce liposomes of various 
transition temperatures and charges and reduce their size sufficiently down to the nanometre 
range.  These liposomes are able to be produced at the same time using exactly the same 
conditions, a big plus compared to the probe sonication method. 
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Figure 2.25: Size (A), PDI (B) and zeta potential (C) for 6 formulations that were investigated. 
DMPC, DMPC: Cholesterol 4:4, PC: Cholesterol 4:4, DSPC: Cholesterol 4:4, DMPC: 
Cholesterol: DMPG 4:4:1 and DMPC: Cholesterol: DOTAP 4:4:1 liposomes were produced 
using the Bioruptor® Standard and then sonicated for 15 minutes of 30, 0 at the power level 
M with a 100 µL volume in a 1.5 mL TPX® tube. 
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2.3.4.15 Discussion 
 
The Bioruptor® Standard data shows that liposome production using a bath sonicator system 
relies on a large number of factors.  All the factors investigated showed some effect on the 
size and PDI of the liposomes produced.  These ranged from the usual time and power levels 
being investigated and it being shown that the longer the liposomes are sonicated for and the 
higher the power level, the smaller the liposomes are produced.  It was also shown that if the 
sonication time stays the same but the off time in between cycles is reduced, this leads to 
smaller liposomes compared to those with larger time off between cycles.  Volume for both 
the large and small tubes was investigated, and it was found that the lower the volume, the 
smaller the liposomes.  It was also shown that the system could be up scaled somewhat within 
the laboratory setting by increasing the tube size from 1.5 mL to 15 mL.  This would allow 
more liposomes to be reduced in size over the same time period, in this case instead of 0.6 
mL (6 x 0.1 mL), 3 mL (6 x 0.5 mL) can be produced over the same time period to a similar 
size and PDI using the same formulation. 
The position test gave some really interesting data as it showed there was some variability 
between each position over a number of tests.  However, this could be due to a number of 
factors such as the size of the MLVs that were placed in each tube which will have varied and 
therefore required a different amount of energy to reduce them to the same size.  Therefore, 
this shows that by increasing the size of the tube, the size variance would be reduced as less 
tubes would be required to reduce the same volume of liposomes in size.  Temperature data 
showed the importance of the transition temperature when sonicating liposomes.  For DMPC 
liposomes, the decrease in size as the temperature was increases was easy to see and also 
showed that even if the water bath was at a set temperature below the transition temperature, 
there was still size reduction.  This is due to there still being energy applied and also the 
temperature within the sample tube is usually higher compared to the water bath as a whole.  
The DMPC: Cholesterol liposomes reduced in size too although at a slower rate.  This is due 
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to the addition of the cholesterol which increases the rigidity of the liposome bilayer, making it 
harder to be broken apart and reduced in size.  Previous data for the Bioruptor® XL and probe 
sonicator back this up as under the same conditions, DMPC: Cholesterol liposomes formed 
larger liposomes compared to their DMPC counterparts.  The PP tubes used, which are not 
Diagenode specific, showed similar results for all the optimisation categories like power, time 
and volume. 
Finally, the choice of formulation was also shown to be vital in how well the liposomes are 
reduced in size.  For example, the addition of cholesterol showed an increase in size but the 
further addition of a positive of negative lipid showed a decrease in the end size.  This could 
be due to a reduction in aggregation and in overall transition temperature.  The use of a smaller 
phospholipid saw a decrease in size, i.e. PC but the use of a much larger lipid, DSPC, saw a 
further increase in size compared to the original DMPC: Cholesterol formulation.  All 
formulations containing just neutral lipids showed zeta potentials of near 0 with the addition of 
a negative lipid causing a negative zeta potential and the addition of a positive lipid causing 
the opposite as expected.   
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2.3.5 Bioruptor® Plus liposome size reduction studies 
 
The Bioruptor® Plus is one of Diagenodes machines that is currently on the market to its 
customers.  This makes it imperative that the Bioruptor® Plus is tested to make sure it can 
produce the liposome size reduction required and is comparable to the other Bioruptor® 
models previously and to the probe sonicator.  This is important as the plus points of using a 
bath sonicator, the ability for it to be ran in sterile conditions, more than one sample at once 
and the lack of titanium contamination, do not mean a lot if the machine does not deliver the 
size reduction required in a good enough time period.   
 
2.3.5.1 Bioruptor® Plus study into how the length of sonication and 
power level affects liposome size reduction 
 
Length of sonication and power level are known to be important factors in the effectiveness of 
the reduction of liposome size using the bath sonicator.  Therefore, it was important to 
investigate using the new Bioruptor® Plus exactly what combination of power level and length 
of sonication gave the smallest liposomes. 
Figure 2.26 and 2.27 shows the size and PDI of DMPC and DMPC: Cholesterol 4:4 liposomes 
sonicated at both low and high power up to 30 cycles in increments of 5 cycles. After just 5 
cycles, the size of the liposomes produced using high power was found to be significantly 
smaller than those formed with low power for DMPC: Cholesterol liposomes and this 
significant increase was seen up to 20 cycles.  DMPC liposomes had no significant differences 
in size until 15 cycles whereby the high-powered liposomes were significantly smaller, and 
this trend continued up to 30 cycles.  For all samples bar the high powered DMPC liposomes, 
the smallest size obtained was after 20 cycles, after which no significant decrease in size was 
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seen.  However, DMPC high power sonicated liposomes continued to reduce in size up to the 
25 cycle mark, and then no significant decrease was seen either.  The size obtained for the 
DMPC liposomes at these cycles were for low power, 110 ± 11 nm, and for high power 85 ± 9 
nm.  For DMPC: Cholesterol 4:4 liposomes, the size obtained at the 20 cycle point were for 
low power, 147 ± 8 nm and for high power, 137 ± 5 nm.  The data shows that the 
polydispersities of the formulations do initially decrease for all the formulations.  However, 
some do begin to increase again, particularly the high powered samples after approximately 
20 cycles.  For DMPC liposomes, the PDI obtained at the 20 cycle point were for low power, 
0.241 ± 0.02 and after 25 cycles for high power, 0.297 ± 0.012.  For DMPC: Cholesterol 4:4 
liposomes, the PDI obtained at the 20 cycle point were for low power, 0.242 ± 0.026 and for 
high power, 0.219 ± 0.02.     
So, what these results show is that by running the sonication for a longer period of time at the 
higher power level, significantly smaller liposomes can be made.  However, there can 
sometimes be an increase in PDI with the higher power level and this could be due to the 
power being too much and causing the liposomes to break apart.  The cholesterol containing 
liposomes were also found to be significantly larger than their non-cholesterol containing 
counterparts. 
146 
 
 
A)
5
1
0
1
5
2
0
2
5
3
0
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
D M P C
n u m b e r o f c y c le s
E
ff
e
c
ti
v
e
 d
ia
m
e
te
r
 /
 n
m
 B)
5
1
0
1
5
2
0
2
5
3
0
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
D M P C :C h o l 4 :4
n u m b e r o f c y c le s
E
ff
e
c
ti
v
e
 d
ia
m
e
te
r
 /
 n
m
       
C)
5
1
0
1
5
2
0
2
5
3
0
0 .0
0 .1
0 .2
0 .3
0 .4
D M P C
n u m b e r o f c y c le s
p
o
ly
d
is
p
e
r
s
it
y
 D)
5
1
0
1
5
2
0
2
5
3
0
0 .0
0 .1
0 .2
0 .3
0 .4
D M P C :C h o l 4 :4
n u m b e r o f c y c le s
p
o
ly
d
is
p
e
r
s
it
y
 
Figure 2.26: A – B) Size of DMPC (A) and DMPC: Cholesterol 4:4 (B) liposomes produced 
using the Bioruptor® Plus at 40°C using 0.1 mL of sample in 1.5 mL tubes.  They were then 
sonicated for 5 to 30 cycles at H power.  C – D) PDI of DMPC (C) and DMPC: Cholesterol 4:4 
(D) liposomes were produced using the Bioruptor® Plus at 40°C using 0.1 mL of sample in 
1.5 mL tubes.  They were then sonicated for 5 to 30 cycles at H power. 
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Figure 2.27: E - F) Size of DMPC (E) and DMPC: Cholesterol 4:4 (F) liposomes produced 
using the Bioruptor® Plus at 40°C using 0.1 mL of sample in 1.5 mL tubes.  They were then 
sonicated for 5 to 30 cycles at L power.  G - H) PDI of DMPC (G) and DMPC: Cholesterol 4:4 
(H) liposomes were produced using the Bioruptor® Plus at 40°C using 0.1 mL of sample in 
1.5 mL tubes.  They were then sonicated for 5 to 30 cycles at L power. 
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2.3.5.2 Bioruptor® Plus study into how concentration affects 
liposome size reduction 
 
The results in Figure 2.28 show that for the different concentrations a 2 mL sample of 8 mM 
DMPC: Cholesterol liposomes was compared to a 2 mL sample of 16 mM and a 2 mL sample 
of 24 mL DMPC: Cholesterol liposomes and no significant changes were seen in either the 
size or PDI of either the 16 mM or 24 mM samples when compared to the 8 mM sample or 
when compared to each other. 
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Figure 2.28: A) Size of DMPC liposomes at 8, 16 and 24 mM produced using the Bioruptor® 
Plus at 40°C using 0.1 mL of sample in 1.5 mL tubes.  They were then sonicated for 15 cycles 
at H power.  B) PDI of DMPC liposomes at 8, 16 and 24 mM produced using the Bioruptor® 
Plus at 40°C using 0.1 mL of sample in 1.5 mL tubes.  They were then sonicated for 15 cycles 
at H power.   
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2.3.5.3 Bioruptor® Plus study into how temperature affects liposome 
size reduction 
 
Temperature is known to be an important factor due to the liposomes transition temperature 
as the results in Figure 2.29 show.  These results showed that for both low and high power, 
DMPC liposomes behaved as expected whereas temperature increased, size decreased, from 
104.7 nm down to 86.7 nm for low power and from 128.1 nm down to 82.4 nm for high power.  
PDI also generally followed the same pattern dropping from 0.396 down to 0.264 for low power 
and from 0.324 down to 0.240 for high power.  DMPC: Cholesterol however showed an 
increase in size from 20 to 30 °C for both high and low power and a further increase at 40 °C 
for low power.  The reasons for this are unclear although a similar pattern was seen for the 
PDI.   
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A)  B)   
Figure 2.29: A) Size of DMPC and DMPC: Cholesterol 4:4 liposomes produced using the 
Bioruptor® Plus at 20, 30 and 40°C using 0.1 mL of sample in 1.5 mL tubes.  They were then 
sonicated for 15 cycles at L and H power.  B) PDI of DMPC and DMPC: Cholesterol 4:4 
liposomes produced using the Bioruptor® Plus at 20, 30 and 40°C using 0.1 mL of sample in 
1.5 mL tubes.  They were then sonicated for 15 cycles at L and H power. 
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2.3.5.4 Bioruptor® Plus study into how volume affects liposome size 
reduction 
 
Volume is also an important factor as shown with the previous Bioruptor® models as shown 
in Figure 2.30.  In this case, DMPC and DMPC: Cholesterol liposomes were tested for their 
size reduction using low and high power from 0.1 to 0.3 mL of sample in a 1.5 mL tube.  What 
these results showed was that as you decreased the volume, there was a corresponding 
decrease in size and PDI for both formulations at both power levels.  DMPC liposomes saw 
size reductions from 139.2 to 90.9 nm and 135.6 to 96.5 nm for low and high power 
respectively.  DMPC: Cholesterol saw size reductions from 224.6 to 129.9 nm and from 191.1 
to 149.3 nm for low and high power respectively.  DMPC liposomes saw a PDI reduction from 
0.377 to 0.255 and from 0.356 to 0.229 for low and high power respectively.  DMPC: 
Cholesterol liposomes saw a PDI reduction from 0.746 to 0.336 and from 0.657 to 0.352 for 
low and high power respectively.   
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  A)  B)  
Figure 2.30: A) Size of DMPC and DMPC: Cholesterol 4:4 liposomes produced using the 
Bioruptor® Plus at 40°C using 0.1, 0.2 or 0.3 mL of sample in 1.5 mL tubes.  They were then 
sonicated for 15 cycles at L and H power.  B) PDI of DMPC and DMPC: Cholesterol 4:4 
liposomes produced using the Bioruptor® Plus at 40°C using 0.1, 0.2 or 0.3 mL of sample in 
1.5 mL tubes.  They were then sonicated for 15 cycles at L and H power.   
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2.3.5.5 Bioruptor® Plus study into how different plastics using a 1.5 
mL tube affects liposome size reduction 
 
The plastic composition was investigated to see whether different plastics would give different 
results.  Initially the 1.5 mL tubes were tested using the Diagenode supplied TPX® plastic and 
PP Eppendorf tubes.  The results in Figure 2.31 showed a significant difference between the 
two plastics for both size and PDI.  TPX® DMPC liposomes had a size and PDI of 96.6 nm 
and 0.234 respectively.  PP tubes however showed a significantly larger size and PDI of 138.5 
nm and 0.267 respectively.  This showed that plastic can be a factor in how well the liposomes 
are reduced in size and therefore was investigated further.   
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Figure 2.31: A) Size of DMPC liposomes produced using the Bioruptor® Plus at 40°C using 
0.1 mL of sample in TPX® or PP 1.5 mL tubes.  They were then sonicated for 15 cycles at H 
power.  B) PDI of DMPC liposomes produced using the Bioruptor® Plus at 40°C using 0.1 mL 
of sample in TPX® or PP 1.5 mL tubes.  They were then sonicated for 15 cycles at H power.   
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2.3.5.6 Bioruptor® Plus study into how different plastics using a 50 
mL tube affects liposome size reduction 
 
The plastic used to sonicate the liposomes could be an important factor in how well the 
liposomes are reduced in size.  This is because the plastic composition will react differently to 
the sonication energy and will transfer different amounts of energy to the liposomes inside.  
Also, the TPX and PP tubes were narrower and taller than the PP and PPCO tubes and this 
different shape could also affect how much the liposomes are reduced in size. 
Figure 2.32 show four different 50 mL plastic tubes sonicated with 0.5 mL of DMPC liposomes.  
Previous work had used the PCT tubes which gave a liposome size and PDI of 76.1 ± 7.5 nm 
and 0.317 ± 0.016 respectively.  With PPCO, there was no significant increase in size and a 
small drop on PDI with size and PDI of 82.9 ± 6 nm and 0.272 ± 0.012 respectively.  TPX® 
and PS however show a significant increase in size compared to both PCT and PPCO, and a 
significant increase in PDI compared to PPCO liposomes.  TPX® had a size and PDI value of 
236 ± 114 nm and 0.305 ± 0.025 respectively and PS had a size and PDI value of 158 ± 18.7 
nm and 0.298 ± 0.02 respectively.  
The data also shows PCT and PPCO plastic tubes being used to form samples of 0.5 mL, 1 
mL and 2 mL.  Both plastics showed a significant increase in size when sonicating the larger 
volumes.  For PCT and PPCO, the PDI firstly significantly increased and then significantly 
decreased from 0.5 mL to 1 mL, and then 1 mL to 2 mL.  For PCT, the 1 mL and 2 mL samples 
had sizes and PDIs of 146 ± 10 nm and 112 ± 13 nm, and 0.338 ± 0.02 and 0.314 ± 0.015 
respectively.  For PPCO, the 1 mL and 2 mL samples had sizes and PDIs of 110 ± 11 nm and 
172 ± 12 nm, and 0.35 ± 0.008 and 0.257 ± 0.027 respectively.   
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Figure 2.32: A - D) Size of DMPC liposomes produced using the Bioruptor® Plus at 40°C using 
0.5, 1 or 2 mL of sample in a TPX® (A), PCT (B), PS (C) or PPCO (D) 50 mL tube.  They were 
then sonicated for 15 cycles at H power.   
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Figure 2.33: A - D) PDI of DMPC liposomes produced using the Bioruptor® Plus at 40°C using 
0.5, 1 or 2 mL of sample in a TPX® (A), PCT (B), PS (C) or PPCO (D) 50 mL tube.  They were 
then sonicated for 15 cycles at H power.   
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2.3.5.7 Bioruptor® Plus study into how different plastics using a 15 
mL tube and power level affects liposome size reduction 
 
Figure 2.34 show the use of PP and TPX® 15 mL tubes sonicated with 0.5 mL DMPC 
liposomes run on both low and high power.  TPX® showed a significant decrease from low 
power to high power in both size and PDI.  Size dropped from 253 ± 43 nm to 175 ± 8 nm and 
PDI dropped from 0.359 ± 0.024 to 0.311 ± 0.009.  However, PP showed no significant change 
in size or PDI.  Low power had a size of 270 ± 53 nm and a PDI of 0.329 ± 0.04 and high 
power had a size of 323 ± 102 nm and a PDI of 0.359 ± 0.033.  Figure 5.5.5 E shows the use 
of the same tubes sonicated with 0.1 mL DMPC liposomes run on both power levels.  This 
time there was no significant difference between the TPX® samples for low and high power.  
Low power had a size of 183 ± 6 nm and a PDI of 0.306 ± 0.026 and high power had a size of 
178 ± 25 nm and a PDI of 0.293 ± 0.027.  However, there was a significant size decrease from 
low to high power for the PP sonicated liposomes, although no significant change was seen 
with the PDI.  Low power had a size of 252 ± 29 nm and a PDI of 0.32 ± 0.019 and high power 
had a size of 132 ± 7 nm and a PDI of 0.322 ± 0.012. 
What this shows is that PPCO can be used as another plastic for the formation of DMPC size 
reduced liposomes as it gave a similar size and a lower PDI compared to the PCT tubes.  
However, TPX® and PS were not as suitable as they gave larger sizes and were not able to 
reduce the size of the liposomes as well as the others.  This could be due to the way the tubes 
are put together whereby the sonication aid within the tube doesn’t reach all the way to the 
bottom as found with the PCT and PPCO tubes.  This could therefore significantly reduce the 
sonication energy being able to be input into the liposomes.  It was also seen that a rise in the 
volume increases the size of the liposomes significantly and that the use of the 15 mL tubes 
did also result in size reduction, although not as much as the 50 mL PCT and PPCO tubes.  
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Finally, the use of power is also important because with both tubes it was found that a further 
size reduction could be obtained by using the higher power level. 
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Figure 2.34: A – B) Size of DMPC liposomes produced using the Bioruptor® Plus at 40°C 
using 0.1 mL (A) or 0.5 mL (B) of sample in 15 mL TPX® or PP tubes.  They were then 
sonicated for 15 cycles at L and H power levels.  C – D) PDI of DMPC liposomes produced 
using the Bioruptor® Plus at 40°C using 0.1 mL (C) or 0.5 mL (D) of sample in 15 mL TPX® 
or PP tubes.  They were then sonicated for 15 cycles at L and H power levels.   
 
 
160 
 
2.3.5.8 Bioruptor® Plus study into how DMPC: Cholesterol ratio 
affects liposome size reduction 
 
Cholesterol is an important part of many liposomal formulations due to its stabilizing effect on 
the lipid bilayer and ability to prevent lipid exchange (Socaciu et al., 2000, Sulkowski et al., 
2005).  Up to 66 mol% of cholesterol can be incorporated into a liposome bilayer depending 
on the lipid used, although 50 mol% is more common (Huang et al., 1999).  Therefore, it is 
important to see whether the addition of the cholesterol has any effect on the size of the 
liposomes formed. 
The results in Figure 2.35 show that with any addition of cholesterol to the DMPC liposomal 
formulation, an increase in size is seen. For the low power sonicated liposomes, DMPC 
liposomes were 110 ± 11.6 nm in size but when cholesterol was added in a ratio of 7:1, an 
increase was seen up to 148 ± 12.6 nm.  However no further significant increases in size were 
seen with the 6:2, 5:3 and 4:4 ratios having sizes of 139 ± 9.6 nm, 143 ± 10.2 nm and 147 ± 
8 nm respectively.  A similar pattern was seen with the high power sonicated liposomes.  
DMPC liposomes were 93.4 ± 10 nm in size, but with the addition of cholesterol in the ratio 
7:1, an increase in size was seen up to 154 ± 8.8 nm. Further increases in cholesterol content 
did not cause any further increases in size with the ratios 6:2, 5:3 and 4:4 having sizes of 152 
± 11.8 nm, 144 ± 15.7 nm and 137 ± 6 nm respectively. 
There is a small drop in the PDI with the high power sonicated liposomes, but no significant 
change with the low power sonicated liposomes.  The high power sonicated liposomes saw a 
PDI value for the DMPC liposomes of 0.297 ± 0.013.  However, with the addition of cholesterol, 
this dropped so for the 7:1, 6:2, 5:3 and 4:4 ratios, a PDI value of 0.236 ± 0.028, 0.261 ± 0.025, 
0.273 ± 0.024 and 0.219 ± 0.02 were achieved respectively.  However no significant change 
was seen with the low power sonicated liposomes with PDI values for the DMPC, 7:1, 6:2, 5:3 
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and 4:4 liposomes being 0.241 ± 0.02, 0.25 ± 0.027, 0.247 ± 0.022, 0.248 ± 0.026 and 0.242 
± 0.026 respectively. 
What these results show is that any addition of cholesterol to the DMPC formulation elicits an 
increase in size but can cause a decrease in PDI.  This is important because it shows that 
even with the same lipid and method; different sizes of liposomes can be obtained simply with 
the addition of exclusion of cholesterol from the formulation. 
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Figure 2.35: A – B) Size of DMPC: Cholesterol liposomes produced using a range of ratios 
using the Bioruptor® Plus at 40°C using 0.1 mL sample in a 1.5 mL TPX® tube.  They were 
then sonicated for 15 cycles at L (A) and H (B) power levels.  C – D) PDI of DMPC: Cholesterol 
liposomes produced using a range of ratios using the Bioruptor® Plus at 40°C using 0.1 mL 
sample in a 1.5 mL TPX® tube.  They were then sonicated for 15 cycles at L (C) and H (D) 
power levels.   
 
 
 
163 
 
2.3.5.9 Bioruptor® Plus study into how lipid concentration affects 
liposome size reduction 
 
Liposomes are made up of lipids, which can be anionic, cationic or zwitterionic.  It is therefore 
important to see how the charge or lack of charge affects the size, PDI and zeta potential of 
the liposomes.  It is also important to see how varying the concentration of the charged lipid 
affects the size, PDI and zeta potential.   
The results in Figure 2.36 and 2.37 show that liposomes made up of just DMPC have a charge 
of -7.8 ± 5.7 mV and with the addition of cholesterol saw it increase in negativity down to -24.8 
± 3.8 mV.  Figure 7.9 also shows what happened to the zeta potential with the addition of a 
cationic lipid, DOTAP.  With the addition of 1 µmole of DOTAP saw an increase in zeta 
potential to 32.7 ± 5.8 mV and with the addition of 2 and 4 mM, no significant increase was 
seen in the zeta potential with results of 29.9 ± 8.1 mV and 36.7 ± 6.8 mV respectively.  With 
the addition of a zwitterionic lipid, DOPE, there was no significant difference between any of 
the formulations to the zeta potential, as seen in Figure 5.8 C.  With the addition of 1, 2 and 4 
mM of DOPE, the zeta potential was -18.2 ± 19.5 mV, -22.8 ± 15.8 mV and -15.2 ± 1.5 mV 
respectively.  Finally, in Figure 5.7 D, the addition of the anionic lipid DMPG saw a decrease 
in the liposomes charge.  There was a significant decrease with the addition of 1 µmole of 
DMPG, down to -69.4 ± 4.2 mV.  There was no significant change between 1 and 2 mM with 
a zeta potential of -67.8 ± 6.1 mV.  The addition of more DMPG, up to 4 mM, saw a further 
significant decrease down to -89 ± 3 mV. 
The data also shows that the addition of 1 µmole of DOTAP, there was no significant change 
in the size or PDI with results of 154.6 ± 27.1 nm and 0.222 ± 0.035 respectively.  The addition 
of 2 mM saw a significant decrease in both size and PDI down to 101.7 ± 3.1 nm and 0.110 ± 
0.042 respectively.  The addition of 4 mM of DOTAP saw no significant change in either the 
size or PDI with a size of 99.1 ± 5.2 nm and a PDI of 0.148 ± 0.037.  The addition of 1 µmole 
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of DOPE there was a significant drop in both size and PDI down to 102.1 ± 5.6 nm and 0.157 
± 0.018 respectively.  However, the addition of 2 mM of DOPE saw a small but significant 
increase in size to 114.3 ± 5.9 nm although no significant change was seen with the PDI, with 
a result of 0.121 ± 0.027.  The addition of 4 mM of DOPE saw a significant decrease down to 
87.7 ± 3.2 nm although again no significant change with the PDI, with a result of 0.141 ± 0.018.  
The addition of DMPG is shown in Figures 5.8 I and J.  The addition of 1 µmole of DMPG saw 
a significant decrease in both size and PDI, down to 89.3 ± 5.8 nm and 0.197 ± 0.026 
respectively.  The addition of 2 mM of DMPG saw a further significant decrease in the size 
down to 72.1 ± 4.6 nm although no significant change was seen with the PDI, with a result of 
0.215 ± 0.012.  The addition of 4 mM of DMPG saw no significant change for either the size 
or PDI, with values of 75.1 ± 5.1 nm and 0.203 ± 0.031 respectively. 
What these results show is that adding a negative or positive lipid to the neutral DMPC: 
Cholesterol formulation decreases both the size and PDI of the formulations.  The zeta 
potential followed the expected pattern of increasing with a cationic lipid and decreasing with 
an anionic lipid.  The addition of DOPE, a zwitterionic lipid, did have an effect on the size but 
no significant effect on the zeta potential, as expected.   This is important because for vaccine 
to work well, a positive liposome allows the depot effect to occur.  The depot effect allows for 
an increase in the amount of time in which liposomes and therefore the antigen stays at the 
site of injection.  This therefore increases the overall immune response because the immune 
system has a longer period of time in which to interact with and take up the antigen.  Therefore 
for vaccine work, the liposomes should be positively charged so they can interact with the 
mostly negative human cells and cause the depot effect to occur (Henriksen-Lacey et al., 
2010). 
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Figure 2.36: A – C) Size of DMPC: Cholesterol liposomes produced with the addition of 1, 2 
or 4 mM of DOPE (A), DMPG (B) or DOTAP (C) lipid.  The Bioruptor® Plus was used at 40°C 
using 0.1 mL sample in a 1.5 mL TPX® tube.  They were then sonicated for 15 cycles at H 
power level.  D - F) PDI of DMPC: Cholesterol liposomes produced with the addition of 1, 2 or 
4 mM of DOPE (D), DMPG (E) or DOTAP (F) lipid.  The Bioruptor® Plus was used at 40°C 
using 0.1 mL sample in a 1.5 mL TPX® tube.  They were then sonicated for 15 cycles at H 
power level.   
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Figure 2.37: A - C) Zeta potential of DMPC: Cholesterol liposomes produced with the addition 
of 1, 2 or 4 mM of DOPE (A), DMPG (B) or DOTAP (C) lipid.  The Bioruptor® Plus was used 
at 40°C using 0.1 mL sample in a 1.5 mL TPX® tube.  They were then sonicated for 15 cycles 
at H power level.   
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2.3.5.10 Discussion 
 
The results showed that the Bioruptor® Plus system can be used to produce SUVs and that it 
is comparable to the probe sonication results.  The cycles and power data showed that as 
expected, an increase in the number of cycles lead to a decrease in liposome size, and that 
the use of the higher power level gave a bigger size reduction compared to the low power.  
The concentration data again tallied with previous data showing that up to in this case 24 mM, 
there was no significant difference in size or PDI.  The temperature data did show that for 
DMPC liposomes at least, the previous data held true showing that as you increase 
temperature, you decrease the size of your finished liposomes.  Volume followed previous 
data showing that a smaller volume gave a smaller liposome.  The cholesterol ratio also 
showed the expected data, filling in the gaps between DMPC, DMPC: Cholesterol 6:2 and 
DMPC: Cholesterol 4:4 showing that as you increase Cholesterol concentration, you increase 
the finished size of your liposome but decrease its PDI.  The plastics data showed that plastic 
is an important factor to consider when producing these liposomes.  TPX® showed to be better 
able to reduce liposome size compared to PP for the 1.5 mL tubes and also in the most part 
for the 15 mL tubes.  However, when comparing the 50 mL tubes, TPX® did not appear to 
work as well.  TPX® did not reduce the liposome size as much as others under the same 
conditions, namely PPCO and PCT.  This could be due to the tubes being a different shape 
and having a different sonication aid used although this would require further investigation.  
However, what this data did show was that 50 mL tubes could be used to produce mL of 
liposomes at a reasonable size under the same conditions used for the much smaller tubes.  
Finally the formulation data showed that as you add additional lipid to a formulation, you are 
liable to change how well that formulation reduces in size, and need to be prepared to change 
the method if a certain size is required.   
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2.3.6 Bioruptor® Pico liposome size reduction studies 
 
The Bioruptor® Pico is another machine currently on the market from Diagenode.  This is a 
smaller machine but does have other advantages.  In particular, its compact nature means 
that the space it requires in a lab environment is smaller.  However its use of only one power 
level could be a problem, and it cannot be used with larger tubes due to the shallow nature of 
the sonication bath itself.   
 
2.3.6.1 Bioruptor® Pico study into how number of cycles affects 
liposome size reduction 
 
The Bioruptor® Pico is another machine used by Diagenode and so it was important to test 
whether liposomes could be made using this machine also.  Number of cycles was first 
investigated as the Pico has no opportunity to change the power output.  The data in Figure 
2.38 showed that as the number of cycles, and therefore sonication time, increased, there was 
a decrease in size and PDI for DMPC liposomes from 3 to 10 cycles of 105.2 down to 75.1 
nm and from 0.426 to 0.268 respectively.  DMPC: Cholesterol liposomes showed a dissimilar 
pattern for size and PDI, with decreases from 3 to 10 cycles of 114.7 to 108.5 nm and 0.456 
to 0.434 respectively.  Both of these drops were not seen to be statistically significant.  What 
this showed is that for DMPC liposomes, size reduction comes relatively easily with increased 
sonication time but with the addition of cholesterol, the liposomes are harder for the Pico to 
reduce in size over time.   
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2.3.6.2 Bioruptor® Pico study into how volume affects liposome size 
reduction 
 
Volume as shown before with previous Bioruptor® systems, is known to be important in how 
well the sonicator works at reducing liposome size.  However this data in part seemed to 
contradict this as shown in Figure 2.38.  DMPC liposomes sonicated with 0.1, 0.2 or 0.3 mL 
of sample in showed no significant difference in size or PDI across the board with sizes of 
80.2, 94.6 and 80.0 nm and polydispersities of 0.346, 0.396 and 0.387 respectively.  DMPC: 
Cholesterol liposomes showed a decrease in size with smaller volumes, down from 159.6 to 
107.7 nm but no significant difference in PDI from 0.41 to 0.397 respectively.   
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A)  B)  
C)  D)  
Figure 2.38: A – B) Size (A) and PDI (B) of DMPC and DMPC: Cholesterol liposomes produced 
using the Bioruptor® Pico at 40°C using 0.1 mL sample in a 1.5 mL TPX® tube.  They were 
then sonicated for up to 10 cycles.  C – D) Size (C) and PDI (D) of DMPC and DMPC: 
Cholesterol liposomes produced using the Bioruptor® Pico at 40°C using 0.1 to 0.3 mL sample 
in a 1.5 mL TPX® tube.  They were then sonicated for 10 cycles.   
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2.3.6.3 Discussion 
 
Liposomes were formed using the Bioruptor® Pico, although only two factors were 
investigated.  These showed however that it is another viable machine to be used for liposome 
size reduction and that with further work, it could be used for liposome size reduction.  In 
particular, its small size and compact nature would lend itself well to a lab environment with 
the sonicator and control mechanism all included in once machine.   
2.4 Conclusion 
 
In conclusion, DMPC and DMPC: Cholesterol liposomes were successfully reduced in size 
using both the probe sonicator and each of the bath sonicators; the XL, the Standard, the Plus 
and the Pico.  The probe sonicator performed as expected compared to the literature and 
reduced the liposome size to below 100 nm in just a couple of minutes.  However this process 
is difficult to control in regards to temperature, cannot be done under sterile conditions and 
required further processing post sonication by using a centrifuge to remove the titanium 
particles that break off from the probe itself during the sonication process.  What each of the 
bath sonicators does is allow for the liposomes to be sonicated in a temperature controlled 
sterile environment without the need for further processing.  This process does require longer 
to sonicate compared to the probe sonicator, up from approximately 6 minutes of probe 
sonication to 15 – 20 minutes of bath sonication, but the ability to sonicate multiple samples 
at once allows for overall more sample to be sonicated at any one time.  Each Bioruptor® was 
individually optimised as subtle changes in the designs and power levels means that such 
parameters as time and pulse need to be calibrated depending upon the machine. 
It was shown that all factors need to be taken into consideration.  These include time, power 
level, concentration, volume, temperature, and pulse.  For example, the choice of plastic for 
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the liposomes to be sonicated in was shown to play an important role when optimised through 
the Bioruptor® Plus and the Bioruptor® Standard.  The choice of plastic was also different 
depending on the size of the tube as it was found that for the 1.5 mL tube, TPX® was the best 
performing plastic at liposome size reduction.  However, for the larger 50 mL tube, it was found 
that PCT was the better performing plastic.  Formulation was also an important factor in how 
much the liposomes were reduced in size.  For example, the addition of just 1 mM of a positive 
or negative lipid to an 8 mM formulation reduced the liposome size significantly to below 100 
nm.  This is important because many formulations that are on the market or being researched, 
require a mix of multiple lipids and other parts to form the final liposome.  It is also known that 
a negatively charged liposome is more efficient than a neutral liposome for internalisation into 
the cells by endocytosis process (Mishra et al., 2011).  However cationic liposomes have been 
shown to be useful for both drug and vaccine delivery due to their interactions with the 
negatively charged human cells (Schwendener, 2014, Vitiello et al., 2015).  
There are some limits to this process however.  The first is that there is not much chance of 
further scale up beyond the lab as a bath sonicator machine generally cannot be up scaled 
enough to meet the demands of an industrial setting.  This is also true for probe sonication but 
other methods such as microfluidics can be scaled up to the litre scale.  Also the transition 
temperature of the lipid is paramount as a higher transition temperature lipid of for example 1, 
2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) of 75 °C would simply not be 
possible with the water bath associated with the Bioruptor® systems (Avanti, 2018).  Also, it 
is known that as temperature increases, sonication efficiency decreases and therefore it will 
reach a point where it simply is no longer efficient to use the bath sonicator.  On one hand, 
high temperatures can help to disrupt solvent-solute interactions, which involve Van der Waals 
forces, H-bonding and dipole interaction, also faster diffusion occurs at higher temperature.  
But  on the second hand, a too  high  temperature  can  also  lead  to  “vaporous” cavitation  
where  acoustic  bubbles  can  do coalescence with natural bubbles of vapour, decreasing the 
efficiency of the ultrasonic effects (Mason, 1991, Niemczewski, 2007, Ali et al., 2014).  
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However, the Bioruptor® bath sonicator systems are very good for producing small quantities 
of most liposomal formulations and is especially useful for the lower transitional temperature 
lipids as the water bath allows for a much more controlled temperature which allows the 
smaller liposomes to form without damaging the lipid due to a high temperature. 
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3 Bioruptor bath sonicator systems: applications in the 
spheres of liposomes, DNA extraction and sonicator 
efficiency 
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3.6 Aims and objectives 
 
The Bioruptor® bath sonication systems can be used for a variety of different techniques 
including DNA extraction, DNA shearing, protein and chromatin analysis.  The second 
objective was to improve DNA extraction through improving the kit currently being offered 
through the company Diagenode.  The final objective was to improve the sonication efficiency 
tests done by the company by using a different technique involving the use of potassium iodide 
and the cavitation effect that occurs during the sonication process. 
 
 
3.2.1 Investigating more cost effective methods of demonstrating bath 
sonicator efficiency 
 
At the start of each day, fresh solutions of Potassium Iodide (KI) 0.29 Mol/L and Ammonium 
molybdate (AM) 3.67 mM/L were formulated.  Before using, 5 parts of KI were mixed with 0.1 
part of ammonium molybdate (e.g. 5 ml plus 0.1 ml) and scaled accordingly to the number of 
samples per day. The KI/AM mix was kept at room temperature (RT) before use. 2 Bioruptor® 
models will be used in the study: Bioruptor® Pico and the Bioruptor® Plus. The Bioruptors 
were used with a cooling system set at 4°C for initial trials as specified below. To note that 
salts can precipitate in samples at 4°C. If salt are observed, use 10°C (or higher T if needed) 
but be sure that the temperature is controlled.  After sonication, the sample was measured at 
352 nm (yellow colour due to I2 formation) on the Smart SpecPlus. A blank was included which 
is KI/AM without sonication. 
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3.2.1.1 Conditions to test on the Bioruptor® Pico: 
 
Each of the following experiments was ran with the following cycle settings and size of 
samples: 
 
3 cycles 30”On/30” OFF x12 samples  
5 cycles 30”On/30” OFF x12 samples  
10 cycles 30”On/30” OFF x12 samples  
15 cycles 30”On/30” OFF x12 samples 
 
Experiment 1: Use 0.65 ml microtubes (ref C30010011)   and a corresponding tube holder 
filled with 100 µl of KI/AM mix and sonicate for  
Experiment 2: Use 0.65 ml microtubes (ref C30010011)   and a corresponding tube holder 
filled with 200 µl of KI/AM mix and sonicate  
Experiment 3: Use 0.5 ml microtubes (refC30010013) filled with 100 µl of KI/AM mix and 
sonicate  
 
Each of the following experiments was ran with the following cycle settings and size of 
samples: 
3 cycles 30”On/30” OFF x6 samples  
5 cycles 30”On/30” OFF x6 samples  
10 cycles 30”On/30” OFF x6 samples  
177 
 
15 cycles 30”On/30” OFF x6 samples 
Experiment 4: Use 1.5 ml microtubes with caps (ref C30010016) and a corresponding tube 
holder filled with 300 µl of KI/AM mix and sonicate for  
Experiment 5: Use 1.5 ml TPX microtubes (refC30010010) and a corresponding tube holder 
filled with 100, 200 or 300 µl of KI/AM mix and sonicate for  
 
 
3.2.1.2. Conditions to test on the Bioruptor® Plus 
 
Each of the following experiments was ran with the following cycle settings and size of 
samples: 
3 cycles 30”On/30” OFF x6 samples  
5 cycles 30”On/30” OFF x6 samples  
10 cycles 30”On/30” OFF x6 samples  
15 cycles 30”On/30” OFF x6 samples 
 
Experiment 6: Use 1.5 ml TPX® microtubes (ref C30010010) and a corresponding tube holder 
filled with 300 µl of KI/AM mix and sonicate at high power  
Experiment 7: Use 1.5 ml TPX® microtubes (ref C30010010) and a corresponding tube 
holder filled with 300 µl of KI/AM mix and sonicate at low power  
Experiment 8: Use 1.5 ml BioSigma microtubes and a corresponding tube holder filled with 
300 µl of KI/AM mix and sonicate at high power  
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Experiment 9: Use 1.5 ml BioSigma microtubes and a corresponding tube holder filled with 
300 µl of KI/AM mix and sonicate at low power 
Experiment 10: Use 1.5 ml TPX® microtubes (ref C30010010) and a corresponding tube 
holder filled with 100 µl of KI/AM mix and sonicate at high power  
Experiment 11: Use 1.5 ml TPX® microtubes (ref C30010010) and a corresponding tube 
holder filled with 200 µl of KI/AM mix and sonicate at high power  
Experiment 12: Use 1.5 ml BioSigma microtubes and a corresponding tube holder filled with 
100 µl of KI/AM mix and sonicate at high power  
Experiment 13: Use 1.5 ml BioSigma microtubes and a corresponding tube holder filled with 
200 µl of KI/AM mix and sonicate at high power 
Experiment 14: Use 1.5 ml BioSigma microtubes and a corresponding tube holder filled with 
100 µl of KI/AM mix and sonicate at high power at 10 °C 
Experiment 15: Use 1.5 ml BioSigma microtubes and a corresponding tube holder filled with 
200 µl of KI/AM mix and sonicate at high power at 10 °C 
Experiment 16: Use 1.5 ml BioSigma microtubes and a corresponding tube holder filled with 
100 µl of KI/AM mix and sonicate at high power at 20 °C 
Experiment 17: Use 1.5 ml BioSigma microtubes and a corresponding tube holder filled with 
200 µl of KI/AM mix and sonicate at high power at 20 °C 
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3.2.2 Investigating more cost effective materials for DNA extraction 
using the Bioruptor® Pico 
Protocol: 
Before starting, ethanol (100 %) was added to the wash buffer and labelled as such.  The 
Bioruptor® Pico was turned on and left at room temperature.  A thermomixer was preheated 
to 56 °C and another to 37 °C with the appropriate amount of extraction buffer placed in to 
preheat to the required 37 °C.  The elution buffer was also equilibrated to room temperature.   
The sections of DNA were placed in a 1.5 mL Bioruptor® tubes and 180 µl of pre-warmed 
FFPE extraction buffer was added.  The sections were cut up when required to ensure they 
were completely immersed in the buffer.  Each sample was then incubated for 10 minutes at 
37 °C.  Each sample was then vortexed and then sonicated using Bioruptor® Pico for 3-5 
cycles 30’’On/30’’Off at room temperature until the paraffin had been emulsified and 
dissociated from the tissue section with the solutions turning milky once complete.  These 
were then briefly spun down and transferred to a new 1.5 ml tube.  20 µl of Diagenode 
proteinase K was then added.  Each sample was incubated for 1 hour at 56 °C in a 
Thermomixer with shaking at 1300 rpm.  4 µl of reversal crosslink buffer was added and then 
each sample was incubated at 65°C for 4h or overnight with shaking at 1300 rpm. 
Each sample was then span down and the supernatant carefully transferred to a DiaFilter 
column to remove paraffin if required.  These were the centrifuged for 2 minutes at 8000 rpm 
at room temperature.  The filter unit was discarded and the collection tube containing the flow-
through was kept.  1 ml of binding buffer and 20 µl of precipitant was then added to the flow-
through or the sample that had not been filtered.  A DiaPure Spin column was placed in a 
collection tube, 600 µl of the mixture from the previous step was loaded and then centrifuged 
for 1 min at 8000 rpm at RT.  The flow-through was discarded and then tube reused with the 
second half of each sample, 600 µl, was added to the column and then centrifuged under the 
same conditions.  The spin columns were then washed twice with 400 µL of washing buffer, 
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following the sample centrifuge protocol as before.  After washing, the spin column was placed 
in a clean 1.5 ml tube and 50 µl of Elution buffer at room temperature was added to the centre 
of the membrane.  This was then left to incubate at room temperature for 3 minutes and then 
centrifuged for 1 minute at 14000 rpm at room temperature.     The eluate contained the purified 
DNA. This was then quantified and analysed.   
 
3.2.2.1 Assay 1.  
 
Sample 1: test the protocol for FFPE DNA extraction replacing original columns and buffers r 
by MicroChIP DiaPure columns and buffers as specify below.  
Sample 2: as sample 1/2 but omitting DiaFilter column at step 8.  
 
3.2.2.2 Assay 2:  
 
Compare 3 different compositions of FFPE extraction buffer  (buffer 1 vs buffer 2 vs buffer 3) 
using the protocol for FFPE DNA extraction as above replacing original columns and buffers 
r by MicroChIP DiaPure columns and buffers as specify below and  
• Sample 1 FFPE extraction buffer 1 
• Sample 2 FFPE extraction buffer 2 
• Sample 3 FFPE extraction buffer 3 
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3.2.2.3 Assay 3.  
Choose the best experimental condition from assay 1 and 2 and compare the efficiency of 
decrossslinking (step 7) 
• 4h at 65° 
• Overnight at 65°C 
• 15 min at 95°C  
 
3.2.2.4 Analysis of DNA ran with DNA fragment analyser 
 
DNA was analysed using the Advanced analytical fragment analyser.  The inlet buffer was 
measured into each well 1 mL at a time and changed daily.  TE buffer was also measured into 
each well, 0.2 mL at a time and again changed daily.  0.022 mL of dilutent marker was added 
to each well a sample was to be added to as well as the final well, #12.  0.002 mL of the ladder 
was added to well #12 only and then 0.002 mL of sample was added to each well with dilutent 
marker in.  In the wells without sample, a blank solution of 0.024 mL was added.  The gel was 
added with the addition of the dye (add 0.001 ml of dye for 10 ml of gel) and conditioning 
solution was topped up.  Each required 5 mL for each lane being ran. 
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3.7 Results and discussion 
 
3.3.2  Investigating more cost effective methods of demonstrating bath 
sonicator efficiency 
3.3.2.1 Bioruptor® Pico 
For experiment 1, 0.65 ml tubes were sonicated with 0.1 ml samples in Pico for 3, 5, 10, 15 
cycles of 30 seconds on, 30 seconds off.  Results were expected to be the best as small tubes 
with smallest volume to back up what the DNA results show.  Results below show a good R 
value of 0.993 with RSD steadily decreasing to 24 % in Figure 3.1.  The data shows the results 
generally stays fairly close to the mean and the steady increase is clear.  Finally the p values 
all show significant differences across with board meaning that as the number of cycles 
increased, the reaction increased so more of the iodine was converted to I2 formation. 
A) B)  
 
Figure 3.1: A) Average absorption for Experiment 1 settings, 0.65 ml tubes were sonicated 
with 0.1 ml samples in Pico, from 3 to 15 cycles with standard deviation. B) Relative standard 
deviation for Experiment 1 from 3 to 15 cycles. 
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 Experiment 2 was done under the same conditions but used a 0.2 ml sample volume and 
showed that doubling the volume did not just decrease the values by half.  The data in Figure 
3.2 shows a significantly smaller absorbance and a much larger scatter over that absorbance.  
The R value is poor at 0.87 and even though the RSD does drop, it drops from above 200 % 
to 44 %, so still pretty high.  Finally the p values show no significant difference between any 
samples apart from between 3 and 15 cycles.  This showed that an increase in volume can 
dramatically reduce the efficacy of sonication to such an extent that it almost completely stops 
the I2 formation. 
A) B)  
Figure 3.2: A) Average absorption for Experiment 2 settings, 0.65 ml tubes were sonicated 
with 0.2 ml samples in Pico, from 3 to 15 cycles with standard deviation. B) Relative standard 
deviation for Experiment 2 from 3 to 15 cycles. 
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Experiment 3 used 0.5 ml tubes with 0.1 ml sample with the smaller tubes comes an overall 
increased percentage volume and therefore a reduction was expected.  The R value was again 
not good at 0.9 and the overall absorbance was lower than the 0.65 ml tube with a 0.1 ml 
sample as shown below in Figure 3.3.  The RSD stayed fairly constant between 58 and 29 %.  
There appeared to be a saturation whereas the cycles were increased, the increase in 
absorption became smaller and smaller in comparison.  Although this is difficult to be sure of 
as the spread of the data, particularly at the 15 cycles, is very large.  There were a few 
significant differences between 3 and 10 to 15 cycles.  What this shown is that as you increase 
the volume of tube to sample volume ratio, there is a decrease in sonication efficacy. 
A) B)  
Figure 3.3: A) Average absorption for Experiment 3 settings, 0.5 ml tubes were sonicated with 
0.1 ml samples in Pico, from 3 to 15 cycles with standard deviation. B) Relative standard 
deviation for Experiment 3 from 3 to 15 cycles. 
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Experiment 4 used the larger 1.5 ml tubes with caps with 0.3 ml sample with the results shown 
below in Figure 3.4.  This was expected to be better than the equivalent TPX® tubes.  This 
showed good r value of 0.994 and gave a good RSD down to below 30 % and there were 
some significant differences.   
 
A) B)  
Figure 3.4: A) Average absorption for Experiment 4 settings, 1.5 ml tubes were sonicated with 
0.3 ml samples in Pico, from 3 to 15 cycles with standard deviation. B) Relative standard 
deviation for Experiment 4 from 3 to 15 cycles. 
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Experiment 5a used the TPX® 1.5 ml tubes with 0.1 ml sample in.  This data shows a more 
confusing picture.  The expectation was that a reduced volume would give a better absorption 
and that this would be up with experiment 1 and 4.  However, the reduction was large 
compared to these two previous experiments as shown in Figure 3.5.  The increase from 3 to 
5 cycles actually saw a small reduction in mean absorption.  There was an increase at 15 
cycles but it was still significantly lower than the other two experiments mentioned.  The r value 
is again poor at 0.91.  This could be due to the different position of the tube within the bath 
due to a lack of cap which can be seen below.  Too little sample means the sonic energy sweet 
spot is too high and therefore does not interact with the sample.  The addition of another 0.1 
ml however means this sweet spot is reach and is shown below in 5b.  This shows that the 
use of the sonication efficiency kit is vital in being able to determine the parameters for the 
research before it is actually carried out.  This means no loss of research samples trying to 
ascertain these parameters. 
 
A) B)  
Figure 3.5: A) Average absorption for Experiment 5a settings, 1.5 ml TPX® tubes were 
sonicated with 0.1 ml samples in Pico, from 3 to 15 cycles with standard deviation. B) Relative 
standard deviation for Experiment 5a from 3 to 15 cycles. 
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Experiment 5b used the same tube as before with 0.2 ml sample.  An increase in sample 
volume was expected to decrease further the absorption but instead the complete opposite 
was seen in Figure 3.6.  The increase in volume saw a large significant increase in absorption 
and with a perfect r value of 1.  There were significant differences across the board apart from 
between 3 and 5 cycles where no significant difference was seen.  This large increase, as 
mentioned before, is because the sample is now in the sonicators sweet spot and therefore is 
getting the maximum sonication and therefore maximum absorption. 
A) B)  
Figure 3.6: A) Average absorption for Experiment 5b settings, 1.5 ml TPX® tubes were 
sonicated with 0.2 ml samples in Pico, from 3 to 15 cycles with standard deviation. B) Relative 
standard deviation for Experiment 5b from 3 to 15 cycles. 
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Experiment 5c used the same tubes as before with 0.3 ml sample and compared directly with 
the tubes with caps in experiment 4.  Here a similar pattern emerges as before with a good 
increase and an r value of 0.988 as shown below in Figure 3.7.  The RSD were relatively good 
at around 30 % although 10 cycles gave a really good reading of below 6 %.  The p values 
show no significant difference between 3 and 5 or between 10 and 15 cycles but the rest were 
significant increases and the overall data showed a decrease compared to the 0.2 mL 
samples. 
A) B)  
Figure 3.7: A) Average absorption for Experiment 5c settings, 1.5 ml TPX® tubes were 
sonicated with 0.3 ml samples in Pico, from 3 to 15 cycles with standard deviation. B) Relative 
standard deviation for Experiment 5c from 3 to 15 cycles. 
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Figure 3.8 below shows the combination of experiments 1 to 5.  What these show is that as 
you increase volume of sample in a tube, the absorption decreases.  This is true if you 
decrease the sample volume to tube volume ratio.  However this was not true for the larger 
1.5 mL tubes whereby a capped tube showed a large absorption for a 0.1 mL sample, the 
TPXC tube had a largest absorption for a 0.2 mL sample.  This shows that the size of the cap 
and the effect this has on where the tube is placed in the water bath has an effect on the 
sonication efficiency. 
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Figure 3.8: (A) Overall line plot showing absorption of the different Pico experiments 
absorption averages.  Absorption peak heights for (B) 3, (C) 5, (D) 10 and (E) 15 cycles. 
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3.3.2.2 Bioruptor® Plus data 
 
Experiment 6 used TPX® 1.5 ml tubes with 0.3 ml sample using the Bioruptor® Plus sonicator 
on high power showed a good absorption at the 3 cycle mark although no significant increase 
was seen with 5 cycles in Figure 3.9.  An increase was seen up to 10 cycles but then again at 
15 cycles, no significant increase was seen.  The RSD were all good at below 30 % and the r 
value was 0.968. 
 
A) B)  
Figure 3.9: A) Average absorption for Experiment 6 settings, 1.5 ml TPX® tubes were 
sonicated with 0.3 ml samples at H power in Plus, from 3 to 15 cycles with standard deviation. 
B) Relative standard deviation for Experiment 6 from 3 to 15 cycles. 
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 Experiment 7 used the same tubes, volume and machine as before with low power and had 
a smilar story as shown below in Figure 3.10.  No significant difference was seen between 3 
and 5 cycles with significant increases for the rest of the samples.  The RSD was again at or 
below 30 % throughout and the r value was near perfect at 0.9998.  There was no significant 
difference between the samples of low and high power showing that the power level does not 
affect sonication efficacy for the type of tube and sample volume used in the experiment. 
A) B)  
Figure 3.10: A) Average absorption for Experiment 7 settings, 1.5 ml TPX® tubes were 
sonicated with 0.3 ml samples at L power in Plus, from 3 to 15 cycles with standard deviation. 
B) Relative standard deviation for Experiment 7 from 3 to 15 cycles. 
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Experiment 8 used the 1.5 mL BioSigma tubes with a 0.3 ml sample at high power.  This was 
expected to form poorly compared to the TPX® tubes but the initial signs were promising.  
There was again no significant difference between the 3 and 5 or 10 and 15 cycles but 
significant difference between the others as shown below in Figure 3.11.  The RSD was again 
at or below 30 % and the r value not bad at 0.9833.  However by the time the number of cycles 
increased to 15, the BioSigma tubes had a reduced sonication efficacy compared to the TPX® 
tubes. 
A) B)  
Figure 3.11: A) Average absorption for Experiment 8 settings, 1.5 ml BioSigma tubes were 
sonicated with 0.3 ml samples at H power in Plus, from 3 to 15 cycles with standard deviation. 
B) Relative standard deviation for Experiment 8 from 3 to 15 cycles. 
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Experiment 9 used the same tubes, volume and machine as before with low power.  Again 
there was no significant difference between 3 and 5 cycles with significant differences after 
this between 5 and 15 cycles as shown below in Figure 3.12.  The RSD was again around or 
below 30 % and the r value was poor at 0.953.  There was no significant difference between 
the low and high power samples again so for this tube at this volume, the power level does 
not significantly affect sonication efficacy.   
A) B)  
Figure 3.12: A) Average absorption for Experiment 9 settings, 1.5 ml BioSigma tubes were 
sonicated with 0.3 ml samples at L power in Plus, from 3 to 15 cycles with standard deviation. 
B) Relative standard deviation for Experiment 9 from 3 to 15 cycles. 
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Experiment 10 used a TPX® 1.5 mL tube with a Bioruptor® Plus at high power with a 0.1 ml 
sample.  Reducing the volume here caused the same problem as before, with a sharp drop in 
the efficiency and overall no significant differences between any of the number of cycles as 
shown below in Figure 3.13.  The r value was poor and the RSDs were not good, especially 
for the later cycles.  This showed that both Bioruptor® systems have a sweet spot where as 
the volume of sample is reduced too much, the sonication energy cannot reach it as well and 
therefore the I2 formation is reduced. 
A) B)  
Figure 3.13: A) Average absorption for Experiment 10 settings, 1.5 ml TPX® tubes were 
sonicated with 0.1 ml samples at H power in Plus, from 3 to 15 cycles with standard deviation. 
B) Relative standard deviation for Experiment 10 from 3 to 15 cycles. 
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Experiment 11 used the same parameters as before with a 0.2 ml sample.  An increase in 
volume this time appeared to show an increase in absorption although this was not significant 
compared to the 0.1 ml sample and not as large as the 0.3 mL sample as shown below in 
Figure 3.14.  Cycle on cycle, the only significant increase was between 10 and 15 cycles.  The 
r value was good at 0.998 and the RSD was good at around or below 30 %.  
 
A) B)  
Figure 3.14: A) Average absorption for Experiment 11 settings, 1.5 ml TPX® tubes were 
sonicated with 0.2 ml samples at H power in Plus, from 3 to 15 cycles with standard deviation. 
B) Relative standard deviation for Experiment 11 from 3 to 15 cycles. 
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Experiment 12 used BioSigma 1.5 ml tubes with a 0.1 ml sample on high power.  The use of 
the different tube did not see a significant increase or decrease in the absorption seen as seen 
in Figure 3.15.  The small sample size did give an r value of 0.99 although the RSD were 
higher than before.  This showed that it was the volume and not the plastic composition of the 
tube in this case which affects sonication efficacy.   
 
A) B)  
Figure 3.17: A) Average absorption for Experiment 12 settings, 1.5 ml BioSigma tubes were 
sonicated with 0.1 ml samples at H power in Plus, from 3 to 15 cycles with standard deviation. 
B) Relative standard deviation for Experiment 12 from 3 to 15 cycles. 
 
 
 
 
 
 
y = 0.0235x + 0.0051
R² = 0.9904
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
0 5 10 15 20
A
b
so
rp
ti
o
n
Number of cycles
0
10
20
30
40
50
60
0 5 10 15 20
re
la
ti
ve
 s
ta
n
d
ar
d
 d
ev
ia
ti
o
n
 /
 %
Number of cycles
198 
 
Experiment 13 used the same criteria as before with a 0.2 ml sample.  Only a significant cycle 
on cycle difference was seen between 5 and 10 cycles as shown in Figure 3.16.  These results 
were significantly smaller than the 0.1 or 0.3 mL sample which was not expected.  The r value 
was good at 0.998 and the RSD were at or below 40 %. 
 
A) B)  
 
  
Figure 3.16: A) Average absorption for Experiment 13 settings, 1.5 ml BioSigma tubes were 
sonicated with 0.2 ml samples at H power in Plus, from 3 to 15 cycles with standard deviation. 
B) Relative standard deviation for Experiment 13 from 3 to 15 cycles. 
 
Figure 3.17 below shows the combined results for experiments 6 to 13.  What these show 
firstly is that there is no significant difference between the absorption seen for low and for high 
power.  However the BioSigma tubes used for experiments 8 and 9 showed an increased 
absorption compared to TPX® tubes.  What experiments 10 to 13 showed was that as you 
decreased the volume from 0.3 mL to 0.2 mL you had an increase in absorption and a further 
increase was seen when reducing the volume from 0.2 mL to 0.1 mL. 
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Figure 3.17: (A) Overall line plot showing absorption of the experiments 10 to 13 absorption 
averages.  Absorption peak heights for (B) 3, (C) 5, (D) 10 and (E) 15 cycles. 
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Experiment 14 used BioSigma 1.5 ml tubes with a 0.1 ml sample at high power at 10 °C.  The 
increase in temperature saw a decrease in the absorption compared to 4 °C, although this 
was not significant as shown below in Figure 3.18.  There was a tailing off at the upper end of 
the cycles, which saw a poor r value of 0.86 and RSD values ranging between 15 and 50 %. 
 
A) B)  
Figure 3.18: A) Average absorption for Experiment 14 settings, 1.5 ml BioSigma tubes were 
sonicated with 0.1 ml samples at H power at 10 °C in Plus, from 3 to 15 cycles with standard 
deviation. B) Relative standard deviation for Experiment 14 from 3 to 15 cycles. 
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Experiment 15 used the same parameters as above with 0.2 ml sample as shown below in 
Figure 3.19.  The increase in volume this time appeared to have a negative impact on the 
absorption with a significantly reduced absorption compared to the 0.1 ml 4 °C sample, 
although not compared to the equivalent 0.2 mL 4 °C sample.  The r value was good though 
at 0.995 although the RSD was relatively high at between 40 and 60 %.  
A) B)  
Figure 3.19: A) Average absorption for Experiment 15 settings, 1.5 ml BioSigma tubes were 
sonicated with 0.2 ml samples at H power at 10 °C in Plus, from 3 to 15 cycles with standard 
deviation. B) Relative standard deviation for Experiment 15 from 3 to 15 cycles. 
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Experiment 16 used the same parameters as above with a 0.1 ml sample at 20 °C as shown 
below in Figure 3.20.  The further increase in temperature saw a further decrease in absorption 
for the 0.1 mL sample.  There was no significant difference due to the high RSD and low 
absorption across the board and the r value being 0.04. 
 
A) B)  
Figure 3.20: A) Average absorption for Experiment 16 settings, 1.5 ml BioSigma tubes were 
sonicated with 0.1 ml samples at H power at 20 °C in Plus, from 3 to 15 cycles with standard 
deviation. B) Relative standard deviation for Experiment 16 from 3 to 15 cycles. 
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Experiment 17 used the same parameters as before with a 0.2 ml sample as shown below in 
Figure 3.21.  Some significant differences were seen between the 5 and 10 cycle runs, 
although there was again a saturation of the absorption after this as no increase was seen at 
15 cycles.  The r value was poor again at 0.838 and a steady increase up to above 60 % was 
seen in the RSD.  
 
A) B)  
Figure 3.21: A) Average absorption for Experiment 17 settings, 1.5 ml BioSigma tubes were 
sonicated with 0.2 ml samples at H power at 20 °C in Plus, from 3 to 15 cycles with standard 
deviation. B) Relative standard deviation for Experiment 17 from 3 to 15 cycles. 
 
Figure 3.22 shows that as you increase temperature of the water bath, absorption is shown to 
decrease.  This shows that sonication power level decreases as the water bath temperature 
increases. 
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Figure 3.22: (A) Overall line plot showing absorption of the experiments 14 to 17 absorption 
averages.  Absorption peak heights for (B) 3, (C) 5, (D) 10 and (E) 15 cycles. 
205 
 
3.3.2.3 Discussion 
 
The overall data compared to one another showed some important results.  Firstly, the top 
experiments we had in terms of absorption were those with the 1.5 ml tubes and with the best 
volumes.  The samples also all showed an increase when sonicated for up to 15 cycles 
compared to the absorption seen with 3 cycles. 
Some significant differences were seen however using the Bioruptor® Pico bath sonicator 
system.  Between experiments 1 and 2, a significant difference was seen from 3 to 15 cycles 
and therefore a significant increase in absorption when using 0.1 ml compared to 0.2 ml.  
Between experiments 1 and 3, no significant difference was seen until 10 cycles and therefore 
no significant difference between using the 0.65 ml or the 0.5 ml tubes until a larger number 
of cycles is used for the same volume.  Between experiments 4 and 5, no significant difference 
across the board was seen between 0.3 ml sample in tubes with caps and TPX® tubes without 
caps which shows that the position in the bath, whilst important, does not exert enough of an 
effect to be significant.  However volume does have a significant effect with the smallest 
volume showing significant difference after 5 cycles and the larger volume of 0.3 ml showing 
a significant difference at 10 cycles. 
All the Bioruptor® Plus experiments together showed a similar pattern throughout and that the 
difference between low and high power and between TPX® and BioSigma tubes were there.  
At 3 cycles, no significant difference was seen between the low and high power samples, but 
significant differences were seen across the board between TPX® and BioSigma tubes, 
although not in the way that was expected.  It was expected that the TPX® tubes would 
perform better, but this data shows that at 3 cycles, it is the BioSigma tubes that perform the 
best. At 5 cycles, the exact same pattern is seen, except the significant difference had 
dropped. At 10 cycles, almost no differences are seen whatsoever with the only one being 
between TPX® high power and BioSigma low power.  This is the first time however a 
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significant difference is seen whereby the TPX® tube significantly better performs compared 
to the BioSigma tubes. At 15 cycles however, no significant differences are seen whatsoever 
across the board.  So at 15 cycles, the tube type and power level makes no significant 
difference to the absorption value seen. 
For the second set of Bioruptor® Plus bath sonicator results, no significant differences were 
found across the board and so with this set up, the use of a different tube or the use of a 
smaller volume did not make a difference.  At 3 cycles, the only significant difference seen 
was between 4 °C and 20 °C for 0.2 mL sample.  At 5 cycles, no significant differences.  At 10 
cycles, some significant differences were found between the 0.1 mL 4 °C sample and the 0.1 
mL 20 °C sample and the 0.2 mL 10 and 20 °C samples.  At 15 cycles, some significant 
differences were found between 0.1 mL 4 °C sample and the 0.1 and 0.2 mL 10 and 20 °C 
samples. 
 
 
3.3.3 Investigating more cost effective materials for DNA extraction 
using the Bioruptor® Pico 
 
DNA extraction is useful for a number of different areas and is done through a number of ways.  
These include organic multistep liquid chemical process, inorganic silica methods, solid phase 
extraction methods or differential extraction.  Diagenode developed a silica based method of 
DNA extraction however this is not cost effective.  Therefore the use of a Bioruptor® to not 
necessitate the use of traditional methods using toxic organic solvents is investigated as well 
as the use of DiaPure columns and buffers to try and keep the production in house and 
therefore cheaper. 
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3.3.3.1 Assay 1 
 
Assay 1 data is shown below in Figure 3.23.  These show the difference between using a 
DiaFilter column or not.  A DiaFilter column is simply a column that fits into the 1.5 mL tube 
provided and removes larger chunks of DNA and paraffin that were not removed during the 
previous processes, giving a purer sample of DNA extracted.  This could be seen as an 
important step to aid in the removal of the paraffin after the use of the Bioruptor® Pico but 
could be seen as a disadvantage whereby it could remove DNA as well.  This data showed 
just that with a reduced concentration of DNA for those samples that used the filter column.  
The samples with the filter gave a concentration of 20.15 ng/ µL and the samples without the 
filter column gave a concentration of 38.19 ng/ µL, but with a p value of 0.19, this was not 
statistically significant.  However in its favour, it did not require any extra time on the centrifuge 
whereby those samples that didn’t use the filter column did require at times an extra minute 
or two on the centrifuge.  This could be due to the paraffin blocking the filter increasing the 
time needed to filter the liquid through the filter. 
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Figure 3.23: Assay 1 results showing the difference in DNA concentration achieved with or 
without a filter stage.   
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3.3.3.2 Assay 2 
 
Assay 2 looked into the use of three different buffers for the DNA extraction numbered 1 to 3 
with results shown below in Figure 3.24.  Buffer number 1 is the buffer normally used with the 
kit and showed good DNA extraction and buffer number 2 showed similar results.  Buffer 
number 3 showed a much greater DNA extraction although not significant due to the high 
standard deviations. 
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Figure 3.24: Assay results showing DNA concentration results for each of the 3 chosen 
buffers. 
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3.3.3.3 Assay 3 
 
Assay 3 was used to compare extraction conditions with changes to how long and at what 
temperature the samples as shaken at after being sonicated.  The three conditions showed 
that temperature was not an important factor as even though the first conditions had the 
highest temperature, it also had the lowest DNA extraction concentration as shown below in 
Figure 3.25.  What the results did show was that the longer the samples were left to shake, 
the more DNA was extracted with an increased concentration from 15 minutes to 4 hours and 
from 4 hours to overnight. 
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Figure 3.25: Assay results showing DNA concentration for three different conditions. 
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3.4 Conclusion 
 
Using the Bioruptor®® Plus bath sonication system, it was also shown that for lipophilic 
drugs, methods 2 and 3 whereby the lipid film hydration part of the methodology was bypassed 
showed a much better drug loading ability.  However, the amount of drug incorporated would 
not be concentrated enough for a clinically relevant dosage for any of the three drugs used in 
this study.  Further work would have to be carried out to see if increasing the concentration up 
to a clinically relevant dosage could be possible without having to increase the volume of the 
formulation to something that would be too large for a child to take.  This is due not only to the 
increase in drug concentration being required, but also the subsequent increase in lipid 
concentration which could affect the ability of the Bioruptor® Plus to form the smaller 
liposomes and load the drug into the lipid bilayer. 
It was also shown that certain drugs such as propofol could have unexpected side effects 
during the process causing them to be unusable for this particular method such as destroying 
the plastic tubes the samples are sonicated in.  Albendazole too was shown not to be able to 
be used for this process due to its ability to aggregate and come out of solution as soon as 
the sonication process was complete.   
Characterisation of the ultrasonic bath is very important for sonochemical reactions. The 
conditions of maximum cavitation intensity can be different for each ultrasonic bath and, due 
to this behaviour, it is very difficult to compare the results obtained with different ultrasonic 
baths even using the same conditions. In analytical chemistry, when reproducible and 
accurate results are required, the experimental conditions (such as water volume, 
temperature, detergent concentration, vertical and horizontal positions, number of tubes, 
sonication time) must be studied, established and rigorously reproduced for each experiment. 
An innovative way to study these conditions was employed in the present work by 
spectrophotometrically following the I2 formation from free radical of iodine (I·) obtained after 
sonication of a KI solution. 
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In conclusion, for the 0.65 ml tubes, clearly the 0.1 ml sample is the better volume giving a 
significantly better result compared to the 0.2 mL sample and it performs better than the 0.5 
ml tube.  For the 1.5 ml tubes, there was no significant difference between the tubes with caps 
and the TPX® tubes.  A decrease in volume to 0.1 ml saw a drop in efficiency with the 1.5 ml 
TPX® tubes under a variety of conditions and a similar pattern was seen with the BioSigma 
tubes.  No significant difference was seen between the low and high power samples.  A 
decrease in temperature saw a decrease in efficiency of the sonochemical reaction.  High 
relative standard deviations means repeatability is the main issue.  Also some results did not 
go the same as previous DNA results and therefore need to be investigated further. 
What the DNA extraction results show is that the addition of a filter does reduce sample prep 
time but does also reduce DNA extraction concentration.  The choice of buffer was also shown 
to have an effect on DNA concentration as did the conditions in which the samples were left 
to shake and extract.  However from these results, none of these differences were statistically 
significant and so more work will need to be done to see whether these are indeed significant 
differences. 
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4. Water dispersion of carbon nanotubes 
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4.1 Aims and Objectives 
 
Carbon nanotubes are inherently insoluble in water due to high Van Der Waals forces.  The 
carbon nanotube surface is made up of benzene rings and need some kind of modification to 
increase their solubility.  This can be through either covalent or non – covalent 
functionalisation.  This study focussed on non – covalent functionalisation which occurs 
through mixing the carbon nanotubes with a surfactant such as SDS, SDBS or a phospholipid 
in water.  Sonication is used to disrupt the surfactant and carbon nanotube molecules which 
allows for them to interact and for the surfactant to non – covalently bond with the carbon 
nanotube surface. 
The aim of this work was to create protocols for the Bioruptor® systems to disperse carbon 
nanotubes.  The objectives were to first of all create protocols for dispersing carbon nanotubes 
using SDS and SDBS using the current Bioruptor® systems.  The second objective was to 
investigate the use of a non – toxic surfactant, MPC, to disperse the carbon nanotubes and 
compare directly to SDS and SDBS. 
 
4.2 Materials and methods 
 
4.2.1 Dispersion of carbon nanotubes using the Bioruptor® Plus 
 
CoMoCat single walled carbon nanotubes, SDBS and SDS were purchased from Sigma 
Aldrich (Sigma Aldrich, Dorset, UK) (Nish et al., 2007).  These were dispersed in deionised 
water at initial concentrations of 0.1 % SDS or SDBS and 0.01 % carbon nanotubes (Yang et 
al., 2013).  10 mL of dispersion was placed into a 50 mL Nalgene™ Polycarbonate tube and 
a metallic bar was placed inside to aid in the dispersion process by reflecting sound waves to 
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produce a better dispersion efficiency.   Sonication was undertaken using the Bioruptor® Plus 
(Diagenode, Liège, Belgium) at power level L which equates to 130 W and at a temperature 
of range between 5 and 40 °C.  This was kept constant through the use of a temperature 
regulator. Sonication took place over 60 cycles of 60 seconds on and 15 seconds off.  Once 
sonication was complete, the dispersion was centrifuged for 150 minutes at 40, 000 G at 17 
°C.  The supernatant was then removed from the samples and analysed using UV – Vis 
spectroscopy and PL. 
 
4.2.1.1 Temperature studies 
 
Carbon nanotubes were made as described previously at 5, 13, 20, 30 and 40 °C.  The 
samples were then analysed using UV – Vis spectroscopy and PL. 
 
4.2.1.2 Cycles study 
 
Carbon nanotubes were made as described previously using a number of different cycle 
settings detailed below in Table 4.1.  The samples were then analysed using UV – Vis. 
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Table 4.1: Bioruptor® Plus bath sonicator system cycle settings used for this study keeping 
the total time as similar as possible. 
Time on /seconds Time off / seconds Number of cycles Total time / minutes 
60 15 60 75 
50 13 75 78.75 
40 10 90 75 
30 8 120 76 
20 5 180 75 
10 5 300 75 
 
4.2.1.3 DMPC study 
 
Carbon nanotubes were made as described previously using 1, 2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) as the surfactant.  The samples were then ran on the UV – Vis 
spectrometer. 
 
4.2.1.4 Dilution study 
 
Carbon nanotubes were made as described previously at 5, 13 and 20 °C.  The samples 
were then diluted 1 in 2 and 1 in 10 and ran on the UV – Vis spectrometer. 
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4.2.1.5 Surfactant study 
 
Surfactant choice is known to have a great effect on how efficacious the dispersion of carbon 
nanotubes is using the Bioruptor® bath sonication system. SDS and SDBS are both standards 
used within the carbon nanotube field but both are toxic to the human body and are therefore 
unsuitable for dispersion of carbon nanotubes for biological purposes. Other surfactants that 
could be used include lysophospholipids. MPC was investigated to see whether it could be 
used to disperse carbon nanotubes, at what concentrations and how it compares to the other 
surfactants. Therefore each surfactant was sonicated at concentrations ranging from 0.1 to 1 
mg / mL with a constant concentration of 0.1 mg / mL of carbon nanotubes. 
 
4.2.1.6 Carbon nanotubes stability study 
 
Carbon nanotubes were made as described previously at two separate sonication 
temperatures of 13 and 40 °C dispersed in SDBS and at 13 °C with SDS and MPC.  Samples 
were then analysed using UV – Vis spectroscopy over a period of 6 months to see if there was 
any change in the spectra.  The samples were left on the benchtop under the same conditions 
to allow direct comparison between the samples. 
 
4.2.2 Dispersion of carbon nanotubes using the probe sonicator 
 
1 mg of carbon nanotubes were dispersed with 10 mL of distilled water and 10 mg of SDBS 
in a glass vial. The vial was placed on the probe sonicator (MSE Soniprep 150 plus with MSE 
PG100 probe (UK)) in an ice bath that was refreshed every 20 minutes. The probe was set to 
5 amps and ran for either 15, 30, 60, 90 and 120 minutes. The samples were then ultra-
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centrifuged as described previously and then analysed using UV – Vis spectroscopy and DLS. 
These were also analysed using PL. 
 
4.2.3 Analysis of carbon nanotubes 
 
Analysis was conducted using the UV – Vis – NIR spectrometer (Lambda 1050, Perkin Elmer, 
USA).  The wavelength scanning range for the UV – Vis spectrometer was from 270 to 1100 
nm using a plastic clear sided cuvette.  The scan interval was set to 1 nm for the UV – Vis 
spectrometer.  3 mL of sample was placed into the cuvette and analysed after a blank of 
deionised water had been ran.  Samples were ran in triplicate. 
 
PL analysis of carbon nanotubes has previously been described by Lutsyk et al and Tan et al 
(Lutsyk et al., 2016, Tan et al., 2007).  Briefly, the fluorescence emission spectra at various 
excitation wavelengths were recorded  using  a  Horiba  NanoLog  excitation–emission  
spectrofluorometer  equipped  with  a  nitrogen-cooled  InGaAs  array  detector  to generate  
PL  excitation-emission  maps,  with  the X-axis representing the wavelength of the PL 
emission, λ emission (EM), and the Y-axis representing the excitation wavelength, λ excitation 
(EX). Entrance/exit slits of 14 nm in width were used for both the excitation and emission 
monochromators in the NIR PL measurements. The PL experiments in the visible range were 
performed using a silicon detector and 2 nm entrance/exit slits for the monochromators.  
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4.3 Results and discussion 
 
4.3.1 Dispersion of carbon nanotubes with the Bioruptor® Plus 
 
4.3.1.1 Water dispersion of carbon nanotubes using SDS as the surfactant 
compared to SDBS 
 
Diagenodes Bioruptor® sonicator systems have been used in studies previously to aid in the 
dispersion of carbon nanotubes (Scardaci et al., 2007, Hasan et al., 2014).  Scardaci et al 
were able to show that after 4 hours of sonication with the addition of SDBS successful 
dispersion was achieved.  Hasan et al were able to show that after the same sonication time 
and using the same surfactant, double – walled carbon nanotubes (DW carbon nanotubes) 
were successfully dispersed.  An important analysis tool is that of PL.  PL comprises both 
fluorescence and phosphorescence processes and originates from an excitation/emission 
process between different electronic energy levels in the material.  PL can be used to gain a 
variety of information such as the diameter of the carbon nanotubes, presence of small 
bundles, quantity of semi – conducting carbon nanotubes in the sample and their chirality (He 
et al., 2013b).  However it has limited use for DW carbon nanotubes and cannot be used at all 
for MW carbon nanotubes as the nanotube – nanotube interactions cause the PL signal to be 
quenched (Satishkumar et al., 2007).  For this work involving single walled carbon nanotubes 
though it is a highly useful tool. 
All the results showed that the samples were too concentrated for PL analysis and therefore 
needed to be diluted.  Figure 4.1 A shows that carbon nanotubes dispersed using SDS at 13 
°C needed to be diluted by a factor of 10 and gave a strong reading for PL excitation at 
approximately 580 nm and emission at approximately 980 nm which corresponds to the 6,5 
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chirality which is the majority chirality found in the original pristine carbon nanotubes.  Figure 
4.1 (B) shows that carbon nanotubes dispersed using SDS at 5 °C also needed to be diluted 
by a factor of 10 and showed a similar dispersion of carbon nanotube chiralities.  Figure 4.1 
(C) shows that carbon nanotubes dispersed using SDBS at 13 °C needed a much larger 
dilution by a factor of 35 and showed an increased affinity for the dispersion of the 6,5 chirality 
compared to the others.  Figure 4.1 (D) shows that carbon nanotubes dispersed using SDBS 
at 5 °C again needed a larger dilution factor of 20 and showed an increased affinity for 
dispersal of other chiralities.  
 
The results show that by using SDBS as opposed to SDS, a much better dispersion of carbon 
nanotubes can be achieved which is shown by the need to increase the dilution factor of the 
SDBS dispersions compared to the SDS.  The increase is required because SDBS at the 
concentrations formulated is too high for the detector to quantify.  This is due to the SDBS 
molecule containing an extra benzene ring which allows aromatic stacking to occur between 
the carbon nanotubes and the SDBS (Guldi and Martín, 2010).   
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A) B)                                                             
C) D)  
Figure 4.1 All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1 % 
surfactant concentration, 5 or 13°C water bath temperature, 2 mL sample size, Nalgene™ 
Polycarbonate tubes, cycle set up of 60 cycles of 60 seconds on, 15 seconds off, L power 
level.  Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) SDS dispersed carbon 
nanotubes at 13 °C. B) SDS dispersed carbon nanotubes at 5 °C. C) SDBS dispersed carbon 
nanotubes at 13 °C. D) SDBS dispersed carbon nanotubes at 5 °C.  
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4.3.1.2 Water dispersion of carbon nanotubes using SDBS as the 
dispersal surfactant 
 
4.3.1.2.1 SDBS dispersed carbon nanotubes sonicated at different 
temperatures 
 
Previous work by Shi et al was able to show that at temperatures at or above 30 °C, SDS has 
a tendency to lapse and to desorb from the carbon nanotube surface (Shi, 2013).  This in turn 
leads to reaggregation of the carbon nanotubes.  However, when they used a sonication 
temperature of 24 °C, the SDS did not lapse and reaggregation did not occur.  Due to the 
ability of the Bioruptor® bath sonicator systems being able to really control the sonication 
temperature, sonication temperature was investigated over a range of temperatures from 5 °C 
up to 40 °C using UV – Vis spectroscopy as it is known that dispersion directly corresponds 
to absorbance strength (Njuguna et al., 2015). 
The results in Figure 4.2 A - C show that initially there is an increase in the dispersion of the 
carbon nanotubes as shown by the increase in the UV – Vis spectrum of the 13 °C (orange) 
sonicated dispersion compared to the 5 °C (grey) sonicated dispersion.  With further increases 
in sonication temperature, a significant drop is seen in the UV – Vis spectrum of the 20 °C 
(blue) and 30 °C (yellow) sonicated dispersions with no further drop seen with the 40 °C 
(green) sonicated dispersion. 
The results show that sonication temperature does have a significant effect on the quality of 
the dispersion of carbon nanotubes using the surfactant SDBS.  With a lower sonication 
temperature of 5 °C, the drop in carbon nanotube dispersion compared to 13 °C could be 
down to the sonication temperature being too low and not inputting enough energy into the 
system.  This means that after the 75 minutes of sonication, not all aggregations had been 
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debundled and SDBS adsorbed onto the carbon nanotube surface as debundling is a dynamic 
process.  Once sonication had stopped, it meant there were more aggregates left over that 
were then subsequently removed during the centrifugation process. 
This could be due to the fact that over a long sonication time, in this case 75 minutes, the 
sonication process increases the temperature in the water bath by several degrees as noted 
in the Bioruptor® manual (Diagenode, 2015).  Dumee et al for example also saw that the 
sonication temperature of their water bath went up from 17 to 25 °C over the sonication 
process (Dumée et al., 2013).  This increase in temperature could be enough to cause the 
SDBS to lapse, as seen by Shi et al, and so cause the decrease in carbon nanotube 
dispersion.  Also the increase in temperature can increase the frequency of collisions and 
contacts between the carbon nanotubes due to Brownian motion and decrease the dispersions 
stability (Dumée et al., 2013, Wong et al., 2009).  It is possible that a combination of these 
processes is what lead to the reduction in the carbon nanotube dispersion.  What this shows 
is that sonication temperature is vital for good carbon nanotube dispersion using a surfactant, 
and that by going either too high or too low, you can get sub optimal carbon nanotube 
dispersion using surfactants such as SDBS.   
 
PL data from the initial runs is shown below in Figure 4.3 A – E.  It shows a reduced dispersion 
concentration at higher temperatures and some electron transfer.  Further runs were 
conducted, as shown in Figures 4.4 A - E, no significant changes were seen in any other PL 
plots and the UV data showed that the carbon nanotubes were broadly of similar dispersion 
efficiencies apart from at 40 °C whereby a reduction in efficiency was seen, correlating with 
previous work which showed that above 30 °C, there is a significant increase in lapsing of the 
surfactant away from the carbon nanotube surface and therefore increasing the hydrophobicity 
of the carbon nanotubes. 
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The decrease in dilution factor once the sonication temperature is increased above 13 °C 
could be due to SDBS lapsing and reunioning together, which allows the carbon nanotubes to 
then reaggregate and be removed during the centrifugation phase (Shi, 2013).  This means 
that sonication temperature is a vital part of the method optimisation for the dispersion of 
carbon nanotubes and that bath sonication is an excellent piece of equipment for this due to 
the water bath being able to keep the temperature at near constant.  The slight downside is 
that it is known that the temperature within the tube being sonicated is known to increase by 
a few degrees due to the sonication energy being imparted, and this could be the reason why 
the 20 °C samples showed signs of reduced dispersion, even though the literature states it 
happens when temperatures exceed 30 °C (Shi, 2013). 
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Figure 4.2 A: All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1 
% SDBS concentration, 2 mL sample size, Nalgene™ Polycarbonate tubes, cycle set up of 
60 cycles of 60 seconds on, 15 seconds off, L power level.  Ultracentrifugation for 150 minutes 
at 40, 000 G at 17°C.    Results represent n = 3. Sonication temperature of 5 °C (grey), 13 °C 
(orange), 20 °C (blue), 30 °C (yellow), 40 °C (green). B) Absorption peak averages for the 
three runs at 976 nm for the 5 temperatures investigated. C) Absorption peak averages for the 
three runs at 566 nm for the 5 temperatures investigated. 
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A) B)   
C) D)  
E)  
Figure 4.3  All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1 % 
surfactant concentration, 5 or 13°C water bath temperature, 2 mL sample size, Nalgene™ 
Polycarbonate tubes, cycle set up of 60 cycles of 60 seconds on, 15 seconds off, L power 
level.  Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) SDBS dispersed carbon 
nanotubes at 5 °C  B) SDBS dispersed carbon nanotubes at 13 °C  C) SDBS dispersed carbon 
nanotubes at 20 °C D) SDBS dispersed carbon nanotubes at 30 °C. E) SDBS dispersed 
carbon nanotubes at 40 °C. 
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A) B)
C) D)  
E)  
Figure 4.4 All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1 % 
surfactant concentration, 2 mL sample size, Nalgene™ Polycarbonate tubes, cycle set up of 
60 cycles of 60 seconds on, 15 seconds off, L power level.  Ultracentrifugation for 150 minutes 
at 40, 000 G at 17°C. A) PL plot of 5 °C sample. B) PL plot of 13 °C sample. C) PL plot of 20 
°C sample. D) PL plot of 30 °C sample. E) PL plot of 40 °C sample. 
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4.3.1.2.2 Dispersion of carbon nanotubes at a number of different cycle 
settings using the Bioruptor Plus 
 
Dispersion of carbon nanotubes is done through multiple cycles of sonication on and off set 
by the Bioruptor® system being used.  Previous work has generally focussed on using 20 
seconds on and 5 seconds off up to 180 cycles.  However with the new machine, the 
Bioruptor® Plus, the number of cycles is limited to 99.  Therefore the cycle settings were 
changed to accommodate this up to 60 cycles of 60 seconds on and 15 seconds off which 
would allow for only one session to be set rather than the 2 or 3 it would take using the old on 
and off times.  This study investigated whether this change caused a difference in the carbon 
nanotube dispersion concentration. 
Figure 4.5 A shows the average UV – Vis spectroscopy data for each of the cycle settings in 
question that were investigated.  What they show is pretty identical spectra with no significant 
differences between them.  This is further compounded in Figure 4.5 B and C which show the 
average peak heights at 566 and 976 nm for these CoMoCat carbon nanotubes.   
What this data therefore shows is that cycle setting doesn’t have a significant effect on the 
concentration of the carbon nanotubes post dispersion using sonication.  I believe this is 
because the sonication process takes 75 minutes and that the amount of sonication time is 
the important factor, not how often the sonicator is turned on and off.  This is particularly 
important for this work as it shows that there is no significant difference between the 60 
seconds on and 15 seconds off used for this work and the 20 seconds on and 5 seconds off 
used for previous work using other Bioruptor® systems.  This shows that this data can be 
compared to that previous work. 
 
228 
 
A)
0 5 0 0 1 0 0 0 1 5 0 0
0
1
2
3
c y c le  s e tt in g s
W a v e le n g th  / n m
A
b
s
o
r
p
ti
o
n
6 0 ,1 5
5 0 ,1 3
2 0 ,5
1 0 ,5
3 0 ,8
 
B) 
6
0
5
0
3
0
2
0
1
0
0 .0
0 .5
1 .0
1 .5
2 .0
5 6 6  n m
C)
6
0
5
0
3
0
2
0
1
0
0
1
2
3
9 7 6  n m
 
Figure 4.5 A) Average UV –Vis spectra showing dispersion of carbon nanotubes using 
different cycle settings. B) Average peak height at each cycle setting at 566 nm. C) Average 
peak height at each cycle setting at 976 nm. 
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4.3.1.2.3 Dilution study of dispersed carbon nanotubes in SDBS 
 
The concentration of carbon nanotubes can be inferred by the strength of the absorption of 
the UV – Vis spectrum (Attal et al., 2006).  The concentration is an important factor in 
determining the efficiency of the method of solubilisation of the carbon nanotubes using a 
surfactant such as SDBS.  Therefore it is important that if a carbon nanotube sample is diluted, 
it can be inferred from the diluted sample what the concentration would be of the starting 
sample.   
Using three samples of carbon nanotubes sonicated at 5, 13 and 20 °C, the samples were 
each diluted 1 in 2 and 1 in 10 with deionised water.  These were then each compared to the 
original 1 in 1 sample to see how close the experimental results were to the theoretical 50 % 
and 10 % values.  Figures 4.6 A, B and C show the spectrum achieved for the three different 
temperatures at the three dilution factors.  Taking the two peaks associated with the 6, 5 
chirality of 566 and 976 nm, the absorption peaks of the three dilution factors for the three 
temperatures were compared.  These results are shown in Figures 4.7 A and B.  What these 
results show in Figure 4.7 A is that the 1 in 2 dilutions were each very close to the 50 % value 
and the 1 in 10 were really close to the 10 % value. 
Quantitatively, this is shown in Figure 4.7 B.  Here the percentage difference between the 
experimental value and the theoretical value are shown.  Each of the values is shown to be 
less than 1 % away from the theoretical value with an average of just 0.49 %.  This means 
that when samples are diluted, it can be inferred from the absorption values what the original 
peaks would be, and therefore the concentration of the carbon nanotubes. 
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A)                            
B)               
C)  
Figure 4.6 All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1 % 
surfactant concentration, 5 or 13°C water bath temperature, 2 mL sample size, Nalgene™ 
Polycarbonate tubes, cycle set up of 60 cycles of 60 seconds on, 15 seconds off, L power 
level.  Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) Carbon nanotubes 
sonicated at 5 °C with no dilution, diluted 1 in 2 and 1 in 10. B) Carbon nanotubes sonicated 
at 13 °C with no dilution, diluted 1 in 2 and 1 in 10. C) Carbon nanotubes sonicated at 20 °C 
with no dilution, diluted 1 in 2 and 1 in 10. 
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A)        
B)  
Figure 4.7 A) 566 and 976 nm peak heights for diluted samples compared to theoretical peak 
height for 50 % and 10 % of initial peak height.  B) Difference from the theoretical value for 
the peak height for the 1/2 and 1/10 dilutions. 
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4.3.2 Probe sonication of carbon nanotubes with SDBS 
 
Probe sonication works in a similar way to bath sonication, and has been shown to also 
disperse carbon nanotubes.  Therefore it is important to compare the two methods to see 
which disperses carbon nanotubes the best.  Previous work has shown that carbon nanotubes 
can be dispersed with a probe sonicator (Tunuguntla et al., 2017, Gao et al., 2015).  Therefore 
the probe sonicator was investigated using a variety of time periods of sonication to see how 
well it compares to the Bioruptor® plus bath sonicator. 
The results in Figure 4.8 A and B show that the probe over the same time period as the bath 
is not quite as efficacious at carbon dispersion.  This is because for the 90 minutes of probe 
sonication, at 976 nm the peak height is 1.281 compared to the standard at 1.567 as shown 
in Figure 4.3.  The same pattern is seen with 566 nm with the peak height of 0.653 compared 
to the standard at 0.875.  However both showed an increase to above the standard after 2 
hours of sonication up to 2.844 and 1.468 for 976 and 566 nm respectively.  This could be 
down to a general increase in concentration caused by the extra half an hour of sonication. 
Figure 4.9 A and B show the samples ran on the DLS.  These show that over the 2 hours of 
sonication, there is no significant change in the size of PDI of the samples, indicating that there 
is no significant changes occurring to the length of the carbon nanotube carbon nanotubes.  
This correlates with other work which shows that probe sonication needs to occur for up to 10 
hours or above before the carbon nanotubes are cut short enough to be shown on a DLS 
(Tunuguntla et al., 2017).  However what it does show is that carbon nanotubes can be 
dispersed using the probe in a similar time frame to that of that Bioruptor® Plus bath sonicator. 
 
Figures 4.10 A - D show the PL map for the probe sonicated carbon nanotubes after each 
time point. After half an hour, Figure 4.10 A shows that increasing the time increases the 
concentration of carbon nanotubes successfully dispersed as the count goes up from 13,350 
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to 15,950. There is also some excitation energy transfer beginning to appear next to the 6, 5 
chirality peak at excitation of 575 nm and emission of 1025 nm. After 1 hour however, as 
shown in Figure 4.10 B, this appears to have diminished once again and another general 
increase in concentration is seen with the count going up to 25,600. After 1.5 hours, as shown 
in Figure 4.10 C, the dilution factor had to be increased to 1 in 50. This sample also showed 
again an increase in the excitation energy transfer seen at emission 1025 nm. This was further 
seen in Figure 4.10 D where an increase in the count was seen up to 23,400 and an increase 
in the intensity was seen with the electron transfer peak to make it the second most intense 
peak after the 6, 5 peak.  
What these showed was that carbon nanotubes can be successfully dispersed using the probe 
sonicator as well as the Bioruptor® bath sonicator. These carbons increase in dispersion 
efficiency the longer they are sonicated and due to the use of an ice bath, there is no significant 
decrease in dispersion due to the surfactant lapsing away from the carbon nanotube surface. 
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Figure 4.8 All runs were with probe sonicator, 0.01 % carbon nanotube concentration, 0.1 % 
surfactant concentration, in an ice bath, 2 mL sample size, 10 amp power level.  
Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) Carbon nanotubes dispersed in 
SDBS over time using the probe sonicator.  Absorption peak height at 976 nm. B) Carbon 
nanotubes dispersed in SDBS over time using the probe sonicator.  Absorption peak height at 
566 nm. 
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Figure 4.9 All runs were with probe sonicator, 0.01 % carbon nanotube concentration, 0.1 % 
surfactant concentration, in an ice bath, 2 mL sample size, 10 amp power level.  
Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) Carbon nanotube size dispersed 
with SDBS at varying times using the probe sonicator. B) Carbon nanotube PDI dispersed with 
SDBS at varying times using the probe sonicator
236 
 
A) B) 
C) D)  
 
Figure 4.10: All runs were with probe sonicator, 0.01 % carbon nanotube concentration, 0.1 
% surfactant concentration, in an ice bath, 2 mL sample size, 10 amp power level.  
Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) PL plot of probe sonicated carbon 
nanotubes after 30 minutes. B) PL plot of probe sonicated carbon nanotubes after 60 minutes. 
C) PL plot of probe sonicated carbon nanotubes after 90 minutes. D) PL plot of probe 
sonicated carbon nanotubes after 120 minutes.
237 
 
4.3.3 Water dispersion of carbon nanotubes using biologically safe 
surfactants 
 
4.3.3.1 Dispersion of carbon nanotubes using MPC as a surfactant 
 
Biologically safe surfactants are an important part of being able to use carbon nanotubes 
within a biological system.  This is because the usual surfactants used, SDS and SDBS, are 
both toxic to the human body and are therefore unsuitable.  The structure of phospholipids 
could lend itself to carbon nanotube dispersion and indeed previous work has shown that 
these could be used.  This work focussed on using MPC and DMPC as the surfactants in 
question due to them being the same lipids used in the previous liposome work.  This would 
mean that if these carbon nanotubes were to be taken forward into liposome complex work, 
the lipid in use would not have a bearing on properties such as liposome charge or immune 
response.  This work therefore focussed on using the MPC and DMPC lipids in the same way 
as SDS and SDBS before so a direction comparison could be made to determine whether 
they could be used going forward. 
Figure 4.11 A and B show the average peak heights for MPC at 566 and 976 nm compared 
to SDS and SDBS.  What these show is that MPC is comparable to SDS is its ability to disperse 
carbon nanotubes with no significant difference shown between the two peak heights at either 
wavelength.  However they both are much reduced compared to SDBS as expected as they 
do not contain the benzene ring which allows for a much better interaction between the carbon 
nanotube surface and the SDBS molecule.  Figure 4.11 C and D show the PL map of MPC 
dispersed carbon nanotubes and MPC on its own.  What these show is that the dispersion 
with carbon nanotubes is a clean dispersion with strong peak heights corresponding to the 6, 
5 dominant chirality of the CoMoCat nanotubes in question with 8, 4 chirality also showing a 
bright response.  What this also shows is that MPC in itself does not illicit a reaction in the PL 
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which means the PL map in Figure 4.11 C is the dispersed carbon nanotubes alone and not 
the surfactant used. 
What this data shows is that carbon nanotubes can be dispersed using MPC as a biologically 
safe surfactant and that these can be comparable to SDS dispersed carbon nanotubes. 
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C) D)  
 
Figure 4.11: All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1 
% surfactant concentration, 13°C water bath temperature, 2 mL sample size, Nalgene™ 
Polycarbonate tubes, cycle set up of 60 cycles of 60 seconds on, 15 seconds off, L power 
level.  Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) Average peak heights at 
566 nm for each of the three surfactants tested. B) Average peak heights at 976 nm for each 
of the three surfactants tested. C) PL dispersion of MPC dispersed carbon nanotubes. D) PL 
of MPC without carbon nanotubes present. 
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4.3.3.2 Dispersion of carbon nanotubes using the phospholipid DMPC 
as the surfactant 
 
Many surfactants used for dispersion of carbon nanotubes, such as SDS and SDBS, are toxic 
and cannot be used for pharmaceutical formulations.  By contrast, double-chained 
phospholipids are considered non – toxic and are used in multiple formulations currently on 
the market.  However, phospholipids are considered to be curvophobic as their 3D structures 
are approximated as cylinders and their packing assumes bilayers. Therefore wrapping 
around a cylindrical object such as a carbon nanotube is not geometrically preferable (Wu et 
al., 2006).  To test this, the lipid DMPC was used to try and disperse SW carbon nanotubes.  
This is different to the MPC previously used as it has two fatty acid chains and not one, which 
alters the shape of the surfactant. 
 
The results in Figure 4.12 show the complete lack of carbon nanotube dispersion with virtually 
no peaks between 370 and 1200 nm.  This is compared to dispersion using SDS and SDBS 
which show good peaks at approximately 570 nm and 980 nm which correspond to the 6,5 
chirality of the carbon nanotubes used.  This confirms the idea that by using a lipid that 
conforms to a cylinder structure, it is unable to wrap around the carbon nanotube and aid in 
the water dispersion.   
 
Although this work has confirmed that double chained phospholipids cannot disperse carbons, 
other work however has shown that it is possible to use phospholipids by adding a small 
amount of 2C18-PEG. Furthermore, the amount of 2C18-PEG needed to disperse the same 
amount of SW carbon nanotubes is greatly reduced by the co-adsorption of common 
phospholipids such as 2C10-choline (Sato and Sano, 2014).  Another possibility would be to 
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use the geometrically preferred lysophospholipids whereby the cone shape allows the 
lysophospholipids to wrap around the SW carbon nanotube in a semi-spherical curvature 
along SWNT axis and along the circumference of SWNT (Wu et al., 2006, Alberts et al., 2015).   
 
 
 
Figure 4.12: All runs were with Bioruptor® Plus, 0.01 % carbon nanotubes concentration, 0.1 
% surfactant concentration, 2 mL sample size, Nalgene™ Polycarbonate tubes, cycle set up 
of 60 cycles of 60 seconds on, 15 seconds off, L power level.  Ultracentrifugation for 150 
minutes at 40, 000 G at 17°C.    Results represent n = 3. DMPC (grey), SDBS (orange) and 
SDS (blue). 
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4.3.4 Combination of surfactants 
 
4.3.4.1 Carbon nanotube dispersion surfactant study comparing like for 
like surfactants 
 
Surfactant choice is known to have a great effect on how efficacious the dispersion of carbon 
nanotubes is using the Bioruptor® bath sonication system. SDS and SDBS are both standards 
used within the carbon nanotubes field but both are toxic to the human body and are therefore 
unsuitable for dispersion of carbon nanotubes for biological purposes. Other surfactants that 
could be used include sodium cholate (SDOC) and lysophospholipids and in this study, it was 
the lysophospholipid MPC that was investigated to see whether it could be used to disperse 
carbon nanotubes, at what concentrations and how it compares to the other surfactants. 
Therefore each surfactant was sonicated at concentrations ranging from 0.1 to 1 mg / mL with 
a constant concentration of 0.1 mg / mL of carbon nanotubes.  
The UV- Vis data clearly shows in Figures 4.13 A – C that the MPC and SDS are similarly 
matched in how efficacious they are at dispersing the carbon nanotubes. Interestingly, the 
MPC showed a shift in the 976 nm peak up to around 995 nm. This could be due to some kind 
of interaction occurring between the carbon nanotubes and the MPC such as dielectric 
screening. It was also shown that SDS continued to show an increase in the dispersion 
efficiency through the concentrations, but MPC maxed out at 0.5 mg mL and showed a small 
but not significant decrease in peak height when 1 mg / mL of MPC was used. SDBS was 
shown to be far and away the best at dispersing the carbon nanotubes under these conditions. 
This is due to the benzene ring being present and interacting with the carbon nanotube surface 
to create π – π bond interactions. This greatly increases the ability of the SDBS to disperse 
the carbon nanotubes individually. 
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The PL data shows the different concentrations of SDBS, shown in Figures 4.14 A - C, at the 
concentrations 0.1 – 0.5 mg / mL diluted to concentrations of 1 in 10, 1 in 25 and 1 in 50. What 
they show is that clearly the concentrations of carbon nanotubes decreases as you decrease 
the surfactant concentration but also that as you decrease the concentration, more of the other 
chiralities such as 7, 5 and 8, 4 are shown and also some electron transfer between them, 
indicating more small bundles present as opposed to individual tubes being the majority seen 
with the 1 mg / mL samples. The SDS, shown in Figures 4.14 D - F, data for 1 and 0.5 mg / 
mL also showed a similar pattern, although at a lower dilution factor and in fact by the time 0.1 
mg is tested, nothing can be seen at all. The MPC data, as shown in Figures 4.15 A - C, 
showed that MPC is far more likely to disperse the tubes individually and preferentially 
disperse 6, 5 tubes as the PL map is very similar to a 1 mg / mL sample and this pattern 
continues down to 0.1 mg / mL. What these figures show is that the different surfactants have 
different dispersal characteristics.  This could be useful is a specific chirality is required as 
choosing a specific surfactant could give rise to an increase in the concentration of that 
particular chirality. 
  Also all the samples showed that as you decrease the concentration of surfactant, you get a 
decrease in carbon nanotube concentration and as this decreases, there is more electron 
transfer seen and more of the other chiralities within the sample seen as well. 
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Figure 4.13: All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1 
to 1 % surfactant concentration, 13°C water bath temperature, 2 mL sample size, Nalgene™ 
Polycarbonate tubes, cycle set up of 60 cycles of 60 seconds on, 15 seconds off, L power 
level.  Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) Absorption peak height at 
566 nm for each sample at each surfactant concentration. B) Absorption peak height at 976 
nm for each sample at each surfactant concentration. C) Absorption peak height at 995 nm 
for each sample at each surfactant concentration. 
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A) B)      
C) D)           
E)   F)  
Figure 4.14 All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1 to 
1 % surfactant concentration, 13°C water bath temperature, 2 mL sample size, Nalgene™ 
Polycarbonate tubes, cycle set up of 60 cycles of 60 seconds on, 15 seconds off, L power 
level.  Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) PL plot of SDBS 5 mg 
sample. B) PL plot of SDBS 3 mg sample. C) PL plot of SDBS 1 mg sample. D) PL plot of 
SDS 5 mg sample. E) PL plot of SDS 3 mg sample. F) PL plot of SDS 1 mg sample. 
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A) B)    
C)  
Figure 4.15: All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1 
to 1 % surfactant concentration, 13°C water bath temperature, 2 mL sample size, Nalgene™ 
Polycarbonate tubes, cycle set up of 60 cycles of 60 seconds on, 15 seconds off, L power 
level.  Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) PL plot of MPC 5 mg 
sample. B) PL plot of MPC 3mg sample. C) PL plot of MPC 1 mg sample.
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4.3.4.2 Stability study of water dispersed carbon nanotubes using 
SDS, SDBS and MPC 
 
Stability studies are an important part to any particle formulation particularly any that could be 
used in a pharmaceutical context.  This is because it is important from both a safety and a 
regulation stand point that it is known what exactly is in a formulation and that over time, this 
will not change in between the formulation being made and it being administered.   
What the stability study data showed was that formulations made using either SDBS or MPC 
were both stable and kept at near 100 % concentration.  This is shown in Figures 4.16 in the 
actual peak height absorption values and in Figures 4.17 as a percentage compared to the 
initial week 0 sample.  This is important because if the carbon nanotubes were to lose the 
surfactant that surrounds them, they will become hydrophobic.  This will cause them to form 
larger and larger bundles which will then come out of solution.  This was only seen with the 
SDS dispersed carbon nanotubes and this could be down to a lack of a benzene ring which 
the SDBS molecule has which adds to the stability.  These results showed that for a 6 month 
period, either SDBS or MPC could be used as a surfactant and not see a significant drop in 
the concentration and therefore stability of the carbon nanotubes it is surrounding. 
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A)  
B)  
Figure 4.16 All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1% 
surfactant concentration, 13 or 40 °C water bath temperature, 2 mL sample size, Nalgene™ 
Polycarbonate tubes, cycle set up of 60 cycles of 60 seconds on, 15 seconds off, L power 
level.  Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) Absorption peak height 
value at 566 nm for each stability study sample.  B) Absorption peak height value at 976 nm 
for each stability study sample. 
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A)                  
B)  
 
Figure 4.17: All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1% 
surfactant concentration, 13 or 40 °C water bath temperature, 2 mL sample size, Nalgene™ 
Polycarbonate tubes, cycle set up of 60 cycles of 60 seconds on, 15 seconds off, L power 
level.  Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) Percentage difference from 
week 0 for each stability study sample at 566 nm.  B) Percentage difference from week 0 for 
each stability study sample at 976 nm. 
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4.4. Conclusion 
 
In conclusion, a number of different factors were shown to have an influence on how a 
surfactant performed at dispersing carbon nanotubes.  It was shown firstly that your choice of 
surfactant has a large effect on how well the carbon nanotubes were dispersed.  It was shown 
that the simple addition of a benzene ring to a molecule was enough to significantly increase 
the carbon nanotubes dispersion, in the case of SDS compared to SDBS.  However with these 
surfactants being toxic, alternatives were required.  The comparison of MPC and DMPC to the 
other two surfactants also showed some key factors.  The addition of a second fatty acid meant 
that DMPC could not conform to the correct shape and therefore dispersed almost no carbon 
nanotubes at all.  However MPC, with its single chain, could disperse carbon nanotubes as 
well as SDS and kept them stable for up to 6 months.  When compared to one another, it was 
shown that MPC had very similar dispersion properties and abilities to SDS which confirms 
that the benzene ring of SDBS is a significant factor in the efficacy of carbon nanotube 
dispersion using SDBS. 
It was also shown that temperature is another important factor to take into consideration.  Even 
though it was never shown that temperature could be used to control bundle size, it was shown 
that too high a temperature would see a comparative drop in the concentration of carbon 
nanotubes.  The sonication time on and off however was shown not to affect carbon nanotube 
dispersion efficacy with 60 seconds on, 15 seconds off and 10 seconds on, 5 seconds off 
having similar dispersion results for the same total sonication time. 
Probe sonication was finally also shown to be a viable alternative for carbon nanotube 
dispersion which is in line with previous work already done.  With the use of an ice bath, carbon 
nanotubes were dispersed successfully using a similar amount of time.  The ice bath was 
important as probe sonication introduces a lot of heat into the system and as shown with the 
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bath sonication work, an increase in temperature does relate to a decrease in carbon nanotube 
dispersion efficacy. 
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5. Carbon nanotube modification and addition to 
liposomal solution 
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5.1 Aim and objectives 
 
Carbon nanotubes are hydrophobic in nature and so need modification if they are to be soluble 
in water and be useful for many different biological applications.  This is done through either 
covalent or non-covalent functionalisation.  Covalent functionalisation works by chemically 
modifying the actual carbon nanotube structure and introducing defects.  These defects are 
then modified with various chemical groups which increase the hydrophilicity of the carbon 
nanotube.  The aim of this work was to investigate carbon nanotube modification through the 
addition of oleum and nitric acid.  The objectives were to formulate a protocol for this 
modification and investigate any post chemical treatment that might be required.  This included 
cutting the carbon nanotubes; either through chemical treatment or through mechanical 
treatment using a bath or probe sonicator.  The final objective was to add some of these 
modified tubes with liposomes and investigate the initial interaction between the two different 
systems. 
 
5.2 Materials and methods 
 
5.2.1 Carbon nanotube carboxylation 
 
5.2.1.1 Chemical treatment procedure 
 
General synthetic procedure. 
40 mg of either HiPco or CoMoCat carbon nanotubes were mixed for 24 hours in 20 ml of 
oleum (20% wt. sulfur trioxide). A homogeneous black solution was formed. A mixture of 
oleum: nitric acid (70%), 10:10 ml was added slowly to the nanotubes solution under cooling. 
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The reaction mixture was kept for 2 hours on the sand bath at either 20 or 65oC. 120 ml of 
water was poured in afterwards slowly and left for coagulation for 12 hours. Black flake-like 
coagulate appeared. The precipitate was separated by filtration through a 5 m Teflon 
membrane under vacuum. The precipitate on the filter is dispersed in 5 ml of methanol, 
coagulated by 20 ml of Diethyl Ether, filtered and washed by Diethyl Ether. Additionally 
washings were conducted with Diethyl Ether and the dry carbon nanotubes were dried in air 
on the filter paper. 
 
5.2.1.2 Dispersion of carbon nanotubes post chemical treatment 
 
0.1 mg / mL of the chemically treated carbon nanotubes were dispersed in water and allowed 
to stand for 5 minutes.  If required, 1mg / mL of SDBS was added to the sample and a short 
period of sonication of 15 cycles of 60 seconds on, 15 seconds off, was applied to disperse 
the treated carbon nanotubes.  SDBS was the only surfactant chosen because it is the most 
efficacious and in this experiment, it was simply used to investigate if any hydrophobic carbon 
nanotube structure still remained.  These were then analysed using UV – Vis – NIR, DLS, 
TEM and PLE. 
 
5.2.2 Carbon nanotube cutting with probe 
 
Initially 1 mg of CoMoCat carbon nanotubes weighed out into glass vial. 10 mg of SDBS added 
along with 10 mL of water. Sample then sonicated for 1 hour using probe sonicator set to 40 
% (100 W) with a pulse cycle set to 0.5. Sample then ultra-centrifuged at 45000 rpm for 2 
hours at 17 °C. This power level was found to be insufficient as nearly all the nanotubes were 
still bundles and therefore were removed during ultra-centrifugation and so was increased to 
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100 %. Sonication time then increased to 2 hours. The probe sonicator was also used with 
samples at 3, 4 hours to increase the chances of cutting the tubes and therefore getting the 
short tubes required and all samples analysed using UV – Vis and PL (Gao et al., 2015). 
 
5.2.3 Carbon nanotube cutting with bath 
 
Initially 1 mg of CoMoCat carbon nanotubes weighed out into glass vial. 10 mg of SDBS added 
along with 10 mL of water. Sample then sonicated for 1 to 3 cycles using low power on the 
Bioruptor® Plus with 60 cycles of 60 seconds on, 15 seconds off at 20 °C. Samples were then 
ultra-centrifuged at 45000 rpm for 2 hours at 17 °C and subsequently analysed using UV – Vis 
– NIR and PL. 
 
5.2.4 Carbon nanotube addition to liposomes 
 
0.2 mg of chemically treated carbon nanotubes that were treated at 65 °C in the previous work 
in a 1 mg / mL solution were added to 1.8 mL of DMPC MLVs that were previously formed 
using the lipid film hydration method into a 50 mL polycarbonate tube with sonication aid.  The 
samples were then sonicated for 15 cycles of 60 seconds on, 15 seconds off at 45 °C at high 
power.  These were then analysed using DLS, UV – Vis – NIR and PL.  This was performed 
in triplicate. 
 
3 samples of 0.2 mL of chemically treated carbon nanotubes that were treated at 20 °C in the 
previous work in a 1mg / mL solution were sonicated for two sets of 60 cycles of 90 seconds 
on, 30 seconds off at 13 °C at high power.  Then these samples were each added to 1.8 mL 
of DMPC MLVs formed using the lipid film hydration method into a 50 mL polycarbonate tube.  
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The samples were then sonicated for 15 cycles of 60 seconds on, 15 seconds off at 45 °C at 
high power.  These were then analysed using DLS, UV – Vis – NIR and PL. 
 
5.2.5 Analysis of carbon nanotubes 
 
5.2.5.1 UV – Vis spectroscopy 
 
Analysis was conducted using the Genesys 10s UV – Vis spectrometer (Thermo Fisher 
Scientific, Waltham, Massachusetts, United States) (Fernandes et al., 2015). The wavelength 
scanning range for the UV – Vis spectrometer was from 270 to 1100 nm using a plastic clear 
sided cuvette. The scan interval was set to 1 nm for the UV – Vis spectrometer. 3 mL of sample 
was placed into the cuvette and analysed after a blank of deionised water had been ran. 
 
5.2.5.2 Photo luminescence mapping 
 
PL analysis of carbon nanotubes has previously been described by Lutsyk et al and Tan et al 
(Lutsyk et al., 2016, Tan et al., 2007). Briefly, the fluorescence emission spectra at various 
excitation wavelengths were recorded using a Horiba NanoLog excitation–emission 
spectrofluorometer equipped with a nitrogen-cooled InGaAs array detector to generate PL 
excitation-emission maps (PLE maps), with the X-axis representing the wavelength of the PL 
emission, λ EM, and the Y-axis representing the excitation wavelength, λ EX. Entrance/exit 
slits of 14 nm in width were used for both the excitation and emission monochromators in the 
NIR PL measurements. Analysis was ran for the EM between 300 and 800 nm in increments 
of 5 nm and EM measured between 815 and 1450 nm using a 30 second integration time. The 
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time-resolved PL decays were measured using a LifeSpec II spectrofluorometer (Edinburgh 
Instruments Ltd., UK) to perform time-correlated single-photon counting (TCSPC) under 
excitation by a picosecond pulsed diode laser at 405 nm. 
 
5.2.5.3 Size analysis using DLS 
 
DLS analysis of carbon nanotubes was ran using a 100 µL sample in 1.9 mL of distilled water 
and were characterised for their size and PDI using a Brookhaven Nanobrook 90 plus zeta 
(Scimed, Cheshire, UK). 
 
5.2.5.4 TEM 
 
The high resolution Transmission Electron Microscopy (TEM) images were obtained with the 
JEOL JEM2100F system equipped Field Emission Electron gun. The measurements were 
carried out at 100kV accelerating voltage. Additionally, the TEM’s Energy Dispersive X-ray 
Spectrometer was used for element analysis of control CNT samples. 
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5.3 Results and Discussion 
 
5.3.1 Chemical cutting and carboxylation of carbon nanotubes 
 
5.3.1.1 Basic HiPco carbon nanotube data 
 
There are two types of carbon nanotubes being investigated for carboxylated functionalisation; 
HiPco and CoMoCat. The HiPco tubes are a different product due to their increased dispersion 
in types of tubes, chiralities and sizes and also the much increased amount of catalyst and 
amorphous carbon found which can take 50 to 80 % of the overall weight. CoMoCat tubes are 
of much better quality with up to 95% of the weight being carbon nanotubes and at least 40% 
being of the single chirality of 6,5. To this end, the initial experiments with carboxylation were 
done with the HiPco tubes to ensure a method is created that can then be used with the 
CoMoCat tubes without wasting too many of the expensive CoMoCat tubes. To this end, HiPco 
tubes were investigated using SDBS to disperse them first of all to give a PL map and UV – 
Vis spectrum to compare to the carboxylated tubes, as shown in Figures 5.1 A - B. It was also 
important to check with the CoMoCat tubes whether any significant peaks were seen over and 
above the 1100 nm wavelength and this was done by using D2O and shown in Figure 5.1 C – 
D. Figure 5.2 A – C shows the structure of these CoMoCat pristine carbon nanotubes.  What 
these show are generally quite tight bundles of tubes and on closer inspection, the tube 
surface is not kinked and shows no sign of breakages with no short tubes shown and no sign 
of defects showing that non – covalent functionalisation has no effect on the actual carbon 
nanotube structure. 
What these show is that HiPco carbon nanotubes are a lot more diverse in the CNT’s 
chiralities. There are many CNT peaks within the 1400 nm zone, which need for analysis D2O 
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to avoid water absorption in the samples.  The CoMoCat samples do not show optical 
absorption beyond 1300nm and therefore can be ran using just normal distilled water. 
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Figure 5.1: All runs were with Bioruptor® Plus, 0.01 % carbon nanotube concentration, 0.1% 
surfactant concentration, 13 or 40 °C water bath temperature, 2 mL sample size, Nalgene™ 
Polycarbonate tubes, cycle set up of 60 cycles of 60 seconds on, 15 seconds off, L power 
level.  Ultracentrifugation for 150 minutes at 40, 000 G at 17°C. A) PL plot of a typical HiPco 
carbon nanotube sample dispersed with SDBS. B) UV – Vis – NIR plot of HiPco carbon 
nanotubes in D2O.C) UV – Vis – NIR plot of CoMoCat carbon nanotubes in D2O. 
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A)  B)  
C)  
Figure 5.2: A - C: The CoMoCat sample initial - All runs were with Bioruptor® Plus, 0.01 % 
carbon nanotube concentration, 0.1% surfactant concentration, 13 or 40 °C water bath 
temperature, 2 mL sample size, Nalgene™ Polycarbonate tubes, cycle set up of 60 cycles of 
60 seconds on, 15 seconds off, L power level.  Ultracentrifugation for 150 minutes at 40, 000 
G at 17°C. CoMoCat nanotubes, dispersed in NMP 0.01 mg / ml (standard US, hard plastic 
Eppendorf), centrifuged at 13400 rpm, 30 min, deposited on a standard TEM grid. 
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5.3.1.2 Carbon nanotubes carboxylated with oleum experiment 
 
Carbon nanotube carboxylation using oleum and nitric acid was developed using the Chen et 
al paper as a starting point.  As the results show, most of the samples show no peaks on the 
UV data or on the PL plots.  The luminescence yield is however extremely sensitive to 
nanotube backbone integrities. In particular, the shortening of nanotube lengths creates a 
number of defect sites (including at the nanotube ends) such that carbon nanotube 
luminescence vanishes when the distance between defect sites becomes shorter than the 
exciton diffusion lengths. This implies that it is challenging to detect luminescent carbon 
nanotubes shorter than typically 100 nm at the single tube level (Gao et al., 2015). 
The UV data in Figure 5.3 shows that none of samples have any peaks once they have been 
treated with acid, owing to the defects that are now present on the carbon nanotube surface.  
This compares to Figure 5.1 D which shows a number of peaks associated with the different 
chiralities found in the CoMoCat tubes.  There are no peaks shown for the samples after 
centrifugation or after surfactant was added.  This infers that the tubes have been heavily 
modified and defected. 
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Figure 5.3: 40 mg initial carbon nanotube weight oleum: nitric acid carboxylation modification 
method, s8 at 65 °C sand bath temperature, s11 at 20 °C sand bath temperature, UV – Vis – 
NIR data for each of the samples.  
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The CoMoCat carbon nanotubes that were treated with the acid at 20 °C were shown to have 
no discernible chirality map using the PL as shown below in Figure 3.3.  After centrifugation 
was completed, the PL data still showed no discernible peaks.  After the surfactant SDBS was 
added however, there were discernible peaks correlating to the CoMoCat carbon nanotube 
shown before in Figure 5.4.  What this shows is that the carbon nanotubes modified at 20 °C 
still retain some of their chirality and structure and therefore that the carbon nanotube structure 
is at least in some way still intact. 
 
The TEM data in Figure 5.5 shows a reduced concentration compared to the initial tubes with 
a much looser spread of carbon nanotubes.  This infers they are better dispersed compared 
to carbon nanotubes non-covalently dispersed with a surfactant such as SDBS.  The close up 
shows the surface is more pockmarked than before which shows defects starting to appear. 
 
A) B)  
Figure 5.4: 40 mg initial CoMoCat carbon nanotube weight, oleum: nitric acid carboxylation 
modification method, s9 at 20 °C sand bath temperature. A) Pre centrifuge sample. B) Post 
centrifuge and surfactant addition sample. 
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A) B) C)
 
Figure 5.5: A - C: Sample D13_17 - CoMoCat nanotubes after oxidative treatment at 20 ° C. 
The dry sample was dispersed in NMP 0.01 mg / ml (standard US, Eppendorf’s from hard 
plastic), centrifuged 13400 rpm, 30 min, deposited on a standard TEM grid. The tubes are 
tangled, but less dense than for initial CoMoCat, there are metal particles in them, but clearly 
there are less of them than in CoMoCat.  Individual tubes are the same curves and dirty. 
Length of tubes: bundles of several microns, as in CoMoCat. It is possible to find individual 
bundles with 200 – 500 nanometres in length. 
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The CoMoCat carbon nanotubes shown below in Figure 5.6 show that at 65 °C sand bath 
temperature, there is again no PL peaks shown which again infers that the carbon nanotubes 
were defected.  However what the TEM data shows is that the tubes were in fact more than 
defected but were almost completely destroyed at the higher temperature.  Instead there are 
other amorphous carbon particles in solution. 
A) B)
C)         D)  
Figure 5.6 A - D: Sample s8_17.  A) PL map of CoMoCat nanotubes after oxidative treatment 
at 65 ° C. B – D) TEM of CoMoCat nanotubes after oxidative treatment at 65 ° C.  The dry 
sample (1 mg / ml) is dispersed (standard US, hard Eppendorf) in aqueous NaOH (10-3 mol / 
L), centrifuged 13400 rpm, 30 minutes (quite a lot of sediment - obviously aging of the sample, 
diluted 10-fold, again sound + centrifugation. The deposition is on the standard TEM grid (in 
Aston). We observes an amorphous matter that clogs the pores of the grating. Perhaps some 
dark particles, about 20 nm in size which are quickly deteriorating under the beam (so we 
could not make a good picture in high resolution).  
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HiPco carbon nanotubes were also dispersed at the 20 and 65 °C temperatures.  Figure 5.7 
A shows that at 65 °C the tubes again lost all the peaks which associate with the chirality of 
the HiPco tubes.  Figure 5.7 B and C show that at 20 °C, tubes were again not seen after 
chemical treatment using the PL, but after centrifugation and addition of the surfactant SDBS, 
the tube map associated with the HiPco tubes was again seen which shows that again at 20 
°C, the tubes are defected but do not lose all their chirality and therefore do not lose all of their 
structure. 
A) B)  
C)  
Figure 5.7: 40 mg initial HiPco carbon nanotube weight, oleum: nitric acid carboxylation 
modification method, s10 at 65 °C sand bath temperature, s11 at 20 °C sand bath 
temperature. A) Pre centrifuge sample. B) Post centrifuge sample. C) Post centrifuge with 
surfactant addition sample. 
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The size and PDI of the carbon nanotubes are shown below in Figure 5.8 to try to determine 
whether DLS can be used to show a reduction in carbon nanotube size.  What was found was 
that carbon nanotubes dispersed at 20 °C showed a large size in the micron scale which would 
indicate a lower level of dispersion compared to those dispersed with surfactant.  However 
once these were centrifuged, the size of the sample reduced down to the nano range indicating 
that large bundles of carbon nanotubes were removed through this process.   However at 65 
°C, the carbon nanotubes stayed in the nano range.  This indicates that these were much 
more dispersed than those treated at 20 °C which follows the TEM data which showed that 
those treated at 65 °C were broken up but those at 20 °C were just defected and still retained 
most of their structure. 
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Figure 5.8: 40 mg initial carbon nanotube weight oleum: nitric acid carboxylation modification 
method, s8 and s10 at 65 °C sand bath temperature, s9 and s11 at 20 °C sand bath 
temperature. A) DLS data for all samples. B) PDI data for all samples. 
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5.3.2 Cutting of carbon nanotubes using the probe and bath sonicators 
 
5.3.2.1 Carbon nanotubes cut using probe sonicator 
 
Previous work has shown that by probe sonicating at high power for a long period of time, it is 
possible to cut carbon nanotubes down to sizes of below 100 nm. The aim of this work was to 
follow their methods and find out whether this is repeatable and whether we could use these 
in conjunction with the covalently functionalized carbon nanotubes and be able to get a direct 
comparison. 
 
Figure 5.9 A and B shows that as you increase the power you get a much improved dispersion 
efficiency as well comparing 40 % to 100 %. This is also obvious as the dilution factors went 
from 1 in 10 to 1 in 50.  What this data also showed was that as we increased the amount of 
time sonicated, an increase in the dispersion concentration was seen which is shown in the 
UV data in Figure 5.9 C. This goes above what was seen previously with the probe sonicator 
and above what was seen with any of the bath sonicator samples and therefore shows as you 
sonicate for longer and longer periods of time, more carbon nanotubes are dispersed.  This 
was shown for up to 4 hours of sonication however no significant changes were seen in the 
samples or in the PL or UV – Vis – NIR data shown in Figure 5.10 which indicated that no 
changes to the structures of the carbon nanotubes were taking place.  Without these changes 
or defects, the carbon nanotubes will remain in their long state and not be cut. 
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A) B)  
C) D) 
E)  
Figure 5.9: A) Probe sonicated carbon nanotubes after 1 hour at 40 %. B) Probe sonicated 
carbon nanotubes after 1 hour at 100 %. C) Probe sonicated carbon nanotubes after 2 hours. 
D) Probe sonicated carbon nanotubes after 3 hours. E) Probe sonicated carbon nanotubes 
after 4 hours. 
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Figure 5.10: F. DLS of probe sonicated carbon nanotubes from 1 to 4 hours. 
 
5.3.2.2 Carbon nanotube cutting using the bath 
 
Similar experiments were carried out using the bath sonicator, the Bioruptor® Plus.  Previous 
discussions with Diagenode had limited the time the sonicator could be used in one sitting 
before allowed to rest and cool as approximately 3 hours.  Therefore up to 3 sets of sonication 
were investigated with either 1, 2 or 3 sets of 60 cycles of 60 seconds on, 15 seconds off. 
 
The results below show in Figure 5.11 no significant changes in any of the PLE maps.  The 
UV data showed that there was an increase in carbon nanotube concentration after 2 sets but 
then it reduced again after 3 sets.  This could be due to the increase in time allowing more 
carbon nanotubes to be dispersed, similar to the data shown with the probe sonicator.  The 
reduction could then be attributed to the surfactant lapsing off the surface of the carbon 
nanotubes as the increase in time means the machine heats up and the solution within the 
plastic tube heats up also. 
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Figure 5.11: A) Bath sonicated carbon nanotubes after 1 cycle. B) Bath sonicated carbon 
nanotubes after 2 cycles. C) Bath sonicated carbon nanotubes after 3 cycles. D) UV – Vis 
peak heights at 566 nm. E) UV – Vis heights at 976 nm. 
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5.3.3 Addition of carbon nanotubes to liposomes 
 
The final part of this work was to try and combine the chemically treated carbon nanotubes 
with liposomes to form a complex.  The method employed involved forming MLVs using the 
lipid film hydration method and then sonicating these with the carbon nanotubes.  The hope 
was that as these were sonicated and broken up and reduced in size to form SUVs, these 
would also interact with the carbon nanotubes allowing the complex to form with the tubes 
either inside the liposome, in the lipid bilayer or on the outside of the liposome. 
The results below in Figure 5.12 showed that the size of the liposomes were reduced to 
between 100 and 200 nm in diameter.  There was no significant size difference shown 
between the 65 °C treated tubes and the 20°C treated tubes once added to the liposomes and 
the solutions were clear.  The UV data in Figure 5.12 C and PL data in Figure 5.13 both show 
that there are no carbon nanotubes present that are free of defects or at least they are unable 
to be detected using these methods.   
What these initial results showed was that the addition of carbon nanotubes to a liposome 
formulation made using the Bioruptor bath sonication systems does not adversely affect the 
liposomes and does form a clear solution that can be analysed.  What the results showed for 
the thesis is that carbon nanotubes and liposomes could be sonicated together.  The next step 
would be to analyse these using TEM and other imaging software to investigate how these 
two entities have interacted, if at all, through this process.  This would then inform whether the 
carbon nanotubes are located within the liposomes or not.  If they were, then this would show 
that sonication could be used as a simple method of forming the complex that was desired for 
this thesis and if not, then other methods such as covalent functionalisation and attachment 
would be investigated as alternate methods for forming the liposome – carbon nanotube 
complex. 
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Figure 5.12: A) DLS size of liposomes in conjunction with carbon nanotubes either sonicated 
beforehand or not.  B) PDI of liposomes in conjunction with carbon nanotubes either sonicated 
beforehand or not. C) UV – Vis data showing both types of carbon nanotubes before or after 
sonication. 
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A) B)  
 
C)  D)  
 
Figure 5.13: A) carbon nanotubes plus liposomes with no sonication – HiPco carbon 
nanotubes. B) Carbon nanotubes plus liposomes with no sonication – CoMoCat carbon 
nanotubes. C) Carbon nanotubes plus liposomes with sonication – HiPco carbon nanotubes. 
D) Carbon nanotubes plus liposomes with sonication – CoMoCat carbon nanotubes. 
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5.4 Conclusions 
 
In conclusion, it was shown that carbon nanotubes could be chemically treated using oleum 
and nitric acid in combination with heat.  These tubes were shown to become defected with 
treated at 20 °C but their structure was destroyed when treated at 65 °C.  This is important to 
know as this implies that by altering the treatment temperature, different carbon structures and 
different rates of defect could be tuned with the carbon nanotubes.  This would then allow a 
multitude of different applications to be investigated depending on the structure required. 
It was also shown that the Bioruptor® Plus could not be used for carbon nanotube cutting as 
the power and time required to do so is beyond the limits of the machine.  However this could 
be used if the carbon nanotubes are already defected, such as those chemically treated at 20 
°C.   
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6. Final discussion and conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
278 
 
6.1 Final conclusions 
 
6.1.1 Liposome formation and size reduction 
 
Liposome size reduction is an important method as it allows for liposomes to become more 
homogeneous in size and composition and for them to hide from the immune system.  This 
lack of detection means the liposomes can reach the site of action and delivery their drug 
payload before they are ingested and removed by the immune system.  For vaccine 
development the size of liposomes can elicit different immune responses which therefore 
means some size reduction from the MLV size range is still necessary.  For example, 
Henriksen-Lacey et al were able to show that different vesicle sizes gave rise to differences 
in cell proliferation, IL – 10 production and the movement of liposomes to the lymph nodes 
(Henriksen-Lacey et al., 2011).   
There are a number of methods for reducing the size of liposomes including extrusion, high 
shear mixing and sonication.  Sonication is split into two methods; probe sonication and bath 
sonication.  Probe sonication is more widely used due to the low cost of equipment, high power 
exerted by the probe and quick turnaround of samples.  However problems occur with 
contamination from titanium particles from the probe, a lack of proper temperature control 
beyond the use of an ice bath and only being able to do one at a time.  Bath sonication seems 
to overcome these problems by sonicating samples in plastic tubes within a temperature 
regulated bath.  This removes the problems of throughput, temperature degradation and 
contamination.  However previous bath sonicators have struggled to have the power required 
to break apart the liposomes allowing them to reform into the smaller spheres.   
This work showed that liposomes could be reduced in size using Diagenodes Bioruptor® bath 
sonication systems.  Once the liposomes were formed using the lipid film hydration method, 
MLV were successfully reduced in size using these systems.  All systems were shown to 
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reduce the liposomes to sub-micron size and some conditions were shown to reduce liposome 
size to below 100 nm.  This would mean these liposomes and therefore these systems could 
be used to reduce liposomes down to a size where they could be used for drug delivery.  Many 
factors were shown to influence the rate at which liposomes were reduced in size.  These 
included time, power level, concentration, volume, temperature, and plastic choice. These 
liposomes were also produced in a sealed environment inside plastic tubes ranging in size 
from 1.5 mL up to 50 mL with sample volumes ranging from 0.1 mL up to 5 mL with between 
3 and 6 samples sonicated in one go.  This range of sample volumes allows for initial testing 
to be done with very small volumes and therefore keeping costs reduced and then once a 
formulation is decided upon, the sample volume can then be increased using the same 
Bioruptor® system.  The temperature control the water bath brings also allows for many 
different lipids to be used without the fear of lipid degradation occurring due to the sample 
being heated up.  With the Bioruptor® systems, liposomes can be sonicated from just above 
freezing up to approximately 50 °C.   
 
6.1.2 Bioruptor® protocols 
 
The Bioruptor® Plus bath sonication system was used to test out drug loading using example 
lipophilic drugs.  These were albendazole, carbamazepine and propofol.  It was shown with 
varying degrees of success that this system could be used to load liposomes with a lipophilic 
drug embedded into the bilayer.  The most successful of the three was carbamazepine using 
methods 2 and 3.  These methods produced better results as the drug was added at a late 
stage.  This meant that there was less chance of the drug being lost due to the number of 
steps in the process.  Albendazole had difficulty being dispersed in the water based liposomal 
solution and was found to instead coat the inside of the plastic tube in which it was being 
sonicated.  This then lead to a reduced loading concentration.  Propofol was also found to 
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interact with the plastic tube and in fact begin to degrade the tube itself.  Though the drug 
loading itself was not successful and could not be taken any further, it was shown that the 
Bioruptor® could be used for drug loading.  It is important to note that unlike probe sonication 
where a glass bottle is used, drugs should be checked to make sure they do not interact with 
the plastic tubes being used.  That being said, the introduction of a water bath and lack of a 
titanium probe does make this process viable for further work as these benefits would still be 
present if a more suitable drug is used. 
 
During my time at Diagenode, I spent some time working on bath sonicator characterisation.  
This characterisation is important because by understanding what happens during the 
sonication process, changes can be made to the design or the method that can improve the 
sonication process and therefore the results achieved.  This can be done through a number 
of methods and the one we looked at was by following the process of I2 formation from the free 
radical of iodine obtained after sonication of a KI solution in the presence of a catalyst.  The 
process of sonication produces H2O2 which interacts with the KI to form the iodine and 
therefore change the colour from clear to yellow.   
What the results showed was that a smaller sample volume gave more complete sonication.  
The reduced sample volume means that there is more of the finite quanta of sonic energy to 
be given per mL to the sample.  This in turn increases cavitation and allows for an increase in 
iodine production.  There was no significant differences seen between the samples when 
sonicated in two different types of plastic and no significant difference either between the low 
and high powered samples.  A decrease in temperature saw a decrease in sonication 
efficiency as is expected as the molecules within the sample move slower at a lower 
temperature.  However at a much higher temperature not conducted during this study, there 
would also be a decrease in sonication efficiency as too high a temperature means that the 
cavitation effect actually starts to decrease.  This feeds back into the liposome formulation 
work as too high a temperature would mean that liposomes would not be broken down and 
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reduced in size as effectively which means high transition temperature lipids would be difficult 
to break down efficiently using these systems. 
 
Another important use for the Bioruptor® bath sonication systems is in the extraction of DNA.  
Therefore efficiency tests were carried out to see whether more components for the 
Diagenode DNA extraction kit could be sourced in house and to see whether further 
improvements in the process could be made.   What the results showed was that the addition 
of a filter lead to reduced sample prep time but also a reduced DNA concentration at the end.  
The choice of buffer results showed an improved DNA extraction from the new buffers 
although these results were not significant.  Finally the longer the samples were left to shake, 
the larger the DNA extraction concentration was found to be.  
 
6.1.3 Non covalent functionalisation of carbon nanotubes 
 
Water dispersion of carbon nanotubes was shown to be successful using a number of different 
Bioruptor® bath sonication systems.  There were a number of different factors that were shown 
to influence carbon nanotube dispersion efficiency.   
Temperature was also shown to affect carbon nanotube dispersion efficiency with either too 
high or too low a temperature reducing the efficacy.  The too low temperature means there is 
not enough energy in the system to break apart the surfactant molecules and carbon nanotube 
molecules to allow them to disperse successfully.  However too high a temperature means too 
much energy in the system.  This high energy means that the surfactant has a tendency to 
lapse away from the carbon nanotube surface that reduces the carbon nanotube dispersion 
efficiency.  
The choice of surfactant was shown to greatly affect the dispersion efficiency of the carbon 
nanotubes.  This is due to the size and structure of the surfactant molecules, the presence or 
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absence of benzene rings that can associate with the carbon nanotube structure using π-π 
bonding in the case of SDBS compared to SDS.  However these surfactants aren’t suitable 
for biological uses and therefore alternatives were investigated. DMPC and MPC are both 
phospholipids with either one or two fatty acid chains.  The presence of two chains in DMPC 
leads to a cylindrical molecular shape which is unsuitable for carbon nanotube dispersion as 
was shown with the results.  However MPC has a more conical shape which allows for them 
to form around the carbon nanotube sphere and disperse the carbon nanotube successfully.  
It was also shown that the SDBS and MPC dispersed carbon nanotubes were more stable 
over a long period of time, in this case 6 months, compared to the SDS dispersed carbon 
nanotubes.  MPC was directly compared to SDS and SDBS and was shown to have similar 
dispersion efficacy compared to SDS which infers that the benzene ring associated with SDBS 
is vital for increasing dispersion efficacy. 
Finally probe sonication was also shown to be a viable way of dispersing carbon nanotubes 
with the aid of an ice bath.  The use of an ice bath is required as probe sonication leads to a 
quick increase in sample temperature which previous work showed a decrease in carbon 
nanotube dispersion efficiency. 
 
6.1.4 Covalent functionalisation of carbon nanotubes 
 
Covalent functionalisation of carbon nanotubes was achieved through the use of nitric acid 
and oleum in combination with heat.  The tubes were either defected at lower temperatures or 
completely destroyed through higher temperatures.  This is important as defects are required 
to start the shortening process but too much heat means the tubes are not only shortened but 
are broken down into small carbon graphene pieces.   
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It was also shown that the Bioruptor® Plus could not be used for carbon nanotube cutting as 
the power and time required to do so is beyond the limits of the machine.  However, this could 
be used if the carbon nanotubes are already defected, such as those chemically treated at 20 
°C.   
 
6.2 Further work 
 
Previously published research has looked into creating complexes formed from carbon 
nanotubes and liposomes.  These have included nanotrains with liposomes attached to the 
surface of a carbon nanotube and nanotube porins which have been carbon nanotubes 
inserted into the bilayer of a liposome.  Previous work has also shown that carbon nanotubes 
could be seen as a valid adjuvant due to their ability to increase the immune system response 
(Gottardi and Douradinha, 2013).  This is dependent on the carbon nanotubes size, chirality, 
number of layers and surface modifications.  Liposomes meanwhile have been shown to allow 
a controlled slow release of an antigen and improve antigen stability and presentation of the 
antigen to the immune system. 
My PhD is a BBSRC case project sponsored by Diagenode and focussed on formulating new 
protocols for the formation of liposomes using their in house Bioruptor®® bath sonicator 
systems.  This was successful and was shown to be comparable to probe sonication whilst 
also allowing for more samples to be sonicated per run and for larger volumes to be sonicated 
as well.  The same bath sonicators were then also shown to be able to disperse carbon 
nanotubes using surfactants including SDBS and MPC which would allow for biologically safe 
surfactant dispersed carbon nanotubes to be used in conjunction with liposomes formed using 
the same bath sonicator. 
Further work would look into formulating several different liposome carbon nanotube 
complexes and to investigate their ability to deliver vaccines with the carbon nanotube acting 
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as the adjuvant.  Several complexes could be formulated initially with carbon nanotubes inside 
the liposome or attached to the outside and with individual complexes and also nanotrains.  
These carbon nanotubes would be either covalently or non-covalently functionalised and 
some would be shortened through a combination of chemical and/or mechanical means.  
Graphene oxide and reduced graphene oxide would also be complexed with the liposomes to 
see whether this carbon based chemical could be used in place of the carbon nanotubes.  This 
is because graphene oxide can be directly dispersed with water, shows less toxicity compared 
to carbon nanotubes and has been shown previously to be a valid adjuvant for a vaccine 
delivery system (Xu et al., 2016).  The formulations that are successfully made during this time 
will then be used for the in vitro work. 
The complexes would then be loaded with an example antigen and tested against the 
component parts with and without the antigen to determine whether the complexes give an 
increased cell response compared to the liposomes or carbon nanotubes on their own.  This 
would be done to show that the complex as a whole would give a larger immune response 
than just its component parts.  This would be done through in vitro work with the ability of the 
complexes to attract the immune system components, how well the antigen is ingested, and 
the toxicology profile of the complexes being investigated. 
Finally, in vivo work would comprise of comparing the complexes against both their 
components and other possible market vaccine delivery systems to see whether there is an 
improvement on the efficacy compared to current systems as well as migration and ingestion 
of the antigen and toxicology of the complex. 
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